The central role of the transcriptional regulator IκBζ in psoriasis by Müller, Anne
The central role of the transcriptional regulator  
IκBζ in psoriasis 
 
 
 
 
 
 
 
 
Dissertation 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Eberhard Karls Universität Tübingen 
zur Erlangung des Grades eines  
Doktors der Naturwissenschaften  
(Dr. rer. nat.) 
 
 
 
 
 
 
vorgelegt von 
Anne Müller 
aus Finsterwalde 
  
 
 
 
Tübingen 
2020 
  
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der 
Eberhard Karls Universität Tübingen. 
 
 
Tag der mündlichen Qualifikation:  10.11.2020 
Stellvertretender Dekan: Prof. Dr. József Fortágh 
1. Berichterstatter: Prof. Dr. Klaus Schulze-Osthoff 
2. Berichterstatter: Prof. Dr. Alexander N.R. Weber 
 
3 
 
Table of Content 
Abbreviations .............................................................................................................. 4 
Zusammenfassung ..................................................................................................... 6 
Abstract ...................................................................................................................... 7 
1 Introduction .............................................................................................................. 8 
1.1 The pathogenesis of psoriasis ........................................................................... 8 
1.2 The NF-κB pathway ......................................................................................... 13 
1.3 The atypical IκB member IκBζ ......................................................................... 15 
1.4 IκBζ in psoriasis ............................................................................................... 17 
1.5 Project objectives ............................................................................................ 18 
2 Results & Discussion ............................................................................................. 19 
2.1 STAT3 and NF-κB mediate the induction of IκBζ in keratinocytes ................... 19 
2.2 IκBζ regulates a subset of IL-36-dependent target genes in two waves .......... 21 
2.3 IL-36-mediated dermatitis: IκBζ function in vivo .............................................. 23 
2.4 Targeting IκBζ in keratinocytes as a new therapy approach for psoriasis ....... 25 
2.5 Initiation of the CDK4/6-EZH2-STAT3 pathway ............................................... 26 
2.6 Does CDK4/6 regulate PRC2-independent functions of EZH2? ...................... 28 
2.7 CDK4/6- or EZH2-mediated inhibition of pSTAT3 at Y705 .............................. 30 
2.8 Prevention of psoriasis and therapeutic application of novel inhibitors ............ 31 
2.9 Working model: IκBζ induction in psoriasis...................................................... 34 
3 References ............................................................................................................ 36 
4 Appendix ................................................................................................................ 44 
Acknowledgements ..................................................................................................... I 
Contributions .............................................................................................................. II 
 
 
 
  
 
4 
 
Abbreviations  
AMP Antimicrobial peptide 
ATP Adenosine triphosphate 
BAFFR B-cell activating factor receptor 
BCL-2  B-cell lymphoma 2 
CAK CDK-activating kinase 
cAMP Cyclic adenosine monophosphate 
CARD Caspase recruitment domain 
CBX Chromobox 
CCL CC-chemokine ligand 
CCL20 CC-chemokine ligand 20 
CD40  Cluster of differentiation 40 
CDK Cyclin-dependent kinase 
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EED embryonic ectoderm development 
ERα  Estrogen receptor alpha 
EZH2 Enhancer of zeste homolog 2 
GWAS Genome-wide association study 
H3 Histone 3 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
ICAM Intercellular adhesion molecule 
IKK IκB kinase 
IL Interleukin 
IMQ Imiquimod 
INK inhibitor of CDK 
IRAK Interleukin-1 receptor-associated kinase 
IκB Inhibitor of NF-κB 
JAK Janus kinase 
KO Knockout 
LCN2 Lipocalin-2 
LPS Lipopolysaccharide 
LTβR Lymphotoxin β receptor 
MALT Mucosa-associated lymphoid tissue 
MAPK Mitogen-activated protein kinase 
mDC Myeloid dendritic cells  
MHC Major histocompatibility complex 
mRNA Messenger ribonucleic acid 
MyD88 Myeloid differentiation primary response 88 
NEMO NF-kappa-B essential modulator 
NF-κB Nuclear factor of kappa light chain gene enhancer in B cells 
NIK NF-κB inducing kinase 
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NLS Nuclear localisation sequence 
PCGF Polycomb group RING finger protein 
pDC Plasmacytoid dendritic cells 
PHC  Polyhomeotic-like protein 
PRC Polycomb repressive complex 
RANK Receptor activator of NF-κB 
Rb Retinoblastoma 
RbAp Retinoblastoma protein associated protein 
RHD Rel homology domain   
RNF2 Ring finger protein 2 
ROR  RAR-related orphan receptor  
SNP Single nucleotide polymorphism 
STAT Signal transducers and activator of transcription 
SWI/SNF Switch/sucrose nonfermenting 
TAD Transactivating domain 
TCF T-cell factor 
Th17 T-helper cells 17 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TRAF TNF receptor associated factor  
VCAM Vascular cell adhesion molecule 
VEGF Vascular endothelial growth factor 
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Zusammenfassung 
IκBζ gehört zur Gruppe der atypischen NF-κB Inhibitoren (IκBs). Im Gegensatz zu 
klassischen IκBs wird IκBζ fast ausschließlich induzierbar im Zellkern exprimiert, wo 
es die Expression von bestimmten Targetgenen nicht nur inhibieren, sondern auch 
aktivieren kann. Das Gen NFKBIZ, welches für IκBζ kodiert, wurde als Risikogen in der 
Psoriasis identifiziert.  
Ebenso sind IκBζ-Knockout-Mäuse in bestimmten Modellen gegenüber einer 
experimentellen Psoriasis geschützt. Ziel dieser Dissertation war es, die Rolle von IκBζ 
in der Psoriasis näher zu beleuchten, um daran anknüpfend neue Therapieoptionen 
zu entwickeln. Es konnte gezeigt werden, dass IκBζ neben dem IL-17 Signalweg auch 
den IL-36 Signalweg reguliert, welcher bei bestimmten Formen der Psoriasis eine 
wichtige Rolle spielt. Die IL-36-vermittelte Induktion von IκBζ wird von NF-κB und 
STAT3 gesteuert und führt zur Expression von bestimmten pro-inflammatorischen 
Genen, welche die Pathogenese der Psoriasis initiieren. Vice versa sind IκBζ-
Knockout-Mäuse gänzlich vor einer IL-36-vermittelten experimentellen Psoriasis 
geschützt. Demnach stellt IκBζ einen zentralen Regulator in der Psoriasis dar, welcher 
unabhängig von der Art des Stimulus die Inflammation fördert. Darauf aufbauend 
folgten Screenings für pharmakologische Inhibitoren, welche die Induktion von IκBζ 
unterdrücken. Dabei konnte ein neuer proinflammatorischer Signalweg identifiziert 
werden, bei dem EZH2, eine Methyltransferase, durch CDK4/6 phosphoryliert wird und 
ihrerseits STAT3 methyliert, welches die IκBζ-Expression induziert. Die 
pharmakologische Hemmung von CDK4/6 oder EZH2 hemmte die Pathogenese von 
Psoriasis in vitro und in vivo.  
Zusammenfassend konnte diese Arbeit IκBζ nicht nur als verantwortlichen Mediator in 
der Psoriasis näher charakterisieren, sondern mit dem CDK4/6-EZH2-vermittelten 
Signalweg auch einen neuen Mechanismus identifizieren, dessen Inhibition eine 
mögliche Therapieoption in der Psoriasis darstellt. 
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Abstract 
IκBζ belongs to the group of atypical NF-κB inhibitors (IκBs). In contrast to classical 
IκBs, IκBζ is only inducibly expressed in the cell nucleus, where it can inhibit, but more 
importantly, also activate the expression of a particular subset of target genes. 
NFKBIZ, the gene encoding IκBζ, has been identified as new risk gene in psoriasis. 
Moreover, IκBζ knockout mice are protected in certain models of experimental 
psoriasis. The aim of this thesis was to examine the global role of IκBζ in psoriasis in 
order to find a new therapy approach. It could be shown that IκBζ is a regulator not 
only of IL-17 but also of IL-36 signaling, which plays a major role in certain forms of 
psoriasis. The IL-36-mediated induction of IκBζ was driven by NF-κB and STAT3, and 
led to the expression of pro-inflammatory genes that initiate the development of 
psoriasis. Accordingly, IκBζ knockout mice were completely protected from IL-36-
mediated experimental psoriasis. Thus, IκBζ represents a central regulator in psoriasis, 
which promotes inflammation regardless of the type of stimulus. Based on this finding, 
screenings for small-molecule inhibitors were performed that are able to repress the 
induction of IκBζ. Thereby, I could identify a new pro-inflammatory signal pathway in 
keratinocytes. In this pathway, CDK4/6 phosphorylated the methyltransferase EZH2, 
which in turn methylated and activated STAT3, which transcriptionally induced IκBζ. 
The pharmacological inhibition of CDK4/6 or EZH2 inhibited the pathogenesis of 
psoriasis in vitro and in vivo. 
In conclusion, this thesis not only validates IκBζ as an essential mediator of psoriasis, 
but also identifies the CDK4/6-EZH2 axis as a novel mechanism whose inhibition could 
provide a potential therapeutic option for the treatment of psoriasis. 
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1 Introduction 
1.1 The pathogenesis of psoriasis  
Psoriasis is a mixed autoinflammatory and autoimmune disease of the skin which 
partially develops due to genetic predispositions, but also due to a variety of 
environmental factors. It is characterized by scaly, erythematous patches, papules, 
and plaques that are often pruritic [1]. Around 2-3% of the worldwide population suffer 
from psoriasis, which affects statistically more women [2]. The most severe forms of 
psoriasis are psoriasis vulgaris (also named plaque psoriasis), inverse psoriasis, 
guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis. Psoriasis is often 
associated with further co-morbidities such as metabolic syndrome, cardiovascular 
disease, psoriatic arthritis or inflammatory bowel disease like Crohn's disease [3]. 
Moreover, psoriasis also represents a possible risk factor for the onset of coronary 
artery disease [4], stroke [5], myocardial infarct [6] hypertension and obesity [7]. 
The strongest genetic risk factor for psoriasis constitutes a single-nucleotide 
polymorphism (SNP) in the class I major histocompatibility complex (MHC I) human 
leukocyte antigen HLA-Cw*06 [8]. Other genetic risk factors have been identified which 
are involved in controlling epidermal barrier integrity (LCE3B, LCE3D), antigen 
presentation (ERAP1) and genes of the innate (NFKBIA) and adaptive immune 
systems (IL12B, IL23R) [9]. Furthermore, mutations in interleukin 36RA (IL-36RA), an 
endogenously expressed antagonist of IL-36 signaling, is associated with pustular 
psoriasis [10]. So far, few genetic variants have been analyzed, although more than 
60 SNPs are known to be associated with psoriasis [11].  
Generally, keratinocyte hyperproliferation and infiltration of immune cells, such as 
neutrophils, T helper 17 cells (Th17) and macrophages, are key features of psoriatic 
skin lesions [12]. Subsequently, psoriasis is a disorder of the innate and the adaptive 
immune systems. In genetically susceptible patients, the triggers for psoriatic lesions 
mostly arise from an injury, trauma, infection (e.g. Streptococcus) or drug (e.g. β-
blocker), followed by the release of antimicrobial peptides (AMP) such as LL-37, β-
defensins, and S100 proteins from keratinocytes, which complex with free DNA or RNA 
(Figure 1). In general, AMPs are absent in healthy keratinocytes and were upregulated 
during epithelial damage [13]. Furthermore, these AMP-DNA/RNA-complexes get 
recognized by Toll-like receptor 7 and 9 (TLR7 and 9) in antigen presenting cells, 
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especially plasmacytoid dendritic cells (pDC) but also myeloid dendritic cells (mDC) 
and a defined subpopulation of monocytes [14]. This initial event starting the 
development of the psoriatic plaque.  
Furthermore, the activation of pDCs leads to the MHC-dependent activation of CD8+ 
T cells and their clonal expansion. This process takes place in the dermis or in lymph 
nodes [13]. Subsequently, this activated CD8+ T cells migrate into the epidermis and 
trigger keratinocytes, in MHC-dependent manner, to secret proinflammatory mediators 
and initiate keratinocyte hyperproliferation. Additionally, activated pDCs produce type 
1 interferons (IFNα and IFNβ), which in turn activate mDC. Furthermore, mDCs drain 
into the lymph nodes to activate the adaptive immune system, especially T cell 
differentiation. This include the maturation to T helper 1 (Th1), Th17 and Th22 cells, 
followed by their infiltration and activation into psoriatic skin lesions [13]. Subsequently, 
the activation of T cell differentiation drives the maintenance phase of psoriatic 
inflammation [14].  
Additionally, the mDC-mediated secretion of tumor necrosis factor α (TNFα), IL-1, IL-
23, and IL-12 leading to the activation of the innate immune system, including the 
recruitment of neutrophils and macrophages into the affect skin area. In turn, Th17 
cells release cytokines such as TNFα, IL-17, IL-22 and IL-23 to drive keratinocyte 
proliferation, impair their differentiation, and promote an inflammatory response by 
activating nuclear factor of kappa B (NF‑κB), signal transducer and activator of 
transcription 1 and 3 (STAT1 and 3), CCAAT-enhancer-binding proteins β and δ 
(C/EBPβ and δ). This leads to the expression of pro-inflammatory molecules, including 
AMP (e.g. S100A7-9 and DEFB4), chemokines (e.g. CCL20, CXCL8 and CXCL2), 
cytokines (TNF, IL-1, IL-6, and IL-36), vascular endothelial growth factor (VEGF) and 
adhesion molecules (e.g. intercellular adhesion molecule 1 (ICAM-1) and vascular cell 
adhesion molecule 1 (VCAM-1)), which promote immune cell extravasation and 
migration at the site of inflammation [13]. Particularly noteworthy here is the IL-1 family 
cytokines. This family also includes IL-36γ, which is induced by keratinocytes in 
paracrine and autocrine loops, leading to the secretion of CXC-motif-chemokine ligand 
8 (CXCL8) and CXCL1 via the IL-36 receptor (IL36R) and consequently to the 
recruitment of neutrophils into lesional skin [15]. In addition, overexpression of IL-36γ 
enhances the response of Th17-driven cytokines in keratinocytes [16, 17]. Finally, a 
circle of inflammation is established.  
 
10 
 
Figure 1: Pathogenic Mechanisms of Psoriasis (Created with BioRender.com). External insults can 
cause the release of self‑nucleotides and keratinocytes-derived antimicrobial peptides (AMPs). These 
components form complexes, which can bind to receptors (TLRs) on plasmacytoid dendritic cells 
(pDCs). This binding trigger MHC-dependent antigen presentation to antigen‑specific CD8+ T cells, 
which were activated and initiate their clonal expansion. This activated CD8+ T cells migrate into the 
epidermis. There they trigger keratinocytes to release soluble factors. This initiate the local inflammation 
and the keratinocyte proliferation. In parallel, activated pDCs release interferons, which stimulate 
myeloid DCs (mDCs) to secrete IL‑12, IL‑23 and tumor necrosis factor (TNF). These proinflammatory 
factors stimulate different T cell populations, such as T helper 1 (Th1), Th17 and Th22 cells to secret 
further cytokines. The combination of IL-17, IL-22, IL-23 and TNF drives the proinflammatory cascade 
in different cell types. Finally, keratinocytes release a variety of chemokines, cytokines and AMPs to 
enhance the migration of immune cells and the inflammation in the psoriatic skin. The figure was adapted 
from [13]. 
 
Current standard therapies against psoriatic lesions constitute glucocorticoids, which 
suppress keratinocyte inflammation, proliferation, and promote differentiation; 
methotrexate, cyclosporin A, fumarate, phototherapy or neutralizing antibodies acting 
along the IL-23/IL-17/IL-22 axis, such as ustekinumab, infliximab, secukinumab, 
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ixekizumab and brodalumab [18]. In addition, antibodies against the IL-36R are 
currently being tested in clinical trials [19]. Numerous topical and systemic therapies 
are available for the treatment of psoriasis. The choice of the appropriate therapy is 
based on various parameters, such as disease severity, relevant comorbidities, costs, 
efficacy, and evaluation of individual patient responses [18]. However, none of the 
treatments effectively addresses the mechanism of the pathogenesis of psoriasis; only 
symptoms are treated or pro-inflammatory cytokines are blocked. Accordingly, novel 
therapies are necessary that act more specifically, thus limiting unwanted site-effects. 
At the moment, there is no mouse model available that fully recapitulates human 
psoriasis. This might be partially due to the fact that mouse and human skin differ in 
their immune cell composition or because psoriasis is a disease arising from multiple 
triggers, that cannot be completely modelled in mice. Therefore, treatment of mouse 
skin with the TLR7/8 agonist imiquimod (IMQ) represents the standard mouse model 
for preclinical investigations of psoriasis at the moment, as most signs of a psoriasis 
pathogenesis are induced, including keratinocyte hyperproliferation and immune cell 
infiltration especially from Th17 cells. However, Th17 cells represent a minority in IL-
17A secretion in mice, whereas γδ-T cells, that are absent in human skin, are the major 
IL-17A-producing population [20]. The importance of the IL-23/IL-17 axis in skin 
inflammation was demonstrated using knockout mice for IL-23p19 or the IL-17A 
receptor (IL-17RA), as these mice are protected from IMQ-mediated psoriasis [21]. 
However, recent studies showed that IL-36R-deficient mice are also completely 
protected in IMQ-mediated psoriasis [22]. This suggests that the IL-36 signaling 
pathway also appears to be a regulator of the IL-23/IL-17/IL-22 axis and disease 
development [22]. This finding is also reflected in a subtype of psoriasis called pustular 
psoriasis, in which a mutation in the IL-36 antagonist IL-36Ra has been frequently 
detected [23]. In contrast to T cell-mediated plaque psoriasis, the innate immune 
system plays a greater role in this subtype [24], including elevated levels of IL-1β, IL-
36α, and IL-36γ [25]. Nevertheless, patients with pustular psoriasis without IL-36R 
mutation show a response to anti-IL-17 treatments [26]. In conclusion, IL-17/IL-23 and 
IL-36 are major cytokines in psoriasis, while these cytokines can also cross-regulate 
each other [17]. 
The key transcription factors that have been identified in psoriasis include the STAT 
family and NF-κB and additionally, cyclic adenosine monophosphate (cAMP). In 
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agreement, elevated expression levels of activated STAT3 are detected in the 
epidermis of psoriatic lesions [27], while an epidermal overexpression of a 
constitutively active STAT3 mutant (STAT3C) leads to the development of psoriasis-
like skin lesions in mice [28]. Furthermore, genome-wide association studies (GWAS) 
identified genes of the JAK-STAT signaling pathway as psoriasis susceptibility loci: 
SNPs at rs744166 in STAT3 and rs10758669 in JAK2, rs367569 in suppressor of 
cytokine signaling 1 (SOCS1), rs34536443 in TYK2, which are involved in STAT-
mediated signaling [9, 29].  
Beside STAT3, lesional psoriatic skin was shown to contain elevated levels of active 
NF-κB compared to non-psoriatic skin [30, 31]. Additionally, GWAS demonstrated that 
several components or pathways, which are regulated by NF-κB, are up-regulated in 
psoriasis: innate immune responses involving TLR2 [32] and caspase-5 [33], apoptosis 
inhibitors such as Bcl-xL and cyclins [34], which lead to an increase of keratinocyte 
survival and epidermal hyperproliferation [35-37]; keratinocyte-derived chemokines, 
CCL20 and CCL27, which recruit DC and Th17 cells [38, 39], adhesion molecules (E‑
selectin, ICAM‑1, and VCAM‑1) to support leukocyte adhesion and migration [40]; and 
pro-inflammatory genes such as cytokines and chemokines in several cell types [41, 
42]. Moreover, CARD14, a member of the caspase recruiting domain family, 
represents the psoriasis susceptibility gene PSORS‑2 [43], which is sometimes found 
to be mutated in psoriasis. These mutations in CARD14 result in its hyperactivation 
leading to the onset of a Th17-mediated psoriasis-like skin disease in mice [44]. In 
detail, CARD14 forms a complex with Bcl10 and MALT1 to recruit downstream 
signaling components, leading to the activation of MAPK and NF-κB signaling [43]. 
Furthermore, CARD14, predominantly restricted to keratinocytes [44], is involved in 
the activation of pro-inflammatory cytokines and chemokines, including IL-36γ, IL-8, 
and CCL20 [45]. Further SNPs in the NF-κB signaling pathway were found for NFKB1 
(rs230526), NFKBIA (rs7152376), and NFKBIZ (rs3217713), which are associated with 
the development of psoriatic lesions [46]. 
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1.2 The NF-κB pathway 
The pleiotropic transcription factor NF-κB is involved in a variety of biological processes 
such as inflammation, immunity, cell proliferation, cell differentiation and apoptosis 
[47]. Consequently, beside its involvement in psoriasis, deregulated NF-κB activity is 
also frequently found in various other inflammatory diseases, such as rheumatoid 
arthritis, inflammatory bowel disease, multiple sclerosis, systemic lupus 
erythematosus, type I diabetes and asthma [48].  
NF-κB is a DNA-binding complex consisting of homo- and heterodimers of the Rel 
family, including: RelA (also named p65), RelB, p50 (also named NF-κB1), p52 (also 
named NF-κB2) and c-Rel, that bind with their Rel homology domain (RHD) to the κB 
binding motif 5´GGGPuNNPyPyCC-3´ [49] at the promoter region of their target genes 
upon stimulation [50]. The stimulus-dependent activation and regulation of NF-κB is 
closely linked to the nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor (IκB) cofactor family (Figure 2), which is characterized by ankyrin repeats [51]. 
IκB proteins can be divided into two subgroups: classical IκBs (e.g. IκBα, IκBβ, IκBε, 
p100 and p105), which are constitutively expressed in the cytoplasm, and so-called 
atypical IκBs (e.g. BCL3, IκBζ, IκBNS), which are mostly inducibly expressed and mainly 
localize to the nucleus.  
Figure 2: IκB family members (Created with BioRender.com). The IκB family can be subdivided in 
classical or cytoplasmic IκBs (IκBα, IκBβ and IκBε), the atypical or nuclear IκB (IκBζ, Bcl-3, IκBNS and 
IκBη) and the precursors which can act as inhibitors in the cytoplasm (p100 and p105). ARD - ankyrin 
repeat domain; DD - death domain; GRR - glycine-rich region; PEST – proline (P), glutamic acid (E), 
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serine (S) and threonine (T)-rich region; RHD - REL homology domain; TAD - transactivation domain. 
The figure was adapted from [52, 53]. 
 
In general, classical IκBs repress NF-κB activation by preventing its nuclear 
localization and DNA binding, whereas the atypical IκBs can act as activating or 
repressing co-factors of NF-κB-mediated target gene expression [47].  
The activation of NF-κB can be divided into a canonical and a noncanonical (or 
alternative) pathway. The activation of the noncanonical pathway is triggered by 
specific stimuli, such as the binding of LTβR, BAFFR, CD40 and RANK. Subsequently, 
NF-κB-inducing kinase (NIK) interacts and activates inhibitor of NF-κB kinase α (IKKα) 
to phosphorylate p100, which is the precursor of p52. The phosphorylation of p100 
triggers its own processing into mature p52, which translocates into the nucleus as a 
heterodimer complex with RelB. The canonical signaling pathway is activated upon 
stimulation of various receptors such as cytokine receptors (IL-1R), pattern-recognition 
receptors, (TLR), T-cell receptor and TNFR [54]. In unstimulated cells, NF-κB is 
inactive due to its interaction with the ankyrin repeat domains of classical IκBs, like 
IκBα, leading to a cytoplasmic localization and masking of the DNA binding domain 
[51]. Upon canonical activation of NF-κB, the IKK complex, consisting of IKKα, IKKβ 
and IKKγ (NEMO), phosphorylates IκBα at serine 32 [55]. Subsequently, 
phosphorylated IκBα gets polyubiquitinated and proteasomal degraded. Consequently 
NF-κB gets released and translocates into the nucleus to induce or to repress NF-κB 
target genes [56]. Of note, IκBα encoded by NFKBIA, is also transcriptionally induced 
by NF-κB. Newly synthesized IκBα therefore binds NF-κB again, masking the NLS and 
exports it back to the cytoplasm, thereby inactivating NF-κB [57]. Thus, activation of 
NF-κB and therefore induction of NF-κB-dependent target gene expression is 
oscillating and exists in multiple waves.  
NF-κB-dependent target genes can be divided into early or primary response genes 
and late or secondary response genes based on the accessibility of their promoter 
regions [58]. Primary response genes are rapidly activated, do not require any 
additional chromatin modifications and can be induced without de novo protein 
synthesis. In contrast, secondary response genes of NF-κB are activated more slowly 
and require de novo protein synthesis and nucleosome remodeling prior to their 
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induction [58]. In detail, nucleosome remodeling makes genomic DNA more accessible 
to transcription factor binding [59]. Lysine acetylation and methylation are the most 
common histone modifications that regulate transcription. Moreover, the SWI/SNF 
complex decondenses the chromatin at low CpG content or directly remodel the 
nucleosome and thus, increases the accessibility of the promoter [60, 61]. 
Furthermore, the SWI/SNF complex also cooperates with transcriptional coactivators 
of NF-κB, which comprise the nuclear IκB proteins such as IκBζ, IκBNS and BCL3 [62]. 
Histone acetyltransferase complexes (HATs), such as the CREB-binding protein 
(CBP)/p300 complex, acetylate histones to activate transcription such as the 
acetylation of p65 at lysine 310 [63], and histone deacetylases (HDACs) remove this 
residue [47]. However, lysine methylation can activate or repress transcription, this 
depends on the specific modified residue [64]. Moreover, in addition to nucleosome 
remodeling there are further ways to regulate the NF-κB-mediated gene expression, 
as for example by transcriptional coactivators, post-translational modifications [65] and 
proteasomal degradation [66].  
Post-translational modifications, such as phosphorylation, ubiquitination, acetylation, 
and methylation, control the nuclear translocation and influence the functions of NF-κB 
subunits including protein degradation, DNA binding, and transcriptional activity [67-
69]. This includes protein kinase A (PKA) or mitogen- and stress-activated protein 
kinase 1 and 2 (MSK1 and 2) mediated phosphorylation at serine 276 of p65 [70, 71], 
IKKα and IKKβ or casein kinase II (CKII) phosphorylation at serine 536 [63, 72, 73] and 
protein kinase C ζ (PKCζ)-dependent phosphorylation of p65 at serine 311 [74].  
 
1.3 The atypical IκB member IκBζ 
IκBζ, encoded by NFKBIZ on chromosome 3q12.3, constitutes an important cofactor 
for NF-κB target gene regulation, as already mentioned before [75]. IκBζ is highly 
conserved in a variety of species such as human, chimpanzee, rhesus monkey, dog, 
cow, mouse, rat, chicken and zebrafish [76]. In addition to a nuclear translocation 
signal (NLS) and transactivating domain (TAD), multiple ankyrin repeats characterize 
the structure of IκBζ, which mainly mediate the interaction with other proteins, such as 
the NF-κB subunits p50 or p52. Proven triggers of IκBζ expression comprise ligands of 
TLR 2, 4, 5, 7 and 9, such as peptidoglycan, flagellin, CpG oligonucleotides or 
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lipopolysaccharide (LPS). Moreover pro-inflammatory cytokines such as IL-1β via its 
receptor IL-1R and IL-17A via a heterodimeric IL-17R complex can induce IκBζ 
expression in different cell types [76]. Upon stimulation of TLRs or IL-1R, myeloid 
differentiation primary response 88 (MyD88) is activated and recruits the serine-
threonine kinases IL-1 receptor-associated kinase 1 and 4 (IRAK1 and 4) to induce 
autophosphorylation of both proteins [77]. Subsequently, phosphorylated IRAK1 
associates with TNF receptor-associated factor 6 (TRAF6), leading to activation of NF-
κB and mitogen-activated protein kinases (MAPK), which then trigger the expression 
IκBζ [78]. Beside a transcription-mediated induction of IκBζ, stabilization of its mRNA 
and post-translational modifications regulate the expression levels of IκBζ. For 
example, translation of NFKBIZ mRNA is regulated via a translation silencing element 
(TSE) at the 3`UTR, which is the target of RNA binding proteins such as monocyte 
chemotactic protein-induced protein 1 (MCPIP1)/Regnase-1. Consequently, binding of 
MCPIP1 via stem-loop structures at the 3`UTR of NFKBIZ results in the degradation 
and therefore suppression of IκBζ expression [79]. Interestingly, however, IL-17 
stimulation via the IL-17R complex triggers the degradation of MCPIP1, leading to an 
increase in NFKBIZ mRNA stability and translation into IκBζ protein. Thus, stimulation 
with TNFα and IL-17 is sufficient to induce IκBζ [53, 80]. 
How IκBζ regulates NF-κB target genes is not fully understood yet. NF-κB-dependent, 
primary response genes, such as Cxcl1 and Il23a, are not directly regulated by IκBζ, 
whereas the expression of a subset of secondary response genes, including Il12b, Il6, 
Ccl2 and Lcn2, is fully dependent on IκBζ expression [81, 82]. Interestingly, IκBζ can 
repress or activate NF-κB target genes, based on its interaction with different NF-κB 
homo- and heterodimers [82, 83]. A complex consisting of IκBζ- and a p50-p50 
homodimer can activate the expression of e.g. Ccl2 and Lcn2 in LPS- or IL-1-
stimulated macrophages [81, 82]. Vice versa, interaction of IκBζ with p65-p50 
heterodimers mostly results in suppression of gene expression through the recruitment 
of histone-deacetylating proteins (HDAC) [84]. Moreover, IκBζ can interact with p52 in 
ABC- diffuse large B-cell lymphoma (DLBCL) to mediate tumor cell survival [85], 
whereas interaction with STAT3 via its coiled-coiled domain seem to inhibit the DNA 
binding capability of STAT3 [86]. Furthermore, IκBζ cooperates with retinoic acid-
related orphan receptors α and γ (RORα and γ) to induce IL-17A expression inTh17 
cells [87].  
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Mechanistically, it has been shown that epigenetic modifiers are recruited by IκBζ to 
certain gene promoters that are characterized by a high content of CpG islands. 
Consequently, cofactors that are recruited by IκBζ, such as Tet2 or the SWI/SNF 
complex alter DNA methylation and remodel nucleosome composition, respectively, in 
order to make promoter regions assessable for transcription factors [62, 88]. Moreover, 
IκBζ can also co-localize with HDAC4 and HDAC5 in matrix-associated deacetylase 
nuclear bodies leading to deacetylation of p65 and therefore repression of target gene 
expression [84]. Additionally, IκBζ is involved in the regulation of histone 3 lysine 4 
trimethylation (H3K4me3) after nucleosome remodeling, which seems to be important 
for the regulation of gene expression [89]. 
Therefore, IκBζ-dependent target genes such as IL-17 in Crohn's disease [90] or LCN2 
in inflammatory bowel disease [91] represent key factors in various inflammatory and 
autoimmune diseases. Moreover, mutations in the NFKBIZ gene locus have been 
implicated in ulcerative colitis [92] and cancer [76]. 
 
1.4 IκBζ in psoriasis 
In psoriasis, a SNP (rs7637230) adjacent to the NFKBIZ gene locus was found to be 
overrepresented in psoriasis patients [93]. Furthermore, elevated mRNA levels of 
NFKBIZ could be detected in psoriatic skin lesions compared to non-lesional controls 
[94]. Therefore NFKBIZ/ IκBζ constitutes a risk gene for the development of psoriasis. 
In agreement, global IκBζ knockout mice are fully protected against experimental 
induced psoriasis-like skin inflammation induced by IMQ or IL-23 treatment. This might 
be due to the fact that IκBζ regulates the expression of IL-17A in Th17 cells, a key 
cytokine in psoriasis [87]. Alternatively, keratinocyte-derived IκBζ might also contribute 
to the development of psoriasis and its associated systemic inflammation, as it 
promotes the expression of psoriasis-associated chemokines and cytokines, leading 
to the recruitment of neutrophils and macrophages [95].  
Generally, global IκBζ-deficient mice develop severe skin irritations in the face, neck 
and periocular regions in adulthood [82]. Furthermore, global knockout leads to chronic 
inflammation of the submucosa due to massive infiltration of immune cells. This 
phenotype corresponds to a Sjögren syndrome-like inflammation of the eye [96]. 
Additionally, these mice are difficult to breed because of high embryonic lethality [97]. 
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What causes this autoinflammatory phenotype in these mice is under debate. In detail, 
a goblet cell disappearance [98] and autoreactive T cells, which attack the 
keratinocytes [99], are discussed. 
 
1.5 Project objectives 
IκBζ is known as a risk factor for psoriasis [46, 93]. Furthermore, global IκBζ knockout 
mice are completely protected against IMQ-induced psoriasis-like skin inflammation as 
opposed to a Tnfa- or Il17a-KO mice, which show only partial protection against IMQ-
mediated skin inflammation. Moreover, IκBζ levels remain elevated in Tnfa or Il17a-
KO mice [94], thereby suggesting alternative signaling pathways that promote IκBζ 
expression in psoriasis. Interestingly, IL-36α and IL-36γ, two cytokines of the IL-1 
family, are upregulated in psoriatic lesions. Moreover, it was shown before that IL-1b 
can also induced IκBζ expression in various cell types [82]. Furthermore, an 
inactivating mutation of IL36RN leads to the establishment of pustular psoriasis [23], 
whereas IL-36R KO mice are fully protected against IMQ-induced psoriasis [22]. 
Therefore, we hypothesized that IL-36, beside of IL-17 can induce IκBζ expression in 
psoriatic lesions, thereby promoting pro-inflammatory gene expression. Accordingly, it 
should be investigated whether IκBζ and IκBζ target genes are regulated under IL-36 
in keratinocytes. Following, the in vivo role of IκBζ in IL-36-driven psoriasis should be 
examined in more detail (Müller et al. 2018). Moreover, we revealed that keratinocyte-
derived IκBζ drives the onset of psoriasis and following, represents an attractive target 
for psoriasis therapy. However, IκBζ cannot be directly targeted, as it lacks any 
enzymatic activity [88]. Finally, a better understanding of the induction of IκBζ should 
find an inhibitor that prevents the expression of IκBζ (Müller et al. 2020).  
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2 Results & Discussion 
In previous studies, IκBζ was identified as a major mediator of IL-17A-mediated 
proinflammatory signaling in keratinocytes [94, 100]. Furthermore, pro-inflammatory 
signaling in keratinocytes is also triggered by IL-36 [101]. Our studies implicate that 
IκBζ bridges IL-36 or IL-17 signaling and psoriasis-associated inflammatory gene 
expression in keratinocytes, as the stimulation with both cytokines triggers similar IκBζ 
induction kinetics. Thus, we hypothesize that IκBζ represents a central player in the 
regulation of the pathogenesis of psoriasis and would be a new target of a small-
molecular inhibitor therapy for the global induction of inflammation. 
 
2.1 STAT3 and NF-κB mediate the induction of IκBζ in keratinocytes 
IκBζ occurs in two functional isoforms: the long IκBζ(L) variant (encoded by 14 exons) 
and the short IκBζ(S) variant, which is N-terminally truncated [76]. By analyzing 
published ChIPseq data [102], we identified that the two isoforms have different 
promoter regions with distinct transcriptional start sites (Figure 2, Müller et al. 2018). 
The isoforms are expressed differently in the respective cell types. Our RNAseq data 
identified the long isoform as the primary IκBζ isoform in keratinocytes. In previous 
analyses, only the promoter of the short isoform was considered [75, 80]. By analyzing 
the promoter region of the long isoform, we identified several putative binding sites for 
transcription factors including NF-κB, STAT3, CEBPβ, AP1, KLF4 and a shared 
binding site of STAT1 and STAT3 (Figure 2, Müller et al. 2018). Further analysis has 
shown that, in addition to NF-κB [84], also STAT3 transcriptionally induced IκBζ in IL-
36- and IL-17/TNFα-stimulated keratinocytes (Figure 2, Müller et al. 2018). This 
observation has already been validated in STAT3-depleted CD4-positive T cells, which 
lack inducible expression of IκBζ [87]. However, activation of the STAT3 signaling 
pathway alone does not seem to be sufficient to induce IκBζ because classical STAT3 
stimuli such as IL-6 or IL-22 do not induce IκBζ expression [87, 103]. This is also true 
for NF-κB-exclusive stimulations such as TNFα [76]. Consequently, these observations 
suggest that activation of IκBζ requires a cooperation between STAT3 and NF-κB, 
either directly on the chromatin, or by supporting the activation of each other.  
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A cooperation of STAT3 and NF-κB, especially the subunits p65 and p50, has already 
been revealed for a variety of target genes. These genes are mainly involved in anti-
apoptotic pathways, cell cycle control and proliferation, such as BCL3 and SOCS3, but 
also encode cytokines and chemokines like IL6 [104]. An example of the mutual 
activation is the link between unphosphorylated STAT3 and the NF-κB/IκBα complex 
upon IL-6 stimulation. This interaction displaces IκBα and thereby facilitates the 
nuclear translocation and activation of NF-κB [104]. As revealed by our ChIP data 
(Figure 2, Müller et al. 2018) it can be assumed that there is a direct interaction 
between NF-κB and STAT3 at the NFKBIZ promoter, which might result in the 
recruitment of additional transcription factors or co-factors. Grivennikov and Karin 
described an interaction of STAT3 with other transcription factors, such as androgen 
receptor and c-Jun, which may further modulate the STAT3-NF-κB interaction [104]. In 
contrast our experiments showed, that different MAPK inhibitors did not alter the 
expression of IκBζ (Suppl. Figure 2, Müller et al. 2018), indicating that STAT3 does not 
recruit transcription factors such as c-Jun to the promoter which might stabilize the 
complex with NF-κB and promote gene expression. 
Possible co-factors of STAT3 and NF-κB are HATs, such as p300, CBP and PCAF, or 
HDACs [105-107]. For example, p300 can acetylate p65 and increases its nuclear 
retention and transcriptional activity [104]. This results in the release of cytokines such 
as IL-6, which by itself activates STAT3 [108]. Additionally, histone acetylation is 
associated with an open chromatin structure to support gene expression. Generally, 
HDACs de-acetylate histones or non-histone targets such as STAT3 and NF-κB to 
repress their activity. For HDAC3, however, it was shown that de-acetylation at 
different NF-κB sites can also positively regulate pro-inflammatory gene expression 
[106]. It is thus tempting to speculate that co-factors may stabilize STAT3-NF-κB at the 
NFKBIZ promoter in order to induce IκBζ.  
Taken together, our experimental results indicate that STAT3 and NF-κB induce the 
IκBζ expression upon IL-36 and IL-17/TNFα stimulation in a cooperative and 
synergized manner. Therefore, it might be speculated that IκBζ is generally induced 
through NF-κB and STAT3, which are directly activated upon stimulation with cytokines 
or TLR ligands. This hypothesis is supported by the fact that both transcription factors 
are activated by different stimuli in various cell types e.g. by LPS in macrophages or 
through IL-1 in fibroblasts [80]. Other stimuli are TLR ligands such as poly(I:C) and 
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flagellin which activate both, STAT3 and NF-κB, and as a consequence induce IκBζ 
expression (Suppl. Figure 1, Müller et al. 2020).  
 
2.2 IκBζ regulates a subset of IL-36-dependent target genes in two waves 
As we identified the IL-36-mediated induction of IκBζ in keratinocytes, it was also of 
interest to identify the IL-36 response genes, which are regulated by IκBζ. By analyzing 
IL-36 responses in IκBζ knockdown keratinocytes, we could demonstrate that the IL-
36-mediated, IκBζ-dependent gene expression occurs in two waves – one 1.5 h and 
the other 24 h after stimulation (Figure 3, Müller et al. 2018). Noteworthy, IκBζ-
dependent gene expression seems to be highly conserved, as we found similar 
changes in the IκBζ-related proinflammatory target gene expression in keratinocytes 
e.g. DEFB4, CCL20, S100A9 and LCN2 upon different stimuli such as IL-36α, IL-36γ, 
IL-1β or IL-17A/TNFα (Figure 3/S4, Müller et al. 2018). 
The proinflammatory gene expression 24 h upon IL-36 stimulation has also been 
described in a variety of ways in keratinocytes [101]. Only about 10% of these genes 
are regulated by IκBζ, all genes that drive inflammation. This set of genes includes in 
particular genes encoding AMPs such as LCN2, S100A genes and DEFB4, which are 
upregulated after 24 h (Figure 3, Müller et al. 2018). These genes indirectly trigger the 
adaptive immune response by dendritic cells to recruit T cells as well as neutrophils 
and macrophages and ultimately activate them. Additionally, proinflammatory chemo- 
and cytokines such as CXCL8, IL23 and IL36G, potentiated the inflammation system 
at 24 h. Vice versa, little is known about the early response genes of the IL-36 mediated 
immune response (1.5 h). We found that in particular chemokines such as CXCL5 and 
CXCL6 are upregulated by IκBζ, which are supposed to respond to the innate immune 
response in order to recruit neutrophils and macrophages into the tissue and proceed 
the inflammation (Figure 3, Müller et al. 2018). Since the IκBζ-mediated gene response 
runs in two waves, it can be assumed that the regulation of the genes differs at the two 
time points. It needs to be clarified whether the two waves are interdependent. 
Following, it can be supposed that the AMP expression after 24 h could be driven 
indirectly by early IL-17C secretion, as already described for S100A and DEFB4 [109]. 
This would coincide with our data that keratinocytes expressed IL17C 1 h upon IL-36 
stimulation (Figure S3, Müller et al. 2018). In addition to the possible partial 
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dependence of the late response genes (24 h) on the early response genes (1.5 h), 
another major difference is the various regulatory mechanisms of the target genes. 
Remarkably, early effects of IL-36 stimulation on gene expression have not been 
investigated before in keratinocytes. We validated defined IL-36 target genes [101] and 
new IL-36-dependent genes (e.g. IL17C, CSF2, CSF3) that encode important 
psoriasis-promoting cytokines [110, 111]. 
The regulatory mechanism of IκBζ at the early point of gene expression (1.5 h) could 
be the direct interaction with transcription factors like NF-κB to activate or repress 
genes. For example, the interaction of IκBζ with p65-p50 heterodimers leads to the 
downregulation of genes like IL6 in monocytes; on the other hand, the interaction with 
p50 homodimers enhances gene expression such as DEFB4 in bronchial epithelial 
cells. Otherwise, IκBζ can also inhibit the DNA binding of STAT3 to regulate cell 
proliferation and apoptosis by interacting with STAT3 [76]. It should be noticed that 
many of the IL-36-mediated target genes are downregulated by IκBζ at the early time 
point (Figure 3, Müller et al. 2018). This could be a hint for repressive interactions of 
IκBζ with e.g. STAT3 or p65-p50 NF-κB heterodimers. 
Genes are also downregulated at the late expression point (24 h). For the repression 
of these genes, the recruitment of histone deacetylases (HDACs) to DNA would be 
possible. Interactions between IκBζ and HDAC4 and HDAC5 have already been 
shown, which lead to de-acetylation of p65 and therefore repression of target gene 
expression [84]. A subsequent HDAC1 interaction and thus limited target gene 
expression was also observed based on a specific phosphorylation of IκBζ [112]. This 
hypothesis can be supported by the fact that HDAC inhibitors are able to reduce 
proinflammatory gene expression in LPS-stimulated human peripheral blood 
mononuclear cells, and especially in keratinocytes to inhibit proinflammatory target 
genes such as IL6, IL20 and S100A9 [112, 113]. The overall role of HDACs in 
inflammation was demonstrated by HDAC3-lacking macrophages upon LPS treatment, 
which were unable to activate almost half of the inflammatory gene expression program 
[114]. Moreover, it was recently shown that IκBζ targeted Tet methyl-cytosine 
dioxygenase 2 (Tet2), which mediates DNA de-methylation. Tet2 in turn recruited 
HDAC2, which repressed Il6 expression by histone de-acetylation to resolve the 
inflammation [115]. This indicates that not only IκBζ regulates gene expression at later 
time points but possibly in a complex with other co-factors such as HDACs to modulate 
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the gene expression. Additionally, to histone modifications mediated e.g. by HDACs, 
general mechanisms like nucleosome remodeling are possible mechanisms for the 
second IκBζ-mediated gene response at 24 h. An IκBζ-dependent transcription-
enhancing H3K4 trimethylation at the CCL2 promoter has already been shown in 
macrophages [81]. In addition, chromatin remodeling factors e.g. the SWI/SNF 
complex may be recruited by IκBζ, which alter DNA methylation and remodel 
nucleosome composition to open the chromatin for transcription [59, 88]. In 
accordance, it was shown that Akirin2 bridges NF-κB and the chromatin remodeling 
SWI/SNF complex by interacting with IκBζ. These mechanisms drive the TLR-
mediated proinflammatory gene expression (Il6 and Il12b) in macrophages during the 
innate immune response to viral or bacterial infection [62]. Additionally, it was observed 
that the SWI/SNF complex is mainly required for the activation of secondary response 
genes (Il12b, Il6, and Nos2), and late primary response genes (Ccl5), but not for rapidly 
induced primary response genes (Cxcl2) in LPS-stimulated macrophages. 
Furthermore, the Mi-2β complex was selectively recruited in addition to the SWI/SNF 
complexes to temper the induction of these secondary response genes [116]. 
Consequently, IκBζ plays a crucial role in the early as well as in the late IL-36 or IL-
17/TNFα-mediated immune response, both as a direct mediator by interacting with e.g. 
NF-κB or STAT3, and as an indirect factor, which can adjust the gene expression by 
recruiting various factors such as nucleosome remodeling (SWI/SNF) and post-
translational modifications-mediating co-factors (HDACs). 
 
2.3 IL-36-mediated dermatitis: IκBζ function in vivo 
A common psoriasis mouse model is the topical application of imiquimod (IMQ), which 
triggers the IL‑23/Th17 immune axis. For this model, it has already been shown that a 
global IκBζ KO mouse is completely protected against a psoriasis-like skin disorder, 
whereas an Il17 KO mouse and a Tnf KO mouse show continuously weak effects in 
preventing disease. Furthermore, the mRNA levels of NFKBIZ in Il17 and Tnf KO mice 
are still upregulated [94]. Remarkably, IL-17 and TNFα play an essential role in 
psoriatic inflammation and drugs that target these cytokines have been used in the 
treatment of psoriasis for several years [117, 118]. This suggests that, in addition to 
the IL-17 pathway, there must be another factor that drives the IMQ-mediated 
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psoriasis-like skin disease and thus the pathogenesis of psoriasis. Moreover, it should 
be emphasized that IκBζ might act downstream from both pathways. Furthermore, it 
has already been described that a subtype of psoriasis, the pustular psoriasis, is driven 
by a genetic defect in the natural antagonist of the IL-36 signaling, IL-36Ra [10]. 
Accordingly, the phenotype of an Il36ra KO mouse is aggravated in an IMQ-mediated 
psoriasis-like skin disease, while IL-36 receptor-deficient mice (Il36r KO) were 
protected [22]. Noteworthy, Il36r KO mice showed stronger protection in the IMQ-
mediated psoriasis-like skin disorder than Il17a KO mice [22]. These data imply that, 
regardless of IL-17, IL-36 plays an essential role in the pathogenesis of psoriasis. In 
accordance, expression data from psoriasis patients validated upregulated NFKBIZ 
and IL36G levels in psoriatic lesions (Figure 4, Müller et al. 2018). The correlation of 
the expression of IL36G and NFKBIZ was even stronger compared to the correlation 
of the expression of IL17A with NFKBIZ.  
As already described, IMQ triggers the IL-23/IL-17 cytokine axis by activating TLR7/8 
primarily on APCs including DCs, monocytes/macrophages and B cells [119]. Thus, 
the induction of the pathogenesis of psoriasis is not based on keratinocytes and does 
not take place directly via a single cytokine such as IL-17 or IL-36. Consequently, to 
investigate the function of IκBζ of an IL-36-driven immune response in vivo, we 
established an IL-36 model with intradermal injection. The application of IL-36, like 
IMQ, led to a psoriasis-like skin disease that is completely IκBζ dependent, as the IκBζ 
KO mice data suggests (Figure 4, Müller et al. 2018). This data implicated that IκBζ is 
both the driver of the IL-17- and IL-36-mediated gene response in psoriasis. 
Furthermore, the involvement of IκBζ in both pathways suggests that IκBζ is an 
interesting target/factor for various subtypes of psoriasis e.g. pustular psoriasis and 
psoriasis vulgaris, thus the inhibition of IκBζ might be a possible approach for a global 
therapy. 
Following this hypothesis, it is also possible that IκBζ plays a role in other IL-36- or IL-
17-driven diseases. For example, it has already been shown that IL-36 plays a driving 
role in the clearance of Candida albicans or Staphylococcus aureus infections or the 
pathogenesis of atopic dermatitis [120, 121]. In addition, IκBζ can also act as an 
important co-factor for the expression of proinflammatory genes in the regulation of 
fungal and bacterial infections [112]. Thus, IκBζ might play a global role in the context 
of an IL-36/IL-17-mediated gene expression in various diseases. 
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2.4 Targeting IκBζ in keratinocytes as a new therapy approach for psoriasis  
As we identified IκBζ as attractive psoriasis target downstream of IL-36 and 
IL-17/TNFα, we screened for potential inhibitors. Since IκBζ has no enzymatic activity, 
it is difficult to find or design an inhibitor directly targeting IκBζ [88]. However, we have 
already shown that IκBζ is regulated transcriptionally below IL-36 and IL-17 (Suppl. 
Figure 1, Müller et al. 2018), thus inhibition of IκBζ expression using small molecule 
inhibitors that target the induction pathway can be implemented. Since NF-κB and 
STAT3 are known to regulate the expression of IκBζ (Figure 2, Müller et al. 2018), 
common co-factors of these transcription factors could be possible targets for the 
inhibitors. However, not all co-factor inhibitors are useful. For example, the specificity 
of p300 or HDAC inhibitors is not sufficient, as they would not only inhibit the induction 
of IκBζ, but also any gene expression. Moreover, they are too toxic [122]. Interestingly, 
we found that CDK4/6 and EZH2 inhibitors regulate the induction of IκBζ by regulating 
STAT3 activity (Figure 3, Müller et al. 2020). 
CDK4/6, which belong to the serine/threonine kinase protein family, are traditionally 
necessary for the transition from G1 to S phase of the cell cycle. Upon activation of 
CDK4/6 through their D-type cyclins and CDK activating kinase (CAK), they are able 
to regulate transcription, differentiation or apoptosis by specifically phosphorylating 
proteins including the retinoblastoma (RB) signaling pathway, which regulates the E2F 
activity of the cell cycle [123, 124]. However, our data implicated that CDK4/6 acts in 
a cell-cycle-independent manner, as RB KO had no impact on IκBζ induction and IκBζ 
is induced in all cell cycle stages (Suppl. Figure 1, Müller et al. 2020). As a 
consequence, CDK4/6 does not only seem to play a role in the cell cycle. This has 
already been shown for proinflammatory gene expression by the direct association and 
regulation of proinflammatory transcription factors such as NF-κB, STAT3 and AP1 
[125]. In detail, CDK4/6 is able to modulate transcription factors in a kinase-dependent 
and -independent manner [126-128]. Especially the interaction of CDK6 and p65, a 
subunit of NF-κB, in human tumors was observed to upregulate NF-κB target gene 
expression which can contribute to chronic inflammation and neoplasia [125, 126]. 
Moreover, it was shown that CDK6 can be recruited to distinct chromatin regions of 
inflammatory genes upon IL-1 stimulation [125]. We propose that IL-36, which belongs 
to the IL-1 family, can also activate CDK6. In accordance, we observed a direct 
interaction of CDK4/6 with STAT3 upon IL-36 treatment (Figure 3, Müller et al. 2020), 
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which is chromatin-bound (Figure 4, Müller et al. 2020). The complex of STAT3 and 
CDK6 was previously detected at the INK4a promoter (inducible CDK4/6 inhibitor of 
the cell cycle) as autoregulatory feedback loop to limit the growth or proliferation [129]. 
In addition to the interaction of STAT3 and CDK6, the presence of EZH2 in this 
complex was also demonstrated (Figure 4, Müller et al. 2020). Furthermore, a 
correlation of EZH2 and CDK6 was shown to regulate angiogenesis in melanoma 
[130]. EZH2 as a part of the polycomb repressive complex 2 (PRC2) generally 
catalyzes the methylation of H3K27 which is a transcriptionally repressive mark by 
chromatin condensation and following, suppression of gene expression [131-133]. 
Gene silencing is associated with increased cell proliferation and survival, as well as 
decreased senescence and differentiation [134, 135]. It was shown that EZH2 is 
frequently mutated or deregulated in various malignancies, including various cancer 
[136-138]. Moreover, EZH2 also plays an important role in differentiation of 
keratinocytes by repressing Ink4A and Ink4B expression and preventing the 
recruitment of the transcription factor AP1 to structural genes of epidermal 
differentiation [139]. Hence it is not surprising that EZH2 is upregulated in lesions of 
psoriasis patients (Figure 5, Müller et al. 2020), as EZH2 has already been identified 
as a mediator of inflammation in inflammatory bowel disease [140]. 
In conclusion, CDK4/6 and EZH2 seem to act independently in inflammation in addition 
to their classically described roles. Moreover, there are first indications that EZH2 and 
the CDK4/6 pathway can interact with each other [139].   
 
2.5 Initiation of the CDK4/6-EZH2-STAT3 pathway 
As described above, CDK4/6 and EZH2 regulated the expression of IκBζ in 
keratinocytes upon IL-36 or IL-17/TNFα treatment. This arised the question how this 
pathway, especially CDK4/6, is activated. 
With regard to the activation of CDK4/6, we were able to confirm the classical activation 
via the associated D-cyclins. However, not all cyclin D proteins contribute to the 
activation of IκBζ. We found that cyclin D1 seem to repress CDK4/6-STAT3-mediated 
NFKBIZ promoter activation, whereas cyclin D2 and D3 promoted its activation by 
CDK4/6 and STAT3 (Suppl. Figure 2, Müller et al. 2020). The repressive role of cyclin 
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D1 has already been shown combined with STAT3 activation as a part of feedback 
network controlling of STAT3 activity. In detail, cyclin D1 is associated with the 
activation domain of STAT3 upon IL-6 stimulation and reduced the STAT3 nuclear 
level [141]. In addition, the cyclin D1 levels in psoriatic lesions are down-regulated 
(Figure 5, Müller et al. 2018), which indicates the lack of a repressive pathway in terms 
of IκBζ induction. In contrast, the cyclin D2 and D3 level are increased in psoriatic 
lesions (Figure 5, Müller et al. 2018). Consistent with this, a functional difference 
between cyclin D1 and D2 was observed in the regulation of RB [142]. This underlines 
the diversity of the individual D-type cyclins [143]. Only 52–64% of the sequence 
between cyclin D1, D2 and D3 is conserved [144]. Additionally, the individual D-type 
cyclins have been shown tissue-specific expression levels like the specific dependence 
of embryonal retina and breast epithelia on cyclin D1 or the unique function of cyclin 
D3 in lymphocyte development [145-147]. For D-type cyclins it is known that their 
expression is regulated by NF-κB [148, 149]. In accordance, we detected the binding 
of the NF-κB subunit p65 to the promoter regions of CCND2 and CCND3 upon 
stimulation of primary keratinocytes. We were also able to determine a p65-dependent 
gene expression of the D-type cyclins at early timepoints upon stimulation (Suppl. 
Figure 2, Müller et al. 2020). This rapid activation of p65 could already be associated 
with pre-bound transcription factors and/or epigenetic marks, which enable the specific 
recruitment of p65 [150]. In addition to NF-κB, other transcription factors could be 
involved in the induction of D-type cyclins in a stimulus- and cell type-specific manner, 
such as STAT3, AP1 and NFAT [151-153]. For example, STAT3 enhanced CCND2 
expression in colorectal cancer [154].  
Conclusively, D-type cyclins seem to act as an adjusting screw for the CDK4/6-
mediated signaling, as cyclin D1 has a negative and cyclin D2 and D3 have a positive 
effect on the induction of IκBζ and finally on the IκBζ-mediated gene expression, which 
leads to the establishment of psoriasis. Figure 3 summarizes our present working 
thesis for activation of CDK4/6 upon IL-36 or IL-17/TNFα treatment.  
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2.6 Does CDK4/6 regulate PRC2-independent functions of EZH2? 
EZH2 classically acts in a complex with the PRC2 components EED and Suz12 to 
mediate H3K27 trimethylation and therefore gene repression [131-133]. Interestingly, 
we showed that CDK4/6 phosphorylation of EZH2 at T345 leads to a non-classical 
EZH2-dependent methylation of STAT3 and therefore its activation (Figure 3/4, Müller 
et al. 2020). It was remarkable, that the PRC2-independent, non-classical function of 
EZH2 was found to induce gene expression by interacting with β-catenin or the 
SWI/SNF complex [155, 156]. In the PRC2 complex, EED classically serves as a 
bridging factor between histone H3 and EZH2. As a consequence, this linker (EED) is 
missing, histone-mediated methylation is no longer possible. Therefore, the question 
arises, if EED and Suz12 are needed for EZH2-mediated methylation of STAT3 in 
keratinocytes, or did the CDK4/6-dependent phosphorylation of EZH2 lead to the 
abrogation of EZH2 and EED/Suz12 interaction? It has already been shown that EZH2 
can be phosphorylated by CDK1/2 at the CDK phosphorylation sites threonine 345 
(T345) and T487 to modulate its function. The CDK1/2-mediated EZH2 
phosphorylation results in the de-stabilization of the PRC2 complex at target gene 
promoters, following of epigenetic silencing of genes at G2 phase [157, 158]. However, 
we examined both sites and identified T345 as essential for the interaction with STAT3, 
Figure 3: NF-κB regulates CDK4/6 activity (Created with BioRender.com). The binding of IL-36 or IL-
17 activates the NF-κB signaling pathway to rapidly induce the CCND2 and CCND3 gene expression. 
The upregulation of the cyclin D2 and D3 expression activates CDK4/6 in a cyclin D-dependent manner.   
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since an EZH2 mutant lacking the CDK4/6-directed phosphorylation site is unable to 
induce IκBζ via STAT3 methylation (Figure 3, Müller et al. 2020). Interestingly, previous 
reports have already been shown that in glioblastoma cells EZH2-directed methylation 
of STAT3 at lysine 180 (K180) is triggered by an Akt-dependent phosphorylation of 
EZH2 at serine 21, leading to the abrogation of EZH2 and EED interaction. Thus, it 
would be possible that the PRC2 complex is dissolved under our conditions in order to 
methylate STAT3 by EZH2. Additionally, we observed that the EZH2-mediated 
methylation of STAT3 leads to an increased STAT3 activity, which is triggered by the 
phosphorylation at tyrosine 705 (Y705) (Figure 3/4, Müller et al. 2020). This non-
classical activation of STAT3 by EZH2 was already described in glioblastoma stem-
like cells [159].  
Finally, phosphorylation of EZH2 might induce a switch in EZH2 function from classical 
function of H3K27 methylation and following transcriptional repression to non-
canonical functions, including STAT3 methylation and gene activation. Therefore, we 
hypothesize that CDK4/6 phosphorylation might induce similar effects in keratinocytes. 
However, it remains open, why EZH2 needs to get phosphorylated at different sites 
(T345 or T487) leading to similar effects. One explanation could be that the CDK4/6-
mediated phosphorylation of EZH2 does not only abrogate its interaction with EED, 
while inducing its interaction with STAT3. Moreover, this might trigger an EZH2-
mediated recruitment of other epigenetic modulators to STAT3 such as HDACs to de-
acetylate STAT3. Corresponding, it was found that inhibition of HDAC activity 
enhanced p300-mediated STAT3 acetylation and supported nuclear export of STAT3 
in B cell lymphoma. Furthermore, HDAC inhibition abolished phosphorylation of STAT3 
at Y705 [105]. Especially with regard to the phosphorylation of STAT3 at Y705, it would 
be possible that HDACs in this pathway contribute to the stabilization of STAT3 in the 
nucleus. 
In summary, there appears to be a functional switch in EZH2 triggered by its 
phosphorylation, which leads either to the methylation of transcription factors 
(phosphorylated EZH2) or to its classical function of histone modification (non-
phosphorylated EZH2). Whether this function is also PCR2-independent requires 
further investigation. 
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2.7 CDK4/6- or EZH2-mediated inhibition of pSTAT3 at Y705 
We could show that inhibitors against CDK4/6 and EZH2, as well as a knockdown of 
the respective genes, reduced not only the methylation of STAT3 at K180 but also the 
phosphorylation of STAT3 at Y705 (Figure 3/4, Müller et al. 2020). These data are 
indicative to a previous report describing that methylation of STAT3 at K180 enhances 
Y705-phosphorylation by protecting STAT3 from de-phosphorylation [159]. 
Furthermore, it seems that CDK4/6 and EZH2 do not only regulate the methylation of 
STAT3, but also alter phosphorylation of STAT3 at Y705 in a K180-methylation-
independent manner. Nevertheless, how does inhibition of CDK4/6 and EZH2 
abrogate the phosphorylation of STAT3 at Y705? STAT3 phosphorylation at this 
position is traditionally mediated by the JAK family. Interestingly, activation of all JAKs 
– JAK1, JAK2, JAK3 and TYK2 – have been implicated in stimulated keratinocytes 
before [160]. JAKs are induced by type I and type II cytokine receptors. The type I 
cytokine receptor superfamily contains the common γ chain (γc) which recognizes IL-
2, IL-4, IL-7, IL-9, and IL-15 via JAK1/JAK3 heterodimers [161]. Further cytokines like 
IL-3 and IL-6 are recognized by type I cytokine receptors acting through JAK1/JAK2 
heterodimers or JAK2 homodimers. The type II cytokine receptor family is activated by 
interferons (IFNs) and IL-10 utilizing heterodimers of JAK1/JAK2 or JAK1/TYK2 [162]. 
Which JAKs are activated in IL-36- or IL-17/TNFα-treated keratinocytes is not clear 
yet. Moreover, as IL-36 or IL-17/TNFα do not directly activate the type I or type II 
cytokine receptors, stimulation with these cytokines needs to trigger an auto-secretion 
of other JAK-activating cytokines.  
Since our experiments were carried out exclusively in keratinocytes, it can be assumed 
that it affects cytokines that are secreted in an autocrine manner. It has already been 
shown that keratinocytes constitutively express IL-15 [163] and IL-7 [164], which can 
be recognized by JAKs. Our RNAseq data (Table S1-2, Müller et al. 2018) included 
deregulation of IL7 upon IL-36 stimulation in an IκBζ-dependent manner. Accordingly, 
it would be possible for CDK4/6-EZH2 to regulate the expression of IL-7 and IL-15. In 
agreement, increased and accelerated expression levels of IL-15R were detected in 
EZH2-inhibited NKp cells [165]. However, as IκBζ is expressed after just 1 hour of 
stimulation, it is unlikely that cytokines will be generated and further secreted to 
activate STAT3 in an autocrine loop. As an alternative it is possible that pre-
synthesized cytokines are stored in Golgi vesicles, which are released upon 
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stimulation. This “pre-stored” cytokines can activate STAT3 signaling and then mediate 
IκBζ expression in an autocrine loop. This mechanism is similar to the release of 
inflammatory compounds from secretory granules in mast cells [166]. Moreover it was 
shown for IL-6 in skin and other tissues that there is a release of pre-stored cytokines 
in systemic inflammatory response syndrome [167]. There is also an evidence of 
STAT3 activation with non-classical stimulants e.g. by IL-1β in IL6 KO MEF cells [167]. 
This supports the previous hypothesis that STAT3 can be induced indirectly by IL-36 
via pre-stored cytokines such as keratinocyte-derived IL-7 and IL-15, as a parallel 
pathway to the CDK4/6-EZH2 axis in order to activate IκBζ and its target genes in 
keratinocytes.  
 
2.8 Prevention of psoriasis and therapeutic application of novel inhibitors 
Some psoriatic studies provide indications for the pathological regulation/expression 
of IκBζ and herein involved pathways. These include that IκBζ has already been 
identified as the driver of inflammation in murine psoriasis model [94]. Furthermore, 
increased NFKBIZ levels have been detected in human psoriatic lesions [95] (Figure 
S5, Müller et al. 2018). In addition, we showed an increased nuclear accumulation of 
EZH2 and elevated cyclin D2 and D3 levels in mouse models of psoriasis (IMQ and IL-
36 intradermal injection) and in human psoriatic skin lesions (Figure 5, Müller et al. 
2020). Moreover, STAT3 mutations are risk factors for the development of psoriasis 
[168] and constitutively active STAT3 was detected in the epidermis of human psoriatic 
lesions [169]. Finally, this collection suggests that the CDK4/6-EZH2-STAT3 pathway 
is hyperactive in psoriatic skin lesions, especially in keratinocytes. Consequently, the 
CDK4/6 inhibitors, abemaciclib and palbociclib, and the EZH2 inhibitor block IL-36- and 
IL-17/TNFα-mediated induction of IκBζ including psoriasis-related genes (Figure 1/3 
and Suppl. Figure 1/3, Müller et al. 2020) and following the whole development of 
psoriasis (Figure 6/7, Müller et al. 2020). The advantage here is the high specificity of 
the inflammatory pathway and the early block in the initiation process of the 
pathogenesis of psoriasis in keratinocytes. 
In contrast, the common forms of therapy such as anti-IL-23 or anti-IL-17 antibodies or 
currently in clinical testing anti-IL-36 antibodies, are directed only against one arm of 
the inflammation and not against the origin of the pathogenesis. Not to mention, 
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psoriasis contains various subtypes that are associated with certain expression 
patterns or mutations, for example, in contrast to psoriasis vulgaris, pustular psoriasis 
is strongly characterized by an imbalance in IL-36 signaling [120]. Accordingly, 
neutralizing antibody therapy that can be used for all subtypes of psoriasis is rather 
ineffective. Supporting this statement, some of the biologics such as anti-TNFα 
antibodies show no effect in the treatment of patients with pustular psoriasis [170]. In 
addition, IL-17 or IL-36 can cross-regulate each other [171], which cannot be prevented 
with monotherapy. It is therefore important to find a therapy that targets the origin of 
the psoriatic inflammation. 
Further clinical tests are carried out with a pan-JAK1/3 inhibitor (tofacitinib), which 
diminished overactive STAT3 signaling in psoriatic lesions [172] and thus for the first 
time does not block a specific cytokine but an entire pathway. In detail, 
pharmacological inhibition of STAT3 ameliorated psoriasis-like skin lesions in mice 
[169, 173]. Furthermore, STAT3 is instrumentally involved in Th17 cell differentiation, 
activation, proliferation, and survival through the regulation of key genes such as 
RORγT, RORα, BATF, IRF4, AHR, IL-6Rα, and C-MAF, as well as in direct IL-17A and 
IL-17F expression. Vice versa, an overexpression of constitutively active STAT3 
upregulates the number of IL-17 producing cells [168]. Nevertheless, a complete block 
of the STAT3 pathway is not advisable due to its involvement in the proliferation, 
proinflammatory gene expression, activation and survival of cells as it is the case with 
treatment of tofacitinib. Moreover side effects of tofacitinib like an increased risk of 
infection, particularly viral (herpetic) infections, elevated level of low-density and high-
density lipoprotein (LDL and HDL), and anemia have already been identified upon oral 
application [174]. 
However, we were able to show that the new (discovered) pro-inflammatory CDK4/6-
EZH2 pathway only works specifically below IL-36 or IL-17/TNFα and that pro-survival 
functions from STAT3 to IL-6 remain intact (Suppl. Figure 4, Müller et al. 2020). 
Furthermore, our results suggest that all main characteristics of psoriasis are 
suppressed: immune cell recruitment, skin inflammation and additionally the cytokine-
mediated induction of IκBζ and pro-inflammatory target gene expression (Figure 6/7, 
Müller et al. 2020). We thus provide a specific target for inflammation in psoriasis, 
where functions like activation and survival are not affected. A welcome side effect of 
a topical application in psoriasis is the proliferation block of  keratinocytes by a CDK4/6 
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inhibitor [175]. Beside the cell cycle control, it was found that CDK4/6 also regulates 
immune cell differentiation and function [176-178]. 
The advantage of the described pathway and the used inhibitors is the high specificity, 
for example, EZH2 is not expressed in normal skin [139]. Furthermore, a topical 
application almost exclusively addresses keratinocytes, which are regarded as one of 
the key players in psoriasis in addition to T cells [179]. In general, the ATP-competitive 
CDK4/6 inhibitors, such as palbociclib, ribociclib or abemaciclib, are already widely 
used in cancer therapy, especially in breast and lung cancer [180], and therefore 
already tested for their effectiveness and side effects. In this context, CDK4/6 have 
been implicated as transcriptional co-factors that activate a subset of NF-κB or STAT3 
target genes [126-128]. Moreover, it was shown that they block the keratinocyte 
hyperproliferation [175]. Thus, an inhibition of EZH2 by small molecular inhibitors to 
diminished trimethylation of H3K27 and upregulation of the silenced transcription, is 
another promising therapeutic approach. As a result, cancer cell growth and tumor 
formation is reduced in EZH2 inhibitor-treated patients with B-cell lymphomas and 
advanced solid tumor [181]. The use of both inhibitors has already been tested for 
various diseases.  
Furthermore, the mode of application is another important point. For example, 
tofacitinib (pan-JAK inhibitor) is administered orally and therefore acts systemically and 
not only locally on the skin. Side effects that are toxic to the liver and kidneys have 
already been identified [168]. Local application, such as topical administration, which 
showed efficacies in our mouse models (Figure 6/7, Müller et al. 2020), would be 
advantageous and would prevent systemic toxicity. Furthermore, topical treatment 
using a cream would no longer require a doctor's visit, like in the case of anti-IL-23 or 
anti-IL-17 therapy, which are administered by intradermal injections. In addition, the 
production costs of monoclonal antibodies for human therapy are very expensive [168]. 
Thus, small molecule drugs such as palbociclib and abemaciclib (CDK4/6 inhibitors) 
have lower costs, and a reduced risk of eliciting adverse immune responses in topical 
application. In addition, neutralizing antibody therapy show rising resistance by anti-
drug antibodies, which diminished the clinical responses over the duration of treatment. 
This phenomenon is not uncommon in psoriasis patients, e.g. infliximab (anti-TNFα 
antibodies) up to 43.6%, adalimumab (anti-TNFα antibodies) up to 44.8% or 
ustekinumab (anti-IL-12/IL-23 antibodies) up to 5.4% [182].  
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Next to psoriasis, this pathway could play a role in other inflammatory diseases or 
autoimmune diseases in which elevated NFKBIZ levels can be detected, such as 
ulcerative colitis [92] and multiple sclerosis [87]. 
 
2.9 Working model: IκBζ induction in psoriasis 
 
Figure 4: CDK4/6-EZH2-STAT3 signaling pathway to induce IκBζ and following psoriasis (Created 
with BioRender.com). The IL-36- or IL-17-mediated activation of CDK4/6 via cyclin D2 and D3 leads to 
the phosphorylation of EZH2 at T345, which in turn methylate STAT3 at K180. This methylation leads 
to the stabilization and further activation of STAT3 (phosphorylation at Y705) whereby STAT3 
translocate into the nucleus and induce IκBζ expression. IκBζ and its target genes are the main driver 
of the pathogenesis of psoriasis including the proinflammatory gene expression, the hyperproliferation 
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of keratinocytes and the migration of immune cells to the inflammation site. The small-molecule inhibitors 
for CDK4/6 (abemaciclib and palbociclib) and EZH2 (CPI-169 and EPZ6438) can inhibit this specific 
proinflammatory pathway to block the induction of IκBζ in keratinocytes and further the onset of 
psoriasis. 
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Proinflammatory cytokine signaling in keratinocytes plays a crucial
role in the pathogenesis of psoriasis, a skin disease characterized
by hyperproliferation and abnormal differentiation of keratino-
cytes and infiltration of inflammatory cells. Although IL-17A and
TNFα are effective therapeutic targets in psoriasis, IL-36 has re-
cently emerged as a proinflammatory cytokine. However, little is
known about IL-36 signaling and its downstream transcriptional
responses. Here, we found that exposure of keratinocytes to IL-36
induced the expression of IκBζ, an atypical IκB member and a
specific transcriptional regulator of selective NF-κB target genes.
Induction of IκBζ by IL-36 was mediated by NF-κB and STAT3. In
agreement, IL-36–mediated induction of IκBζ was found to be re-
quired for the expression of various psoriasis-related genes in-
volved in inflammatory signaling, neutrophil chemotaxis, and
leukocyte activation. Importantly, IκBζ-knockout mice were pro-
tected against IL-36–mediated dermatitis, accompanied by reduced
proinflammatory gene expression, decreased immune cell infiltra-
tion, and a lack of keratinocyte hyperproliferation. Moreover, ex-
pression of IκBζ mRNA was highly up-regulated in biopsies of
psoriasis patients where it coincided with IL36G levels. Thus our
results uncover an important role for IκBζ in IL-36 signaling and
validate IκBζ as an attractive target for psoriasis therapy.
NFKBIZ | IκBζ | IL-36 | keratinocytes | psoriasis
Transcription factor NF-κB has been implicated in severalinflammatory diseases, including psoriasis, by activating var-
ious proinflammatory target genes (1). The classical activation of
NF-κB is controlled by cytoplasmic inhibitory proteins, such as
IκBα, which sequester NF-κB in the cytoplasm (2). Inflammatory
stimulation of cells results in the rapid activation of IκB kinase
(IKK), which triggers the phosphorylation-induced degradation
of IκBα, leading to NF-κB’s nuclear translocation and tran-
scriptional activation. Recent evidence, however, suggests that
the activation of NF-κB target genes is more complex and is
dependent on the particular gene context or stimulus, which is
thought to facilitate selective gene regulation in distinct physio-
logical settings (3). Whereas the rapid activation of primary re-
sponse genes is directly induced by the classical NF-κB pathway,
expression of so-called “secondary-response genes” requires prior
protein synthesis of additional NF-κB regulators (4). In this
context, we and others have identified IκBζ, an atypical nuclear
IκB protein, which functions not only as a repressor but, more
importantly, also as an activator of a selective subset of NF-κB
target genes (5–8). The mechanisms of this differential gene
regulation by IκBζ remain largely unknown, but increasing evi-
dence suggests that the transcriptional activity of IκBζ is mainly
mediated at the level of chromatin remodeling (6, 9, 10).
In keratinocytes (KCs), IL-17A and, more potently, its com-
bination with TNFα induce IκBζ expression (11). Subsequently,
IκBζ mediates the induction of important psoriasis-related gene
products, including chemokines (e.g., CXCL8 and CCL20), cy-
tokines (e.g., IL22 and IL17C), and antimicrobial proteins, such
as S100 calcium-binding proteins (e.g., S100A9), β-defensin-2
(DEFB4A), or lipocalin-2 (LCN2). Antagonists of TNFα and IL-
17A have therefore been approved for the treatment of psoriasis
(12). Moreover, NFKBIZ, the gene encoding IκBζ, has been iden-
tified as a psoriasis-susceptibility locus (13). Global Nfkbiz-KO mice
are resistant to imiquimod (IMQ)- or IL-23–induced psoriasis-like
skin inflammation (11). In contrast, Tnfa- or Il17a-KO mice,
which are only partially protected against IMQ-induced psoria-
sis, still show elevated IκBζ mRNA levels in inflamed skin areas
(11). These observations imply an additional IL-17A/TNFα–
independent pathway which drives IκBζ expression and thereby
contributes to inflammatory gene expression in psoriasis.
Recently, IL-36 cytokines have received attention as thera-
peutic targets for psoriasis (14). This subfamily of IL-1–related
cytokines consists of three proinflammatory members, IL-36α
(encoded by IL1F6/IL36A), IL-36β (encoded by IL1F8/IL36B),
and IL-36γ (encoded by IL1F9/IL36G) (15–17). All family
members bind to a common heterodimeric receptor, composed
of IL-36R (also termed “IL-1RL2”) and IL-1RAcP, leading to
the recruitment of the adapter MyD88 and subsequent activation
of NF-κB and MAPK (18). A fourth IL-36 member, IL-36RN,
acts as a natural antagonist of IL-36 signaling, as it binds to
IL-36R but does not recruit the coreceptor IL-1RAcP (19, 20).
Significance
Psoriasis is an autoinflammatory disease characterized by
cytokine-driven keratinocyte proliferation and infiltration of
immune cells. While IL-17A and TNFα are established targets in
psoriasis therapy, IL-36 is emerging as an important cytokine in
this disease. The mechanisms of IL-36–driven proinflammatory
responses are largely unknown. Here we identified IκBζ, a
transcriptional regulator of selective NF-κB target genes, as a
crucial mediator of IL-36 action. In keratinocytes, IκBζ was re-
quired for the expression of several psoriasis-related cytokines
and chemokines. Moreover, genetic deletion of IκBζ prevented
IL-36–mediated dermatitis induction in mice. Since IκBζ is es-
sential not only for IL-36 but also for IL-17 signaling, our results
suggest that inhibition of IκBζ function could be a future
strategy in psoriasis therapy.
Author contributions: K.S.-O., S.H., and D.K. designed research; A.M., A.H., S.L., P.G., and
D.K. performed research; A.M., A.H., S.L., and D.K. analyzed data; and K.S.-O., S.H., and
D.K. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. S.G. is a guest editor invited by the
Editorial Board.
This open access article is distributed under Creative Commons Attribution-NonCommercial-
NoDerivatives License 4.0 (CC BY-NC-ND).
Data deposition: RNA-sequencing data have been deposited in the National Center for
Biotechnology Information BioProject database (ID PRJNA465504; Sequence Read Archive
accession no. SRP144926).
1To whom correspondence should be addressed. Email: daniela.kramer@uni-tuebingen.de.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1801377115/-/DCSupplemental.
Published online September 17, 2018.
10088–10093 | PNAS | October 2, 2018 | vol. 115 | no. 40 www.pnas.org/cgi/doi/10.1073/pnas.1801377115
D
ow
nl
oa
de
d 
at
 U
ni
ve
rs
ita
et
 T
ue
bi
ng
en
 o
n 
A
ug
us
t 1
9,
 2
02
0 
Importantly, while full-length IL-36 proteins seem to be biolog-
ically inactive, activation of IL-36 signaling requires their
N-terminal proteolytic processing (19, 21).
IL-36 contributes to skin inflammation by acting on KCs and
immune cells. Interestingly, IL-36 can induce a subset of proin-
flammatory target genes similar to those induced by IL-17A in
KCs, including CXCL8, IL23A, DEFB4, or LCN2 (22–24). Vice
versa, IL-17, which is typically expressed by immune cells, in-
duces IL-36γ expression in KCs (25, 26). Therefore, IL-36 ap-
pears to have a central position in the interplay between immune
cells and KCs. In patients with psoriasis vulgaris, IL-36α and
IL-36γ are overexpressed, whereas inactivating mutations of
IL36RN are enriched in a psoriasis subtype, called “generalized
pustular psoriasis” (22, 23, 27, 28). In agreement, mice over-
expressing IL-36α in basal KCs exert skin inflammation at 3 wk
of age, which is augmented in an IL36RN-deficient background
(20, 29). In contrast, mice deficient for the IL-36R are fully
protected against IMQ-induced psoriasis (30).
Despite its involvement in psoriasis, little is known about IL-36
signaling and its transcriptional responses. In the present study,
we found that IL-36α and IL-36γ are potent inducers of IκBζ
expression. Moreover, we identified MyD88, NF-κB and STAT3
as crucial components for IL-36–induced IκBζ expression. Si-
lencing of IκBζ in primary human KCs prevented IL-36–
mediated up-regulation of multiple psoriasis-associated genes,
while a global knockout of IκBζ protected against IL-36–
mediated psoriasis-like dermatitis in mice. These results and
our finding of a strong correlation of NFKBIZ and IL36G ex-
pression in psoriatic lesions uncover an important role for IκBζ
in IL-36 signaling and thus validate IκBζ as an attractive target
for psoriasis therapy.
Results
IL-36 Induces IκBζ Expression in KCs. To investigate the relationship
between IL-36 and IκBζ, we treated the keratinocyte cell line
HaCaT and primary human KCs with recombinant IL-36α for 1–
24 h. Whereas untreated KCs lacked IκBζ expression, 1 h of
stimulation with IL-36α was sufficient to induce sustained IκBζ
expression on the mRNA and protein level (Fig. 1A). As
revealed by the addition of actinomycin D to IL-36α–treated
cells, the increased NFKBIZ mRNA levels resulted from tran-
scriptional up-regulation of NFKBIZ rather than from mRNA
stabilization (SI Appendix, Fig. S1A). Importantly, full-length IL-
36α, which supposedly lacks biological activity, failed to induce
IκBζ expression, whereas IL-17A, either alone or combined with
TNFα, induced IκBζ expression with kinetics similar to those of
truncated IL-36α (Fig. 1A and SI Appendix, Fig. S1 B and C). As
some reports implied distinct target gene regulation by the
different IL-36 members (14, 24, 25), we also stimulated
HaCaT cells and primary KCs with IL-36γ. IL-36γ induced
NFKBIZ mRNA and protein expression with kinetics and po-
tency similar to that of IL-36α (Fig. 1B).
We next investigated whether other psoriasis-associated cyto-
kines, such as IL-1β, IL-17A, TNFα, or IFNγ, could potentiate
the effect of IL-36α on IκBζ protein expression (Fig. 1C). Al-
though certain differences were noted between HaCaT cells and
primary KCs, most of the tested cytokines enhanced IL-36α–
mediated IκBζ expression. Importantly, the combination of IL-
17A and IL-36α was clearly more effective in triggering IκBζ
expression than were the single cytokines alone.
Induction of IκBζ by IL-36 Is Mediated by MyD88, NF-κB, and STAT3.
As IκBζ is also induced by IL-17A, we further dissected the
mechanism of IκBζ expression induced by IL-36 compared to IL-
17A. IL-17A binds and activates the IL-17RA/IL-17RC receptor,
followed by the recruitment of the adapter protein Act1 and the
activation of MAPK and NF-κB (31). In contrast, IL-36 utilizes a
divergent proximal signaling cascade by binding to the IL-36
receptor complex, composed of IL1RL2 and its coreceptor IL1RAP,
leading to the recruitment ofMyD88 and activation ofMAPK andNF-
κB (17). Indeed, knockdown of MyD88 revealed that it was in-
dispensable for IκBζ expression upon IL-36α stimulation, while
it had no effect in IL-17A–treated cells (Fig. 2A and SI Ap-
pendix, Fig. S2A).
As IκBζ is transcriptionally induced by IL-36, we explored the
NFKBIZ promoter region to identify relevant transcription fac-
tors. Two major IκBζ isoforms have been described, including a
long isoform (IκBζL) of 718 aa and a N-terminally truncated
isoform (IκBζS) of 618 aa that is thought to be generated by
alternative splicing (8, 32). By analyzing published DNase I and
Pol II ChIP-sequencing (ChIP-seq) data (33), we identified that
the two isoforms arise not only from alternative splicing but also
from two different promoter regions with distinct transcriptional
start sites (Fig. 2B). Moreover, our own RNA-sequencing (RNA-
seq) data revealed that KCs use only the proximal promoter 2
that is translated into the IκBζL isoform. Previous promoter
A
B
C
Fig. 1. IL-36 induces IκBζ expression in KCs. (A and B) HaCaT cells (Left) or
human primary KCs (Right) were treated with 100 ng/mL IL-36α (amino acids
6–158) (A) or 100 ng/mL IL-36γ (amino acids 18–169) (B) for the indicated
times. IκBζ protein was analyzed by Western blotting. Relative mRNA levels
of NFKBIZ were measured in parallel and normalized to the reference
RPL37A. (C) HaCaT cells (Upper) and primary KCs (Lower) were treated for
2 h with 100 ng/mL IL-36α alone or in combination with 100 ng/mL IL-17A,
10 ng/mL TNFα, 100 ng/mL IFNγ, or 100 ng/mL IL-1β. IκBζ was detected by
Western blotting. HSC70 or β-actin served as loading controls.
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analyses, however, had examined only promoter 1, which is
located ∼20 kb upstream of promoter 2 (32, 34, 35). This distal
promoter is used in several cell types for transcription of
NFKBIZ variant 2, which lacks exon 3 and thus is translated to
the IκBζS variant.
Bioinformatic analysis of the NFKBIZ promoter 2 revealed
putative binding sites for STAT3, NF-κB, AP1, KLF4, and
STAT1. To uncover the contribution of these sites to NFKBIZ
induction, we cloned the promoter region (∼1.5 kb upstream of
the transcription start site of IκBζL) into a luciferase construct
and generated deletions lacking one of the predicted binding
sites. Expression of the constructs was analyzed after transfection
of HaCaT cells followed by stimulation with IL-36α. Indeed,
expression of the NFKBIZ promoter 2 was significantly increased
by IL-36α, whereas deletion of the STAT3- or the NF-κB–
binding site inhibited NFKBIZ promoter expression (Fig. 2C).
In accordance, ChIP identified a direct physical binding of NF-
κB p65 and STAT3 to NFKBIZ promoter 2, along with the
binding of phosphorylated RNA polymerase II as a marker for
active transcription (Fig. 2D). IL-36α also triggered the early
activation of STAT3, NF-κB, and MAPK in HaCaT cells or
primary KCs (Fig. 2E and SI Appendix, Fig. S2B). Interestingly, a
similar activation of STAT3 and NF-κB was detected in IL-17A–
treated cells (SI Appendix, Fig. S2C). Whereas inhibition of
MAPK did not affect IκBζ expression in IL-36α–treated
HaCaT cells (SI Appendix, Fig. S2D), the blocking of NF-κB
activation by IKK inhibition or knockdown of p65 efficiently
prevented IκBζ expression upon IL-36α stimulation (Fig. 2 F and
G). Moreover, depletion of STAT3 by two different shRNAs
strongly inhibited IκBζ mRNA and protein expression (Fig. 2H).
Similarly, depletion of p65 or STAT3 impaired IκBζ induction
after stimulation with IL-17A (SI Appendix, Fig. S2 E and F).
Thus, IL-36α and IL-17A both employ NF-κB and STAT3 for
IκBζ induction.
IκBζ Is a Key Mediator of IL-36–Induced Gene Expression in KCs.Next,
we investigated the function of IκBζ in IL-36 signaling and
therefore first explored the time course of IκBζ-modulated gene
expression. We stimulated control and NFKBIZ-knockdown
HaCaT cells for 0–24 h with IL-36α and analyzed selected IL-
36 target genes. IL-36α stimulation led to the induction of
IL36G, IL17C, CXCL5, or S100A9 with different kinetics (SI
Appendix, Fig. S3A). Surprisingly, NFKBIZ silencing not only
prevented the induction of late-responsive genes such as S100A9
but also affected early gene induction, e.g., of IL36G or IL17C.
To reveal a global picture of IL-36–driven gene expression by
IκBζ, we generated control and NFKBIZ-depleted primary KCs
and performed transcriptome analyses after 1.5 and 24 h of IL-
36α stimulation (Fig. 3 A and B). Silencing of IκBζ resulted in
the deregulation of several hundred target genes in IL-36α–
stimulated primary human KCs (SI Appendix, Tables S1 and
S2). Interestingly, early after IL-36α stimulation most genes were
down-regulated by IκBζ, including genes for antiinflammatory
phosphatases (DUSP2 and DUSP9). In contrast, after 24 h most
IκBζ-modulated genes were positively regulated and hence were
down-regulated by the NFKBIZ knockdown. Many of these
IκBζ-inducible genes are typically overexpressed in psoriasis,
including genes for antimicrobial proteins (DEFB4 and LCN2),
S100 proteins (S100A7, S100A8, and S100A9), and chemo- and
cytokines (CSF2, CSF3, CXCL8, IL23A, and IL36A).
Principal component analysis (PCA) revealed that the gene-
expression profile not only differed between untreated and IL-
36α–stimulated cells but was also divergent after 1.5 and 24 h of
IL-36α stimulation (SI Appendix, Fig. S3B). Moreover, as shown
in the Venn diagrams in Fig. 3 C and D, only a subset of the IL-
36α–regulated genes was IκBζ-dependent (83 of 607 genes after
1.5 h and 86 of 800 genes after 24 h of IL-36α stimulation). Gene
ontology (GO) term analysis of the affected genes uncovered
that IκBζ mostly regulated inflammatory responses, neutrophil
chemotaxis, and leukocyte function downstream of IL-36 (Fig.
3D). We also compared our RNA-seq analyses with a previously
defined IL-36 core signature comprising 182 genes that were
regulated by IL-36 after 24 h in human KCs (14). The compar-
ison not only revealed a high overlap with our RNA-seq analyses
but also identified 39 of the 182 IL-36 core target genes as IκBζ-
dependent (SI Appendix, Fig. S3 C and D).
The IκBζ-dependent gene regulation by IL-36α in primary
KCs at early and late time points was confirmed by qPCR of
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Fig. 2. Molecular dissection of IκBζ induction by IL-36. HaCaT cells were
stimulated for the indicated times with 100 ng/mL IL-36α. (A) Cells stably
expressing a control (sh ctrl) or two different shRNAs targeting MyD88 were
treated for 2 h with IL-36α and were analyzed by Western blotting. (B)
Analysis of NFKBIZ promoter accessibility and structure. The genomic region
around NFKBIZ was analyzed from a published DNase I dataset and a poly-
merase II ChIP-seq track (33). Exon reads of NFKBIZ were derived from our
own RNA-seq data of HaCaT cells stimulated for 1.5 h with IL-36α. (C)
Analysis of the NFKBIZ promoter 2 region in IL-36α–stimulated HaCaT cells
using luciferase reporter constructs harboring deletions of transcription
factor-binding sites. (D) P65, STAT3, and RNA polymerase II (Pol II) bind to
NFKBIZ promoter region 2 in IL-36α–treated cells. ChIP was performed from
HaCaT cells treated for 30 min with IL-36α. The promoter region of the
muscle-specific gene MYOD1 represents a negative control. (E) Immunoblot
analysis of IL-36α–induced signaling pathways. Active NF-κB and STAT3 were
detected by the phosphorylated forms of IκBα (p-IκBα at Ser32), p65 (p-p65 at
Ser536), and STAT3 (p-STAT3 at Tyr705). MAPK activation was detected by
phosphorylated JNK (p-JNK at Thr183/Tyr185) and ERK (p-p44/42 at Thr202/
Thr204). (F) Cells were treated for 1 h with IL-36α in the presence or ab-
sence of the vehicle DMSO or 10 μM of the IKK inhibitors BMS-345541 or
IMD0354. NFKBIZ mRNA and IκBζ protein levels were measured after 2 h of
IL-36α stimulation. Detection of p-IκBα served as a control for NF-κB in-
hibition. (G and H) Gene expression and Western blot analysis of IκBζ in
control and RELA (p65)-knockdown (G) or STAT3-knockdown (H) cells
after 1 h of IL-36α treatment. Knockdown was controlled by detection of
p65 or STAT3. ***P < 0.001.
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selected genes, such as IL36G, S100A9, LCN2, DEFB4, CXCL8,
and CCL20 (Fig. 3E). Importantly, regulation of these IκBζ
target genes was conserved in IL-17A– and TNFα–treated pri-
mary KCs as well as in IL-36α–, IL-36γ–, and IL-1β–treated
HaCaT cells (Fig. 3F and SI Appendix, Fig. S4 A–C). These
findings thus implicate IκBζ as a master regulator of proin-
flammatory gene expression not only in IL-36–stimulated but
also in IL-17A–,TNFα–, or IL-1β–treated KCs.
IκBζ Promotes IL-36–Driven Psoriasis-Like Disease in Vivo. Global
Nfkbiz-KO mice are protected against IMQ-induced psoriasis-
like skin inflammation (11). Since the TLR7 agonist IMQ di-
rectly activates the innate immune response, it is difficult to
discriminate between the contribution of IL-17 and IL-36 to
the disease onset. Moreover, global Nfkbiz-KO mice develop an
autoinflammatory phenotype in adulthood (36, 37), which could
influence the skin inflammation of IMQ-treated mice. We
therefore generated a mouse model using tamoxifen-inducible
Nfkbiz-KO mice that received intradermal injections of active
IL-36α into the ears. Tamoxifen-induced Cre recombinase acti-
vation just before IL-36α application led to an effective KO of
IκBζ, thereby preventing potential congenital off-target effects
(Fig. 4A). Intradermal injection of IL-36α into the ears of control
animals induced Nfkbiz transcription (Fig. 4A) and, moreover,
triggered ear swelling, scaling, epidermal thickening, KC hyper-
proliferation and increased infiltration of immune cells (Fig. 4 B
C
F
E
A B
D
Fig. 3. IκBζ regulates a subset of psoriasis-related IL-36 target genes. Pri-
mary KCs or HaCaT cells were transduced with a control or NFKBIZ-specific
shRNA. Triplicates of each time point and shRNA were analyzed by RNA-seq
or qPCR and were normalized to the reference gene RPL37A. (A) Control of
NFKBIZ-knockdown efficiency. (Upper) IκBζ protein was detected in primary
KCs treated for 1 h with 100 ng/mL IL-36α. (Lower) NFKBIZ mRNA levels were
measured after 1.5 h and 24 h of IL-36α stimulation. (B) After library prep-
aration from total RNA, primary KC samples were sequenced, and reads
were aligned to the human genome hg19. Depicted are two separate
heatmaps with normalized z-scores of IκBζ target genes after 1.5 h and 24 h
of IL-36α treatment. As a cutoff, genes with a minimum fold change of 1 and
a P value < 0.05 were considered. (C) Venn diagrams showing the fraction of
IκBζ target genes among IL-36α–regulated genes 1.5 and 24 h after stimu-
lation of primary KCs. (D) GO term analysis of significantly enriched IκBζ-
dependent gene sets after 1.5 and 24 h of IL-36α treatment. (E) Validation of
selected IκBζ target genes by qPCR in primary KCs after 1.5 and 24 h of in-
cubation with 100 ng/mL IL-36α. (F) Gene-expression analysis of IκBζ target
genes in primary KCs stimulated with 100 ng/mL IL-17A and 10 ng/mL TNFα
for 1.5 and 24 h. *P < 0.05; **P < 0.01; ***P < 0.001.
A
C
E
G
F
B
D
Fig. 4. Characterization of the IL-36/IκBζ axis in vivo. (A, Upper) Scheme of
tamoxifen and IL-36α treatment of control and inducible Nfkbiz-KO mice.
(Lower) Verification of Nfkbiz deletion at the protein and mRNA level. For
induction of IκBζ KO, Nfkbiz flox/flox (Ctrl) and Rosa-creERT2 Nfkbiz flox/flox
(KO) mice received i.p. injections of tamoxifen (75 mg/kg) for four
consecutive days to induce activation of Cre recombinase. Afterward, 1 μg
murine IL-36α or PBS control was intradermally injected into one ear of the
mice for five consecutive days. (B) Ear and epidermal thickness (± SEM) of
PBS- and IL-36α–treated mice at day 5 from two (for PBS) or six (for IL-36α)
animals per group. Pictures were taken at day 5 to show scaling at the
treatment area. (C) H&E staining of ears from PBS- and IL-36α–treated
control and KO mice. (Scale bars: 140 μM.) (D) Immunohistochemistry for
the macrophage marker F4/80 and the neutrophil marker MPO. (Scale bars:
80 μM) (E) Characterization of CD45+ immune cell infiltrates by flow
cytometry. Neutrophils were characterized as CD45+ Ly6G+ and macro-
phages as CD45+, CD11bhi and F4/80+. Error bars indicate results from two
independent experiments. (F) Psoriasis-related gene expression in ears from
IL-36α–treated mice. Results are shown as means ± SEM; n = 6 animals per
group. (G) Expression data from skin biopsies of 64 healthy individuals and
58 psoriasis patients were analyzed from the Gene Expression Omnibus
profile dataset GDS4602. Shown are normalized expression values of NFKBIZ
and IL17A or NFKBIZ and IL36G, which were plotted against each other in
every single nonlesional and lesional biopsy. Depicted is the regression co-
efficient (R2) from the expression values of the psoriatic skin biopsies. *P <
0.05; **P < 0.01; ***P < 0.001.
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and C and SI Appendix, Fig. S5A). These alterations were nearly
absent in the IL-36α–treated KO mice. Histological and flow
cytometric analyses revealed a marked increase in infiltrating
CD45+ immune cells, macrophages, and neutrophils in the IL-
36α–treated control animals, which was significantly blocked in
the KO mice (Fig. 4 D and E). T cell infiltration was reduced in
the KO animals as well, although the degree of T cell infiltration
was generally low in the ears of IL-36α–treated mice (SI Appendix,
Fig. S5B). Importantly, expression of several psoriasis-associated
target genes, similar to those identified by transcriptome analysis
of IL-36α–treated KCs (Fig. 3), was up-regulated in the ears of IL-
36a-treated control but not in IL-36α–treated KO mice (Fig. 4E).
Likewise, the expression of IκBζ-dependent proteins involved in
granulocyte and leukocyte chemotaxis was also decreased in the
KO mice (SI Appendix, Fig. S5C). Thus, IκBζ KO strongly pro-
tected against IL-36–driven psoriasis-like disease in vivo, which
could be mediated by effects of Nfkbiz deficiency in KCs as well as
in immune cells.
As previously reported (11, 13), we validated increased
NFKBIZ expression in lesions from psoriasis patients, as com-
pared with nonlesional skin areas or unaffected individuals (SI
Appendix, Fig. S5D). Expression of IL17A and especially IL36G
was elevated in psoriatic lesions. We then correlated the ex-
pression of NFKBIZ, IL36G, and IL17A in nonlesional and
lesional samples in the individual patients to obtain an idea of
the relevance of the two cytokines in driving NFKBIZ expression
in psoriatic tissue. The correlation of IL36G and NFKBIZ was
stronger than the link between IL17A and NFKBIZ, implicating
IL-36 as an important driver of NFKBIZ expression in psoriasis
(Fig. 4G). Moreover, as IL-36–mediated NFKBIZ induction
could account for increased expression of psoriasis-related cy-
tokines, we correlated the expression of LCN2, a bona fide IκBζ
target gene (38), to IL36G, NFKBIZ, and IL17A expression.
Indeed, the expression level of LCN2 matched strongly IL36G
and NFKBIZ expression, whereas it was only weakly correlated
to IL17A expression patterns in psoriatic lesions (SI Appendix,
Fig. S5E). These findings support a major role of IκBζ in IL-36
signaling in KCs and psoriasis and suggest IκBζ as an attractive
therapeutic target which mediates proinflammatory signaling
downstream of IL-17A and IL-36.
Discussion
Previous studies by us and others found that IκBζ is overex-
pressed in psoriatic lesions, whereas Nfkbiz KO mice are pro-
tected against IMQ-induced psoriatic skin inflammation (11, 13).
In these and follow-up studies, IκBζ was identified as a major
mediator of IL-17A signaling, leading to the induction of
proinflammatory signaling in KCs (11, 39). Interestingly, in
Il17a- or Il17ra- KO mice neither induction of Nfkbiz nor skin
inflammation were fully blocked after IMQ treatment (11, 40),
implying additional pathways of NFKBIZ induction and
promotion of psoriasis.
Recently, IL-36α and IL-36γ have been identified as being
overexpressed in psoriatic lesions (22, 23). In agreement, IL-36
treatment of KCs induced proinflammatory signaling (14),
whereas KO of the IL-36 receptor inhibited IMQ-induced skin
inflammation in mice. Our results show that IκBζ provides an
important link between IL-36 signaling and psoriasis-associated
inflammatory gene expression. We revealed that IL-36 mediates
IκBζ expression in HaCaT cells and primary KCs, which fol-
lowed kinetics similar to those seen with IL-17A/TNFα treat-
ment, implying similar signaling pathways in IκBζ induction.
By ChIP-seq data and our own RNA-seq analyses we identi-
fied that KCs induce transcription of NFKBIZ from the yet
uncharacterized proximal promoter 2, which contains several
conserved binding sites for proinflammatory transcription fac-
tors. Indeed, IL-36 and IL-17A stimulation led to the activation
of NF-κB, whereas knockdown of the NF-κB subunit p65
prevented IκBζ induction.
Besides NF-κB, we identified STAT3 as a regulator of IκBζ
expression, as its depletion was sufficient to block IL-36– and IL-
17A–mediated induction of IκBζ. These findings are intriguing,
as STAT3 itself can drive proinflammatory gene expression in
psoriasis (41). Constitutively active STAT3 in the epidermis of
psoriatic lesions is often detectable, whereas pharmacological
inhibition of STAT3 ameliorated psoriasis-like skin lesions in
mice (42, 43). Moreover, STAT3 was proposed to control IκBζ
expression in T cells (44). As STAT3 is especially involved in IL-
36–driven induction of IκBζ expression, STAT3 inhibitors could
be promising agents for the effective treatment of general pus-
tular psoriasis, which is caused by mutations of IL36RN and
hyperactivation of the IL-36 pathway (27, 28).
Our gene-expression profiling revealed that IL-36 affected the
expression of hundreds of genes at early and late stimulation
time points. As early effects of IL-36 stimulation on gene ex-
pression have not been investigated before in KCs, we could not
only validate defined IL-36 target genes (14) but also identify
previously unknown IL-36 dependent genes (e.g., IL17C, CSF2,
CSF3) that encode important psoriasis-promoting cytokines (45–
46). Of note, NFKBIZ knockdown led to the deregulation of a
specific subset of IL-36 target genes at early and late stimulation
time points. Most of these IκBζ-dependent IL-36 target genes
regulate antimicrobial and proinflammatory responses, neutro-
phil chemotaxis, and leukocyte activation and hence have been
implicated in the pathogenesis of psoriasis. Moreover, IκBζ-
dependent gene expression seems to be highly conserved, as
we found similar changes in the expression of IκBζ-dependent
genes (e.g., DEFB4, CCL20, S100A7, S100A9, and LCN2) in
HaCaT cells and primary KCs as well as upon IL-36α, IL-36γ, or
IL-17A/TNFα stimulation.
Employing an inducible Nfkbiz-KO model, we further dem-
onstrate that the absence of IκBζ also impaired psoriasis-related
gene expression under in vivo conditions of IL-36α stimulation.
Nfkbiz-KO mice exhibited significantly reduced skin pathology,
including less ear swelling and KC proliferation, and a strongly
reduced infiltration of immune cells, in particular neutrophils.
The results are consistent with findings in Il36r-deficient mice
that are also protected in the IMQ psoriasis model (30). Notably,
our previous study demonstrated that Nfkbiz-KO mice were even
more protected than Il17a-deficient mice (11), supporting the
idea that IκBζ might also be involved in IL-17–independent ef-
fects of psoriasis development. Of note, Il36r-deficient mice also
showed stronger protection in the IMQ model than Il17a-KO
mice (30).
In agreement with our findings in cultured KCs and Nfkbiz-
KO mice, expression data from psoriasis patients validated
elevated NFKBIZ and IL36G levels in psoriatic lesions as
compared with nonaffected skin areas or skin from unaffected
healthy individuals. Moreover, the expression of IL36G and
NFKBIZ was strongly correlated with the IκBζ target gene LCN2
compared with a much weaker correlation of IL17A with
NFKBIZ and LCN2 expression levels. These data strengthen the
hypothesis that IL-36 is an initial driver for NFKBIZ expression
in psoriasis.
While our results clearly position IκBζ downstream of IL-36,
IL-17A and IL-36, in turn, are also transcriptional targets
downstream of IκBζ (SI Appendix, Fig. S4D). Likewise, IL-17A,
especially in combination with TNF, is a strong inducer of IκBζ
expression but can be also induced downstream of IκBζ. Thus,
the strong expression of NFKBIZ in psoriasis patients might be
caused not only by elevated IL-36 expression but also by in-
creased IL-17–type responses. The exact contribution of each
cytokine is complicated by the existence of multiple members of
the IL-17 and IL-36 families. Because IL-17 and IL-36 can mu-
tually reinforce each other (25, 26), the two cytokines drive
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complex autoamplification loops in which IκBζ seems to have an
integral role in promoting skin inflammation (for a scheme see
SI Appendix, Fig. S6). In fact, our present and previous results
(11) suggest a dual requirement for IκBζ in IL-36 signaling of
innate epithelial cells, such as KCs, as well as in IL-17A signaling
of T cells, both of which might be necessary to drive full-blown
psoriasis.
In conclusion, our findings reveal that two major cytokines, IL-
36 and IL-17A, promote psoriasis by inducing IκBζ expression.
While IL-17A antibodies have proven therapeutic efficacy,
blocking of IL-36 might represent an alternative for patients
resistant to anti–IL-17A therapy. Moreover, targeting their
common mediator IκBζ might lead to future approaches for
efficient long-term treatment of psoriasis patients.
Materials and Methods
Detailed information on cell culture experiments, generation of knockdown
cells, luciferase reporter assays, ChIP, analyses of RNA and protein expres-
sion, RNA-seq, cytokine antibody arrays, generation of Nfkbiz-KO mice,
flow cytometry, histology, and analysis of patient data is provided in
SI Appendix.
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Supplementary Information Text 
SI Materials and Methods 
Cell culture and treatment. HaCaT cells were maintained in DMEM with 10% FCS and 
antibiotics. Human primary KC were freshly isolated from foreskin and maintained in CnT-07S 
medium with gentamycin (CELLnTEC). Recombinant human IL-36α (aa 6-158), full-length IL-
36α (aa 1-158), IL-36γ (aa 18-169) or mouse human IL-36α (aa 6-160) were purchased from R&D 
or kindly provided by Amgen. Recombinant IL-17A (11340174), TNFα (11343013), IFNγ 
(11343536) and IL-1β (11340013) were from Immunotools. The following inhibitors were 
purchased from Selleckchem: Trametinib (MEK1/2 inhibition), SCH772984 (ERK1/2 inhibition), 
BMS-345541 (IKK1/2 inhibition) SP600125 (JNK inhibition), IMD0354 (IKK2 inhibition). 
 
Generation of knockdown cells. Lentiviral particles were produced in HEK293T cells using the 
lentiviral vector pMD2.G and a second-generation packaging system (psPAX2, Addgene). HaCaT 
cells or primary KC were transduced in the presence of 8 μg/mL polybrene, packaging plasmids 
and 5 μg of the respective shRNA construct: pLKO.1-puro (sh ctrl); pLKO.1-TRCN0000147551 
(sh NFKBIZ); pLKO.1-TRCN0000014686 (sh RELA); pLKO.1-TRCN0000008025 (sh1 MyD88); 
pLKO.1-TRCN0000011223 (sh2 MyD88); pLKO.1-TRCN0000020840 (sh1 STAT3); pLKO.1-
TRCN0000020843 (sh2 STAT3), followed by puromycin selection (1 ng/mL, Invitrogen). 
 
Luciferase constructs and reporter assays. The promoter 2 region of NFKBIZ (chr3: 101848459-
101850067) containing the binding sites for STAT3 (CTTCCAGGAC), NFκB 
(CGGGGTTTCCC), AP1 (TGACTCC), KLF4 (TGGGCGGAGCCGGGCGGGCGGGGC) and 
STAT1/STAT3 (ATTTTACTGGAAATC) was cloned into a pGL3 basic construct. For deletion 
of transcription factor-binding sites a double PCR was performed using specific forward and 
reverse primers (Table S4). Successful generation of the constructs was checked by sequencing. 
For transfection 105 HaCaT cells were transfected with 5 µg luciferase construct and 1.25 µg TK-
Renilla-expressing construct using Lipofectamine 3000 reagent (Life Technologies). 24 h later, 
cells were stimulated for 24 h with 100 ng/mL IL-36α or 200 ng/mL IL-17A, before luciferase 
activity was measured with the Firefly Luciferase Assay Kit (Promega). Expression of the reporter 
constructs was calculated as fold induction over unstimulated transfected cells from data of three 
independent experiments. 
 
Western blot analysis. Cells were washed in PBS and resuspended in lysis buffer containing 20 
mM TRIS-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM Na2EDTA, 1 mM EGTA, 1 mM 
β-glycerophosphate, 2 M urea and 1x protease inhibitor cocktail (Roche). After 10 min on ice, 
samples were briefly sonicated to disrupt DNA–protein complexes. Afterwards, samples were 
separated by SDS-PAGE and transferred to a nitrocellulose membrane. The following antibodies 
were used for Western blot analysis and purchased from Cell Signaling: anti-IκBζ (9244), anti-p-
STAT3 (phospho-STAT3 at Tyr705; 9145), anti-STAT3 (12640), anti-p65 (8242), anti-p-p65 
(phospho-p65 at Ser536, 3031), anti-p-JNK (phospho-JNK at Thr183/Tyr185, 4668), anti-JNK 
(9252), anti-p-p44/42 MAPK (phospho-Erk1/2 at Thr202/Tyr204, 4370), anti-p44/42 MAPK 
(4695), anti-p-IκBα (phospho-IκBα at Ser32, 2859), anti-IκBα (4814), anti-MyD88 (4283), anti-
GAPDH (2118) and anti-β-actin (3700). Anti-HSC70 (sc-7298) was obtained from Santa Cruz 
Biotechnology. For detection of mouse IκBζ, a self-made antibody was used. 
 
Chromatin immunoprecipitation. ChIP assays were performed as described (1). After 
sonification, chromatin was incubated with protein G-coupled Dynabeads (Invitrogen) and 2 μg of 
p65 (Diagenode, C15310256), STAT3 (Thermo Fisher, MA1-13042), RNA-polymerase II 
(Abcam, ab5095) or IgG control antibodies (Abcam, ab46540) overnight at 4°C. The promoter 
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region of MYOD1 served as an internal negative control (forward: 5´-
CTCTGCTCCTTTGCCACAAC-3´, reverse: 5´-GAGTGCTCTTCGGGTTTCAG-3´). ChIP 
primers corresponding to the promoter region 2 of NFKBIZ variant 1 were self-designed (primer 
for readout of STAT3 ChIP: forward 5´-GCCTTAACTGGGCTAACAGC-3´, reverse 5´-
CTGGCAAGTCCTGGAAGGAG-3´; primer for readout p65 and Pol II ChIP: forward 5´-
GAAGGGCAGGCAAACAAC-3´, reverse 5´-GATGCGTCCGATTTCCAG-3´). Data are 
presented as the percentage of input from 2 independent experiments. 
 
Gene expression analysis by qPCR. Total RNA was isolated using Qiazol (Qiagen). After 
digestion of genomic DNA with DNase I, cDNA synthesis was performed using M-MuLV reverse 
transcriptase and random hexamer primers (Thermo Fisher Scientific). Relative gene expression 
was quantified by real-time PCR using Maxima SYBR Green master mix (Thermo Fisher 
Scientific) and self-designed primers (Suppl. Table S3). PCR conditions were as follows: initial 
denaturation 15 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 45 s. Relative 
mRNA levels were calculated by normalization to the reference genes RPL37A or ACTB using the 
2-ΔΔCT method. 
 
RNAseq. For RNAseq analysis, libraries were constructed with the Ultra RNA Library Prep Kit at 
the Core Facility Genomics in Münster, Germany. Sequencing was performed using the Illumina 
NextSeq High Output kit. Mapping against the human reference genome hg19 was performed by 
HISAT2 (2). From raw gene counts, differentially expressed genes between wild-type and 
knockdown cells were computed using the Bioconductor R package DESeq2. Genes were called 
differentially expressed if their adjusted p-value (false discovery rate) was < 0.05 and the absolute 
fold change > 1.  
 
Mice. Experiments were conducted in accordance with the German law guidelines of animal care. 
Tamoxifen-inducible IκBζ knockout mice were generated by crossing B6.Cg-Nfkbiz<tm1.1Muta> 
mice (RIKEN) to B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J mice (Jackson Laboratory). IκBζ deletion 
was induced by intraperitoneal injection of 75 mg/kg tamoxifen (T5648, Sigma-Aldrich) for 4 
consecutive days. As control, Nfkbiz flox/flox mice (B6.Cg-Nfkbiz<tm1.1Muta>) received 
tamoxifen injections in parallel. Three days after the last tamoxifen injection, mice received for 5 
consecutive days intradermal injections to the ear, containing 1 µg murine IL-36α or PBS vehicle 
alone. At day 6, mice were sacrificed and analyzed. 
 
Flow cytometry. Three ears per group were chopped and digested with 300 µg/ml Liberase 
(Roche) and 50 U/ml DNase I (Thermo Fisher) in 5% FCS in RPMI for 2 h at 37°C. For generation 
of single cell suspensions, cells were passed through a cell strainer (100 µm). After cell counting, 
105 cells were treated with Fc-Block (BioRad, BUF041) and surface-stained with the following 
antibodies from BioLegend: anti-CD45 FITC (103107), anti-CD3 PerCP (100325), anti-CD4 PE 
(100407), anti-CD8 APC (100711), anti-CD11b PacificBlue (101223), anti-Ly6G PE (127607), 
anti-F4/80 APC (123115). Anti-γδ-TCR APC was from Thermo Fisher. Data were acquired on a 
LSRII flow cytometer (Becton Dickson) and gates were set based on the respective isotype controls. 
 
Histology. After fixation in formaldehyde and paraffin-embedding, 5-µm sections were prepared 
and incubated with the following antibodies: MPO (AF3667, R&D, 1:200), F4/80 (70076, Cell 
Signaling, 1:400) or Ki67 (ab15580, Abcam, 1:1000). Antigen retrieval was performed in 1 mM 
EDTA pH 8.0 for MPO, and in 10 mM citrate pH 6.0 for F4/80 and Ki67. After incubation with 
peroxidase-coupled secondary antibodies, sections were stained with DAB substrate. 
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Cytokine antibody array. For detection cytokine secretion, protein lysates from 2 mouse ears per 
group were pooled. 600 µg total protein lysate was analyzed with a cytokine array (R&D Systems, 
ARY006). Mean pixel density of each spot was quantified using the dot blot analyzer (ImageJ). 
 
Analysis of patient data. Gene expression data originated from GEO data set GSE13355 (3, 4). 
Pre-normalized gene expression values from each sample was directly taken from the GEO profile 
data set GDS4602. The following reporters were taken for analysis: NFKBIZ: ID 223218_s_at, 
IL17A: ID 216876_s_at, IL36G: ID 220322_at and LCN2: ID 212531_at. 
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Fig. S1. Induction of IκBζ protein expression by full-length and truncated IL-36α as well as 
by IL-17A and TNFα. (A) IκBζ is transcriptionally induced by IL-36α. HaCaT cells were pre-
treated for 30 min with 100 ng/mL of active IL-36α followed by the addition of 5 µg/mL 
actinomycin D or a DMSO control for 30 min. NFKBIZ mRNA levels were analyzed by qPCR and 
normalized to RPL37A. IκBζ protein levels were detected by Western blot in parallel. (B) IκBζ is 
not induced by full-length IL-36α. HaCaT cells were stimulated for 24 h with 2 µg/mL biologically 
inactive full-length IL-36α (aa 1-158) or 200 ng/mL truncated IL-36α (aa 6-158), followed by 
immunoblot analysis. (C) IL-17A, alone or in combination with TNFα, induces IκBζ. HaCaT cells 
were treated for the indicated times with 100 ng/mL IL-17A alone (left) or in combination with 10 
ng/mL TNFα (right). 
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Fig. S2. Mechanism of IκBζ induction by IL-17A. In all experiments, HaCaT cells were 
stimulated with 200 ng/mL IL-17A. (A) HaCaT cells stably expressing a control shRNA (sh ctrl) 
or two different shRNAs targeting MyD88 were treated for 2 h with IL-17A and analyzed by 
Western blotting. (B) Upstream signaling of IL-36α-treated primary KC. Cells were stimulated with 
100 ng/mL IL-36α for the indicated time. NF-κB activation was detected by staining for the 
phosphorylated forms of IκBα (p-IκBα at Ser32) and p65 (p-p65 at Ser536). Activation of the 
MAPK pathway was detected by phosphorylated JNK (p-JNK at Thr183/ Tyr185). (C) Immunoblot 
analysis of IL-17A-treated HaCaT cells. NF-κB and STAT3 activation was detected with antibodies 
against the phosphorylated forms of IκBα (p-IκBα at Ser32) p65 (p-p65 at Ser536) and STAT3 (p-
STAT3 at Tyr705). (D) HaCaT cells were either left untreated (Ctrl) or stimulated for 2 h with 100 
ng/mL IL-36α together with the vehicle control DMSO, 50 nM Trametinib (MEK inhibitor), 1 µM 
SCH772984 (ERK1/2 inhibitor) or 10 µM SP600125 (JNK inhibitor). The status of phosphorylated 
ERK (p-ERK1/2) and p-JNK was measured as a control for kinase inhibition. (E) Gene expression 
and Western blot analysis of IκBζ in control and RELA (p65) knockdown cells after 1 h treatment 
with IL-17A. Knockdown efficiency was controlled by immunoblot detection of p65. NFKBIZ 
mRNA levels were normalized to RPL37A. (F) Relative mRNA and protein levels of IκBζ in 
control and STAT3 knockdown HaCaT cells after 1 h of treatment with IL-17A. Knockdown 
efficiency of STAT3 was controlled by immunoblot analysis. mRNA levels were normalized to 
RPL37A. 
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Fig. S3. Characterization of IκBζ-mediated gene expression in keratinocytes. (A) Induction of 
psoriasis-related gene expression by IL-36α in the presence and absence of IκBζ. Biological 
triplicates from control and NFKBIZ shRNA-transduced HaCaT cells were stimulated with 100 
ng/mL IL-36α for the indicated times. Expression of IL36G, S100A9, IL17C and CXCL5 was 
analyzed by qPCR and relative mRNA induction was calculated after normalization to the reference 
gene RPL37A. Significance is shown by asterisks (*p < 0.05; ** p < 0.01; *** p < 0.001). (B) 
Principle component analysis (PCA) of IL-36α-modulated gene expression in primary KC 
expressing a control or NFKBIZ-specific shRNA. PCA revealed only minor variances between the 
triplicate samples, whereas the transcripts of untreated cells or cells treated with IL-36α for either 
1.5 h or 24 h were strongly different. Moreover, comparison of the transcript clusters between 
wildtype and NFKBIZ knockdown cells revealed that only a specific subset of IL-36α-regulated 
genes was affected by IκBζ depletion. (C) Venn diagram showing the overlap of IL-36-regulated 
genes identified in our RNAseq analysis and previously published data (5). A core set of 182 IL-
36 target genes defined by Mahil et al. (Ref. 5) was compared to our RNAseq data containing the 
merged sets of IL-36 target genes after 1.5 and 24 h of stimulation. Note that our data set included 
genes of a late (24 h) and early (1.5 h) stimulation time point which latter was not analyzed by 
Mahil et al. (2017). (D) Overlap of the IL-36 core target gene set (Ref. 5) and IκBζ-dependent 
target genes. Examples of overlapping target genes are depicted below. (E) Western blot analysis 
of the IκBζ knockdown in HaCaT cells expressing a control or NFKBIZ-specific shRNA after the 
indicated times of treatment with IL-36α or IL-36. 
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Fig. S4. Characterization of the IL-36/IκBζ axis in keratinocytes. Control and NFKBIZ 
knockdown HaCaT cells (corresponding to Fig. S3E) were treated for 2 and 24 h with 100 ng/mL 
IL-36α (A), for 1.5 and 24 h with IL-36 (B), or for 1 h with 100 ng/mL IL-1β (C). Expression of 
IL36G, S100A9, DEFB4, LCN2, CCL20 and CXCL5 was analyzed by qPCR and normalized to the 
reference gene RPL37A. (D) IL-36 protein levels in cytokine-stimulated HaCaT cells. Control and 
NFKBIZ-depleted HaCaT cells were stimulated for 48 h with IL-36α (100 ng/mL), IL-17A (100 
ng/mL) or IL-17A (100 ng/mL) + TNFα (10 ng/mL). 30 min before harvest cells were additionally 
treated with 5 mM ATP to facilitate IL-36γ release by P2X7 receptor-mediated exosome formation. 
IL-36γ was determined in the supernatant using an IL-36G ELISA. Significance is shown by 
asterisks (*p < 0.05; ** p < 0.01; *** p < 0.001).  
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Fig. S5. Further characterization of the IL-36/IκBζ axis in vivo. (A) IHC analysis of Ki67 in IL-
36α-treated ears as a marker for keratinocyte hyperproliferation. (B) Analysis of T-cell 
subpopulations in PBS and IL-36α-treated ears by flow cytometry. Single cell suspensions were 
prepared from 3 pooled ears per group and T-cells were identified as CD45+ and CD3+ cells. For 
further discrimination of T-cell subpopulations cells co-stained with CD4 or CD8. T-cells were 
identified as CD45+, CD3+ and γδ-TCR+. Error bars derive from two independent measurements 
(*p < 0.05; ** p < 0.01; *** p < 0.001). (C) Quantification of secreted cytokines in IL-36α-treated 
ear tissue. Pooled protein lysates of two ears from either IL-36α-treated control or KO mice were 
analyzed using a cytokine antibody array. For both samples, equal amounts of protein were used, 
and equal loading controlled by analyzing reference spots on the membranes. Depicted is the mean 
pixel density of two dots per cytokine. Significance is shown by asterisks (*p < 0.05; ** p < 0.01; 
*** p < 0.001; n.s. = not significant). (D) Expression data from skin biopsies of 64 healthy patients 
and 58 psoriasis patients were analyzed from the GEO profile data set GDS4602 (48, 49), using the 
GEO Dataset Analysis Tool (GDS browser from NCBI). Shown is the mean normalized expression 
of NFKBIZ (ID: 223218_s_at), IL17A (ID: 216876_s_at) and IL36G (ID: 220322_at) in normal 
skin (NN) of healthy individuals as well as in uninvolved skin (PN) and psoriatic lesions (PP) from 
psoriasis patients. (E) Normalized expression values from LCN2 (ID: 212531_at) were plotted 
against NFKBIZ, IL36G and IL17A.  
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Fig. S6. Simplified model of IL-36-driven IκBζ signaling in keratinocytes. Binding of IL-36 to 
its receptor triggers the expression of the transcriptional regulator IκBζ, which then 
transcriptionally upregulates several antimicrobial peptides, cytokines and chemokines 
involved in the pathogenesis of psoriasis. Among others, induction of IκBζ target genes results in 
the recruitment and activation of immune cells. Important IκBζ target genes are also IL-17 and IL-
36 itself, triggering an amplification loop of proinflammatory IκBζ signaling in keratinocytes.  
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Table S1. List of genes regulated by NFKBIZ knockdown in primary KC after 1.5 h of IL-
36α treatment 
 
  Base Mean log2 
fold 
Change 
lfcSE stat P value P value adj. 
NTSR1 36.69 3.57 0.47 -7.63 2.26554E-14 2.80042E-11 
RMRP 15.62 2.55 0.67 -3.82 0.00013082 0.003760604 
DOK7 236.97 2.43 0.35 -6.87 6.54443E-12 4.04476E-09 
UBBP4 13.30 2.35 0.60 -3.95 7.91843E-05 0.002581941 
MATK 19.32 2.32 0.51 -4.59 4.3557E-06 0.000297611 
RAMP1 206.36 2.26 0.35 -6.50 7.95432E-11 3.37984E-08 
DUSP9 53.29 2.23 0.41 -5.43 5.74436E-08 9.29835E-06 
SYT12 117.45 2.20 0.41 -5.34 9.2756E-08 1.33006E-05 
ASCL2 32.82 2.18 0.47 -4.65 3.37294E-06 0.000240115 
CRLF1 58.59 2.11 0.38 -5.49 4.07773E-08 7.20064E-06 
SPRY4 642.68 2.09 0.22 -9.50 2.00174E-21 9.07253E-18 
LYNX1 189.12 2.04 0.40 -5.12 2.99845E-07 3.2616E-05 
DUSP2 409.28 2.02 0.35 -5.85 4.97137E-09 1.16544E-06 
USH1G 13.45 2.02 0.62 -3.24 0.001212883 0.016508214 
KIAA1644 25.47 2.01 0.45 -4.49 7.10439E-06 0.000429326 
DEGS2 46.57 1.99 0.46 -4.35 1.38739E-05 0.00072277 
PTGES 125.49 1.97 0.34 -5.76 8.25718E-09 1.78211E-06 
TMEM105 20.05 1.93 0.46 -4.17 3.09087E-05 0.001334178 
CX3CL1 33.79 1.93 0.47 -4.10 4.14642E-05 0.001713643 
SNCB 58.08 1.91 0.42 -4.55 5.39648E-06 0.000342878 
HAS1 18.97 1.90 0.48 -3.95 7.95946E-05 0.002589111 
CPLX1 21.35 1.90 0.48 -3.99 6.55802E-05 0.002306451 
STMN3 122.69 1.89 0.37 -5.17 2.33847E-07 2.64968E-05 
KRT1 188.81 1.88 0.29 -6.61 3.85818E-11 1.69225E-08 
DNLZ 22.01 1.87 0.59 -3.18 0.001486806 0.018753345 
GRIA1 19.04 1.87 0.50 -3.73 0.000189181 0.004844251 
LRFN1 90.52 1.85 0.38 -4.91 8.97741E-07 7.71716E-05 
CITED4 2028.14 1.84 0.30 -6.06 1.36946E-09 4.43346E-07 
FOXL1 13.71 1.83 0.54 -3.40 0.000679254 0.011530356 
PLLP 142.79 1.79 0.26 -6.85 7.49452E-12 4.43057E-09 
PALD1 34.37 1.78 0.40 -4.50 6.93618E-06 0.00042382 
CAPN8 90.37 1.75 0.32 -5.44 5.40551E-08 8.96571E-06 
GPR153 2211.19 1.75 0.33 -5.33 9.87708E-08 1.39894E-05 
SYT8 300.56 1.75 0.30 -5.87 4.30154E-09 1.05144E-06 
DCN 19.76 1.74 0.45 -3.85 0.000117377 0.003492291 
ENTPD2 328.87 1.74 0.32 -5.53 3.21671E-08 5.91049E-06 
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SLC22A17 329.90 1.74 0.30 -5.75 9.08664E-09 1.9288E-06 
PTGS1 202.11 1.72 0.26 -6.65 2.97177E-11 1.49656E-08 
EDN2 26.70 1.71 0.38 -4.49 7.17739E-06 0.000431819 
EGFL7 324.81 1.70 0.42 -4.08 4.41959E-05 0.001793826 
TNFRSF18 311.45 1.69 0.32 -5.34 9.2929E-08 1.33006E-05 
SH3TC1 1053.00 1.69 0.36 -4.65 3.3605E-06 0.000240115 
RP11-1055B8.6 15.98 1.67 0.54 -3.11 0.001858448 0.021601366 
TP73 23.76 1.67 0.46 -3.61 0.000304315 0.006739047 
MROH6 3512.63 1.66 0.33 -5.10 3.34272E-07 3.55086E-05 
BGN 16.86 1.66 0.53 -3.11 0.001880921 0.021784395 
SLC19A1 1829.84 1.66 0.37 -4.48 7.57219E-06 0.00044571 
TH 116.02 1.65 0.33 -4.98 6.23379E-07 5.6133E-05 
KLK14 51.87 1.65 0.39 -4.20 2.65412E-05 0.001191025 
RP11-1275H24.1 55.10 1.63 0.42 -3.93 8.55968E-05 0.002747145 
PTPRU 2427.25 1.63 0.32 -5.07 3.90059E-07 4.05098E-05 
NAPRT1 1086.21 1.63 0.31 -5.24 1.57862E-07 2.00602E-05 
CDT1 2468.96 1.62 0.32 -4.99 5.94145E-07 5.53328E-05 
CPNE5 32.61 1.62 0.36 -4.55 5.3036E-06 0.000338559 
ABCA2 528.66 1.62 0.34 -4.77 1.85847E-06 0.000144398 
NUDT8 189.96 1.62 0.42 -3.89 0.000102143 0.003156451 
GDNF 35.28 1.61 0.34 -4.76 1.94597E-06 0.000150337 
FAM132A 82.35 1.61 0.40 -3.99 6.57703E-05 0.002306451 
FGFR4 330.38 1.61 0.35 -4.55 5.48997E-06 0.000345589 
LINC00173 14.42 1.61 0.59 -2.73 0.00640307 0.046458131 
COL5A3 97.34 1.59 0.35 -4.55 5.47311E-06 0.000345589 
PLK1 2492.76 1.59 0.27 -5.84 5.31008E-09 1.22375E-06 
OLFM2 237.37 1.58 0.33 -4.84 1.27851E-06 0.000105357 
EEF1A2 31.73 1.58 0.38 -4.21 2.55856E-05 0.001159625 
RP11-770E5.1 17.62 1.58 0.46 -3.44 0.000578136 0.010235564 
KCNK5 128.56 1.57 0.28 -5.64 1.73734E-08 3.32713E-06 
TONSL 1878.45 1.57 0.34 -4.58 4.57553E-06 0.000303651 
WNT7B 1240.12 1.55 0.32 -4.90 9.73165E-07 8.27008E-05 
GJC2 76.42 1.55 0.42 -3.67 0.000239484 0.005702741 
CTD-2555C10.3 51.20 1.54 0.41 -3.76 0.000172436 0.004535047 
GAREML 77.41 1.54 0.30 -5.04 4.63403E-07 4.47349E-05 
SLC52A3 439.00 1.53 0.26 -5.88 4.1459E-09 1.04392E-06 
HPDL 120.37 1.53 0.29 -5.36 8.16353E-08 1.21613E-05 
AC018638.1 21.57 1.52 0.50 -3.07 0.002158634 0.023670122 
C15orf39 3127.90 1.52 0.35 -4.37 1.2356E-05 0.000666683 
TMEM121 33.87 1.51 0.48 -3.15 0.001652997 0.02019389 
PROB1 480.44 1.51 0.33 -4.58 4.60044E-06 0.000303651 
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PRRT4 127.54 1.50 0.36 -4.12 3.71906E-05 0.001565573 
NPAS1 54.44 1.50 0.41 -3.63 0.000286895 0.006501514 
GPAA1 6340.25 1.50 0.35 -4.24 2.26669E-05 0.001059113 
PROM2 2941.51 1.50 0.32 -4.65 3.28821E-06 0.00023656 
C1orf145 18.13 1.50 0.47 -3.18 0.001457413 0.018554718 
PLEKHA7 188.14 1.49 0.22 -6.77 1.31768E-11 7.16657E-09 
LPHN1 126.92 1.49 0.37 -4.07 4.75998E-05 0.001878553 
KCNMA1 121.21 1.49 0.27 -5.47 4.59965E-08 7.81768E-06 
LINC00162 35.08 1.48 0.40 -3.69 0.000226536 0.005475789 
CTB-102L5.4 34.47 1.47 0.47 -3.15 0.00160817 0.019842369 
IRF2BPL 1128.35 1.47 0.29 -5.01 5.44604E-07 5.14235E-05 
SLC16A3 3228.38 1.47 0.36 -4.08 4.50465E-05 0.001817499 
FASN 96217.62 1.47 0.36 -4.04 5.42499E-05 0.002046291 
IGFBP2 5259.48 1.46 0.34 -4.37 1.22969E-05 0.000666137 
CBX2 339.33 1.46 0.34 -4.31 1.63281E-05 0.000816227 
TAS1R3 76.91 1.46 0.36 -4.10 4.04412E-05 0.001681587 
AC079250.1 42.29 1.45 0.39 -3.73 0.000188518 0.004839375 
KIF18B 1034.89 1.45 0.24 -5.97 2.4432E-09 6.92087E-07 
GALK1 231.14 1.45 0.38 -3.85 0.00012019 0.003544967 
CDC42BPG 2591.47 1.45 0.34 -4.25 2.10619E-05 0.000997833 
FURIN 11269.18 1.44 0.34 -4.28 1.8625E-05 0.000904443 
LRP3 1688.33 1.44 0.36 -4.01 6.11098E-05 0.00222205 
MFSD3 1337.78 1.44 0.32 -4.48 7.30959E-06 0.000437835 
FLJ27365 1882.10 1.43 0.33 -4.34 1.40193E-05 0.000727079 
SH2D2A 301.43 1.43 0.31 -4.60 4.24967E-06 0.000293314 
TMEM201 1333.13 1.43 0.37 -3.86 0.00011361 0.003402546 
GAS2L1 3357.03 1.42 0.35 -4.09 4.34396E-05 0.00176841 
AMN 57.17 1.42 0.40 -3.57 0.000358417 0.0076028 
SLC39A4 1011.15 1.42 0.37 -3.83 0.000126202 0.003666611 
ZNHIT2 408.48 1.42 0.36 -3.96 7.554E-05 0.002503256 
AQP3 2941.08 1.42 0.32 -4.45 8.41513E-06 0.000486896 
MMP9 284.79 1.41 0.32 -4.41 1.05104E-05 0.000585699 
EFR3B 61.07 1.41 0.29 -4.80 1.57838E-06 0.000124861 
N4BP3 1574.65 1.41 0.29 -4.82 1.43298E-06 0.000115291 
ICAM1 1169.32 1.41 0.26 -5.48 4.19055E-08 7.30499E-06 
RECQL4 1722.72 1.41 0.31 -4.58 4.58649E-06 0.000303651 
GCHFR 113.17 1.41 0.37 -3.84 0.000121533 0.003553739 
C3 64.73 1.41 0.28 -5.04 4.63898E-07 4.47349E-05 
COL18A1 3120.75 1.40 0.33 -4.22 2.47191E-05 0.001127872 
TNNI2 23.89 1.40 0.42 -3.34 0.000826532 0.013144283 
ARHGAP4 37.37 1.40 0.40 -3.51 0.000452464 0.008864767 
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TELO2 4341.95 1.40 0.33 -4.19 2.78231E-05 0.001224305 
TROAP 553.42 1.40 0.26 -5.36 8.38118E-08 1.22536E-05 
MDFI 6269.58 1.40 0.32 -4.34 1.41705E-05 0.000727079 
C17orf70 2465.73 1.40 0.35 -4.00 6.23973E-05 0.002238565 
ADRA1B 117.18 1.39 0.24 -5.89 3.86772E-09 9.92253E-07 
NOTCH3 2944.00 1.39 0.34 -4.05 5.10446E-05 0.001971743 
PRR12 2128.98 1.39 0.35 -3.97 7.18753E-05 0.00244527 
RP11-509E16.1 36.54 1.39 0.42 -3.34 0.000846042 0.01332845 
PDGFB 117.64 1.39 0.30 -4.67 2.95589E-06 0.000216703 
BCAM 5055.45 1.39 0.35 -3.96 7.43063E-05 0.002488529 
RP11-328M4.2 24.40 1.39 0.37 -3.73 0.000194687 0.00492037 
MIDN 3529.69 1.39 0.32 -4.33 1.51615E-05 0.000763523 
SLCO4A1 744.48 1.38 0.27 -5.04 4.56923E-07 4.47349E-05 
PKMYT1 6033.67 1.38 0.33 -4.13 3.55551E-05 0.00151076 
FBXL16 91.25 1.38 0.32 -4.26 2.03352E-05 0.000970165 
C1orf233 756.41 1.38 0.36 -3.81 0.000137218 0.00387086 
RAVER1 2235.36 1.37 0.37 -3.67 0.000243298 0.005783442 
RABL6 5465.28 1.37 0.32 -4.28 1.82986E-05 0.000894986 
HPCAL1 1749.61 1.37 0.30 -4.52 6.15698E-06 0.00038402 
NME3 779.59 1.37 0.36 -3.85 0.000119222 0.003524046 
KCNH3 57.12 1.37 0.37 -3.66 0.000249712 0.005894669 
DNASE1L2 101.76 1.37 0.33 -4.08 4.46195E-05 0.00180563 
FUOM 535.34 1.37 0.35 -3.87 0.000110039 0.003324876 
LINC01023 13.90 1.37 0.49 -2.76 0.005752889 0.04355347 
E2F2 110.11 1.36 0.35 -3.92 8.68174E-05 0.002777543 
FGFRL1 919.77 1.35 0.31 -4.30 1.69464E-05 0.000844028 
GAMT 179.20 1.35 0.38 -3.52 0.000435231 0.008713117 
WTIP 959.53 1.35 0.32 -4.24 2.26612E-05 0.001059113 
GCAT 389.12 1.35 0.36 -3.74 0.000182912 0.004755364 
PDLIM2 2653.01 1.35 0.33 -4.06 4.94549E-05 0.001937864 
C16orf59 629.54 1.35 0.34 -3.90 9.58857E-05 0.002990272 
RPS6KA4 9670.96 1.34 0.35 -3.87 0.000108537 0.003308931 
FAM203A 61.21 1.34 0.35 -3.79 0.000149382 0.004095066 
C20orf195 25.04 1.34 0.47 -2.88 0.003981263 0.034283237 
RP11-94H18.1 18.24 1.34 0.43 -3.12 0.001833697 0.021530899 
TGM3 14.91 1.33 0.49 -2.75 0.005951514 0.044406436 
PIDD 958.54 1.33 0.35 -3.77 0.000162192 0.004341182 
IGSF9B 119.71 1.32 0.33 -4.02 5.83159E-05 0.002148837 
KRT24 13.48 1.32 0.48 -2.77 0.005597304 0.042780518 
WDR18 3831.34 1.32 0.35 -3.79 0.000152259 0.004140542 
AGRN 39952.14 1.32 0.36 -3.69 0.00022466 0.005454828 
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RTEL1 57.36 1.32 0.36 -3.63 0.000285977 0.006491527 
SCRN2 526.82 1.32 0.30 -4.39 1.13603E-05 0.000617863 
DIRAS1 25.22 1.31 0.47 -2.78 0.005478644 0.042293811 
PYCRL 1028.07 1.31 0.35 -3.70 0.000211958 0.005259106 
ADAM8 9775.55 1.31 0.31 -4.28 1.90483E-05 0.000915193 
GPX1 9013.76 1.31 0.35 -3.73 0.000190361 0.004847066 
LFNG 1803.78 1.30 0.33 -3.93 8.41492E-05 0.00271132 
LAMA5 11199.37 1.30 0.36 -3.57 0.000357171 0.007588206 
GPSM1 2890.20 1.30 0.35 -3.70 0.000219024 0.0053532 
PIM3 7092.94 1.30 0.32 -4.06 4.89632E-05 0.001924139 
CD320 1093.13 1.30 0.36 -3.59 0.000335898 0.007284227 
KCNAB2 146.70 1.30 0.31 -4.24 2.28352E-05 0.001063321 
POLD1 3651.02 1.30 0.32 -4.03 5.64893E-05 0.002110122 
CENPM 436.70 1.30 0.35 -3.75 0.000179517 0.004694911 
FCRLB 26.12 1.30 0.47 -2.77 0.005596439 0.042780518 
RNF26 2097.26 1.30 0.36 -3.56 0.000375498 0.007854851 
H2AFX 5018.73 1.29 0.32 -4.08 4.59253E-05 0.001827923 
CAPN15 2199.98 1.29 0.33 -3.88 0.000102903 0.003172729 
FSCN1 34967.91 1.28 0.34 -3.75 0.000174741 0.00458678 
HR 3930.76 1.28 0.34 -3.76 0.000172075 0.004534317 
TMEM238 210.07 1.28 0.34 -3.78 0.000154824 0.004193518 
INTS1 11915.94 1.28 0.35 -3.64 0.000272527 0.006306864 
PFAS 2113.70 1.28 0.28 -4.48 7.54242E-06 0.00044571 
MIR3648 40.25 1.28 0.46 -2.76 0.005848651 0.044016309 
SLC4A2 5966.52 1.27 0.36 -3.58 0.00034312 0.007393672 
ISYNA1 338.21 1.27 0.33 -3.81 0.000139766 0.003926455 
WDR90 2511.18 1.27 0.31 -4.15 3.38966E-05 0.001453919 
STX1A 188.68 1.27 0.28 -4.52 6.19671E-06 0.000384733 
REEP4 3088.80 1.27 0.33 -3.83 0.000128168 0.003707862 
KREMEN2 437.56 1.27 0.32 -3.95 7.85505E-05 0.002578656 
GDPD2 24.43 1.27 0.41 -3.10 0.001937903 0.022142576 
IMPA2 1886.85 1.27 0.24 -5.38 7.60731E-08 1.16221E-05 
UNC93B1 1011.28 1.27 0.32 -3.92 8.99804E-05 0.002845264 
PLXNB2 14746.49 1.27 0.31 -4.02 5.7754E-05 0.002137774 
PAK6 243.65 1.27 0.35 -3.58 0.000347505 0.007452949 
NFKBID 1982.99 1.27 0.32 -4.00 6.46196E-05 0.002288107 
TSKU 3249.79 1.26 0.32 -3.94 8.13311E-05 0.002632998 
FHOD1 1461.24 1.26 0.30 -4.19 2.80027E-05 0.001228236 
PLEC 143550.89 1.26 0.35 -3.62 0.000294712 0.00661254 
MMP17 908.43 1.26 0.35 -3.63 0.000285812 0.006491527 
TTLL12 9007.03 1.26 0.33 -3.80 0.000142379 0.003975199 
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RIN1 1375.33 1.25 0.36 -3.45 0.000561586 0.010034017 
SRM 8146.16 1.25 0.34 -3.74 0.000187584 0.00483913 
LINC00472 20.42 1.25 0.46 -2.74 0.006079827 0.044976826 
NUDT16L1 914.77 1.25 0.34 -3.65 0.000266995 0.006226993 
MTSS1L 694.87 1.25 0.35 -3.58 0.000345473 0.007432585 
DCAF15 1693.72 1.25 0.30 -4.22 2.40036E-05 0.001101457 
SLC6A17 46.59 1.25 0.40 -3.08 0.002082431 0.023170877 
NRGN 57.27 1.25 0.39 -3.22 0.001275995 0.017089493 
MESP2 23.54 1.24 0.46 -2.70 0.006926515 0.048496306 
TMEM158 130.00 1.24 0.32 -3.84 0.00012125 0.003553124 
FOSL1 13941.72 1.24 0.27 -4.56 5.06496E-06 0.000327944 
RELT 1312.93 1.24 0.31 -4.04 5.43148E-05 0.002046291 
GNB1L 461.38 1.24 0.35 -3.56 0.00037404 0.007836401 
MBLAC1 43.77 1.24 0.33 -3.80 0.000143291 0.003992463 
C14orf80 1321.43 1.24 0.34 -3.63 0.000279434 0.006407181 
PIGQ 2932.88 1.24 0.37 -3.39 0.000710157 0.011906298 
CRISPLD2 128.30 1.24 0.24 -5.05 4.38716E-07 4.41868E-05 
GPR3 45.08 1.23 0.33 -3.71 0.000203529 0.00509647 
SLC5A5 20.84 1.23 0.43 -2.88 0.003916143 0.034098918 
PRSS21 142.03 1.23 0.30 -4.17 3.08373E-05 0.001334178 
ASPG 51.03 1.23 0.36 -3.45 0.000564166 0.010053696 
FBXW5 5827.71 1.23 0.35 -3.49 0.000477305 0.009080612 
C2 25.58 1.23 0.40 -3.05 0.002256431 0.024234356 
NPR1 328.31 1.23 0.25 -4.91 9.02426E-07 7.71716E-05 
SLC16A5 441.87 1.23 0.31 -3.97 7.22645E-05 0.002450326 
EPN1 9428.18 1.23 0.36 -3.44 0.000586778 0.010348154 
WNT10A 788.66 1.22 0.26 -4.69 2.75261E-06 0.00020452 
EMR2 302.05 1.22 0.18 -6.64 3.22297E-11 1.51113E-08 
PIF1 243.31 1.22 0.20 -5.99 2.05776E-09 6.21762E-07 
C9orf142 947.16 1.22 0.33 -3.71 0.000208862 0.005191762 
RARG 3752.50 1.22 0.31 -3.95 7.86443E-05 0.002578656 
INF2 9094.24 1.22 0.34 -3.64 0.000273574 0.006315419 
SPRY2 343.56 1.22 0.17 -7.09 1.3528E-12 1.02189E-09 
FAM110A 790.49 1.22 0.30 -4.02 5.85485E-05 0.002151577 
RP11-21L23.2 41.27 1.22 0.31 -3.88 0.00010579 0.003247022 
MFSD2B 325.29 1.22 0.38 -3.21 0.001345697 0.017625853 
MPND 178.40 1.22 0.35 -3.44 0.000584384 0.010319309 
KLHDC7B 24.69 1.21 0.45 -2.72 0.006493208 0.046862077 
CTXN1 284.01 1.21 0.37 -3.24 0.0011925 0.01641136 
SAPCD2 236.09 1.21 0.34 -3.52 0.000428185 0.008612481 
TMEM180 295.65 1.21 0.33 -3.63 0.00028259 0.006446932 
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CENPB 5729.18 1.21 0.34 -3.56 0.000373778 0.007836401 
CCNF 369.90 1.21 0.27 -4.47 7.91325E-06 0.000461787 
PLXNA1 11975.75 1.21 0.31 -3.92 8.89154E-05 0.002818143 
CHTF18 2776.72 1.21 0.32 -3.79 0.000151102 0.004126072 
SLC6A8 3677.92 1.21 0.34 -3.52 0.000439203 0.008718017 
DLX3 218.33 1.21 0.28 -4.31 1.61137E-05 0.000808482 
SYTL1 1975.77 1.21 0.30 -4.01 6.02155E-05 0.002206872 
TSPAN4 3314.16 1.21 0.33 -3.66 0.000254529 0.005987599 
NACC1 4270.71 1.21 0.35 -3.46 0.000550061 0.009880018 
FDXR 819.55 1.20 0.34 -3.55 0.000382614 0.007930493 
LY6E 11113.91 1.20 0.34 -3.50 0.000465945 0.008986356 
TMEM54 192.13 1.20 0.33 -3.68 0.000236449 0.005640787 
CDC25B 3436.51 1.20 0.28 -4.33 1.4998E-05 0.000758095 
ZNF295-AS1 20.21 1.20 0.44 -2.73 0.00624201 0.045926736 
SULT2B1 1498.70 1.20 0.28 -4.25 2.17138E-05 0.001025147 
LZTS1 247.60 1.20 0.34 -3.51 0.000452182 0.008864767 
SLC25A10 1723.12 1.20 0.36 -3.33 0.000881238 0.01358526 
NAT14 542.48 1.20 0.30 -3.95 7.87043E-05 0.002578656 
TMEM129 1167.55 1.19 0.31 -3.83 0.000129003 0.003724098 
BRAT1 2240.40 1.19 0.34 -3.44 0.000572276 0.010158271 
DPP7 2300.92 1.19 0.34 -3.54 0.000405013 0.008243955 
BCL9L 9299.58 1.18 0.34 -3.52 0.00043822 0.008718017 
ZBTB7B 2370.59 1.18 0.33 -3.59 0.000325255 0.007121569 
POLRMTP1 290.54 1.18 0.40 -2.98 0.002858843 0.02800554 
DOT1L 2546.66 1.18 0.33 -3.55 0.000389898 0.00803199 
ACOT11 204.72 1.18 0.33 -3.55 0.000381463 0.007918697 
BCL2L12 1643.39 1.18 0.29 -4.05 5.22739E-05 0.002007819 
MMP28 239.03 1.18 0.24 -4.93 8.01708E-07 6.996E-05 
DDN 43.77 1.18 0.39 -3.04 0.002404528 0.025188262 
CYP1B1-AS1 27.53 1.18 0.38 -3.14 0.001701251 0.020543438 
ZNF668 579.01 1.18 0.31 -3.81 0.000140646 0.003943025 
SLC25A22 2693.53 1.18 0.34 -3.43 0.00059561 0.010436215 
EMC10 386.78 1.18 0.35 -3.32 0.000907026 0.013810567 
MNT 2013.89 1.18 0.34 -3.45 0.000559413 0.010008348 
TMEM161A 1554.04 1.17 0.34 -3.40 0.000663688 0.011336885 
DHRS13 121.14 1.17 0.32 -3.68 0.000234954 0.005624424 
NFIC 4031.53 1.17 0.35 -3.35 0.000817746 0.013035047 
NDUFS7 1482.17 1.17 0.36 -3.23 0.001224933 0.016589053 
ATP5D 3032.23 1.17 0.33 -3.56 0.000366206 0.007731829 
TTLL10 214.13 1.17 0.23 -4.98 6.21691E-07 5.6133E-05 
TMEM8A 2493.82 1.16 0.34 -3.41 0.000654155 0.011216325 
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PLXND1 102.71 1.16 0.36 -3.27 0.001086366 0.015375861 
ZNF358 252.68 1.16 0.35 -3.37 0.000754833 0.012425503 
FOXD2-AS1 55.80 1.16 0.38 -3.06 0.002193656 0.023839395 
UNC13D 286.03 1.16 0.40 -2.89 0.003834848 0.033801146 
PELP1 3658.21 1.16 0.34 -3.43 0.000600215 0.010489881 
EREG 1538.55 1.16 0.22 -5.32 1.0161E-07 1.40979E-05 
TBL3 3464.34 1.15 0.35 -3.27 0.001070781 0.015293502 
CALM3 3296.49 1.15 0.26 -4.48 7.48667E-06 0.000444525 
FAM173A 686.07 1.15 0.33 -3.53 0.000419079 0.008466887 
NACC2 1178.86 1.15 0.31 -3.77 0.000162844 0.004350084 
PSKH1 662.01 1.15 0.31 -3.73 0.000187914 0.00483913 
CNN2 12302.18 1.15 0.33 -3.50 0.000467261 0.008986356 
ARHGEF16 955.94 1.15 0.32 -3.57 0.000351208 0.007508458 
FBXO46 1182.99 1.15 0.28 -4.04 5.27179E-05 0.002013497 
MT2P1 2239.63 1.15 0.27 -4.21 2.57591E-05 0.00116361 
EPPK1 8883.83 1.15 0.35 -3.27 0.001066295 0.015261482 
C1orf132 53.48 1.15 0.31 -3.69 0.000223139 0.005427575 
TCIRG1 2570.29 1.15 0.33 -3.53 0.000420124 0.008475404 
MRPS31P2 23.78 1.15 0.40 -2.85 0.004328283 0.03624117 
INTS5 1533.46 1.15 0.35 -3.32 0.000904932 0.013807599 
EFHD2 4821.89 1.15 0.29 -3.90 9.45193E-05 0.002968082 
CARD10 12538.49 1.15 0.33 -3.48 0.000499952 0.009310594 
DKFZP761J1410 1237.49 1.15 0.35 -3.30 0.000976658 0.01450839 
VPS51 3044.41 1.15 0.33 -3.51 0.000446611 0.008815268 
ST6GALNAC4 791.61 1.15 0.37 -3.13 0.001772348 0.021129455 
CASKIN2 947.05 1.15 0.35 -3.25 0.001171826 0.016245854 
TRMT61A 1714.09 1.15 0.36 -3.20 0.00135727 0.017710947 
GNAO1 24.84 1.15 0.41 -2.79 0.005260531 0.041155027 
CDHR1 228.93 1.15 0.25 -4.55 5.30121E-06 0.000338559 
MT2A 34609.61 1.15 0.27 -4.20 2.68113E-05 0.001199186 
COMTD1 1200.86 1.14 0.30 -3.84 0.000121251 0.003553124 
SH2D5 6792.14 1.14 0.28 -4.09 4.27068E-05 0.001743797 
TMEM109 47.38 1.14 0.37 -3.05 0.002271862 0.024304096 
BCAR1 7059.72 1.14 0.33 -3.51 0.000449173 0.008838507 
SLC2A4RG 2388.72 1.14 0.33 -3.43 0.00059295 0.010416453 
PRODH 200.72 1.14 0.26 -4.36 1.28721E-05 0.000689063 
PLA2G4F 832.23 1.14 0.30 -3.76 0.00016776 0.004452725 
C2CD4D 31.73 1.14 0.38 -3.00 0.002728715 0.027361611 
EFNA3 229.87 1.14 0.33 -3.42 0.000632855 0.01093384 
JAG2 5544.67 1.14 0.33 -3.44 0.000575174 0.010196404 
HMGA1 25419.87 1.14 0.34 -3.32 0.00091445 0.013855665 
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TACC3 2981.72 1.13 0.22 -5.27 1.3687E-07 1.78945E-05 
ADAM15 13591.22 1.13 0.35 -3.28 0.001021985 0.014830238 
SLC25A11 1917.13 1.13 0.32 -3.53 0.000413983 0.00838886 
MESDC1 2089.55 1.13 0.28 -4.00 6.44132E-05 0.002287225 
TMEM63C 205.57 1.13 0.32 -3.59 0.000337006 0.007296609 
POLRMT 2876.10 1.13 0.34 -3.34 0.00082395 0.013118563 
FYB 17.80 1.13 0.42 -2.70 0.006863255 0.048223635 
CSF1 1501.52 1.13 0.26 -4.34 1.42746E-05 0.000729669 
FAM195A 554.06 1.13 0.32 -3.54 0.000399555 0.008157277 
LEPREL2 668.88 1.13 0.34 -3.37 0.000760889 0.012510048 
MIER2 1206.91 1.13 0.34 -3.35 0.000817466 0.013035047 
SF3A2 3907.26 1.13 0.35 -3.24 0.001195644 0.016423036 
FBXL18 1375.47 1.13 0.32 -3.47 0.000519056 0.009537305 
PPP1R26-AS1 34.87 1.13 0.34 -3.31 0.000932528 0.014052646 
MSLN 3178.56 1.13 0.33 -3.42 0.000622658 0.010798827 
SREBF1 11755.72 1.13 0.32 -3.50 0.000466607 0.008986356 
EPHB6 194.10 1.12 0.38 -2.97 0.003006479 0.028849042 
PDDC1 2620.77 1.12 0.30 -3.74 0.0001843 0.004780133 
P2RY2 289.17 1.12 0.30 -3.76 0.00017098 0.004522987 
HAGHL 511.21 1.12 0.32 -3.48 0.000494722 0.009265476 
CCDC85B 6120.98 1.12 0.32 -3.56 0.00037008 0.007797304 
PQLC1 4256.82 1.12 0.34 -3.33 0.000868772 0.013500224 
HSPBP1 4426.06 1.12 0.33 -3.43 0.000598507 0.010473493 
GS1-393G12.12 43.31 1.12 0.37 -3.01 0.002590203 0.026369027 
PDLIM7 3714.62 1.12 0.30 -3.77 0.000160882 0.004323151 
MYBBP1A 6640.68 1.12 0.32 -3.46 0.000549043 0.009874793 
NAB2 1954.12 1.12 0.29 -3.89 9.83776E-05 0.003060961 
PHYHIP 134.90 1.12 0.34 -3.26 0.001103067 0.015542387 
TNRC18 9129.18 1.12 0.33 -3.36 0.000767287 0.012566419 
EXOSC4 636.55 1.12 0.36 -3.07 0.002143543 0.023580707 
NECAB3 188.49 1.12 0.33 -3.40 0.000671803 0.011445771 
KIAA1875 80.37 1.12 0.33 -3.36 0.000792717 0.012740625 
SPHK1 6487.16 1.11 0.32 -3.49 0.000476229 0.009080612 
MAFK 659.14 1.11 0.35 -3.15 0.001650963 0.020187177 
IFRD2 5528.99 1.11 0.30 -3.71 0.000208407 0.005191762 
AGAP3 6981.84 1.11 0.31 -3.56 0.000373948 0.007836401 
FAM83H 22302.93 1.11 0.34 -3.26 0.001109241 0.015597054 
ZNF865 797.81 1.11 0.31 -3.58 0.000347516 0.007452949 
TPRG1 41.60 1.11 0.31 -3.55 0.000379473 0.007914274 
PPDPF 6459.78 1.11 0.33 -3.35 0.00081519 0.01302484 
ZNF628 501.29 1.11 0.38 -2.94 0.003252789 0.03043921 
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C1orf86 1716.94 1.11 0.33 -3.33 0.000853183 0.013364898 
TTYH3 5900.85 1.11 0.35 -3.12 0.001816749 0.02139627 
RHBDF1 1337.58 1.11 0.29 -3.87 0.000106932 0.003267315 
MIR429 165.56 1.11 0.32 -3.45 0.000565993 0.010073044 
FAM155B 595.11 1.11 0.34 -3.27 0.001083015 0.015375861 
IRAK3 56.53 1.10 0.30 -3.64 0.000270825 0.00628396 
LLGL1 2596.87 1.10 0.32 -3.47 0.000511825 0.00945555 
PCAT6 40.00 1.10 0.39 -2.81 0.005027863 0.039932155 
PAQR5 25.84 1.10 0.36 -3.05 0.00232153 0.024660816 
FGFR3 2217.87 1.10 0.29 -3.73 0.000191818 0.004875038 
EHD1 14554.26 1.10 0.30 -3.72 0.000197978 0.004994262 
DGAT1 1640.21 1.10 0.33 -3.33 0.000878068 0.01356715 
REXO1 3249.12 1.10 0.35 -3.15 0.001632914 0.020056663 
BCL3 2167.42 1.10 0.34 -3.24 0.00118778 0.016379554 
TOR4A 1356.01 1.10 0.33 -3.33 0.000872242 0.013538674 
BOP1 914.25 1.10 0.33 -3.33 0.000880439 0.01358526 
ANO7 37.78 1.10 0.39 -2.80 0.005170873 0.040711269 
MAZ 769.32 1.10 0.31 -3.49 0.000479799 0.00909879 
RP11-478C19.2 222.05 1.10 0.32 -3.40 0.000668854 0.011410793 
PIEZO1 16376.30 1.10 0.33 -3.34 0.000838364 0.013247296 
SPPL2B 1421.42 1.09 0.32 -3.43 0.000595051 0.010436215 
AURKB 1836.26 1.09 0.25 -4.42 9.78805E-06 0.000552233 
COL7A1 25312.35 1.09 0.32 -3.41 0.000641781 0.011066297 
MST1R 4253.20 1.09 0.30 -3.69 0.000226272 0.005475789 
C1orf159 1403.04 1.09 0.32 -3.41 0.00064215 0.011066297 
SECTM1 182.56 1.09 0.33 -3.31 0.00093326 0.014052646 
KLF16 1436.81 1.09 0.32 -3.36 0.000787091 0.012719583 
MXRA8 320.81 1.09 0.31 -3.53 0.000410814 0.008337063 
PPP1R3F 134.69 1.09 0.35 -3.13 0.001737409 0.020795379 
ATP13A1 4023.79 1.09 0.33 -3.26 0.001127781 0.015808701 
GRWD1 4603.67 1.09 0.34 -3.24 0.001201632 0.01644112 
SBNO2 4887.78 1.09 0.32 -3.42 0.000619986 0.010779682 
C2orf48 103.98 1.08 0.27 -3.98 6.8751E-05 0.002366601 
SPHK2 696.87 1.08 0.37 -2.92 0.003459981 0.03161447 
ANGPTL4 367.42 1.08 0.33 -3.25 0.001139777 0.015890257 
TGFBR3L 45.45 1.08 0.39 -2.80 0.005059876 0.040116114 
CARD14 51.23 1.08 0.31 -3.50 0.000471381 0.009014579 
MAPK8IP2 230.07 1.08 0.33 -3.30 0.00098137 0.014551458 
RP11-611L7.1 692.21 1.08 0.31 -3.44 0.000588208 0.010359928 
PLEKHJ1 1966.51 1.08 0.31 -3.46 0.000541924 0.009798591 
CDHR2 57.22 1.08 0.31 -3.52 0.000439146 0.008718017 
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STAT5A 1472.92 1.08 0.24 -4.43 9.52257E-06 0.000539493 
DUS3L 1534.85 1.07 0.31 -3.42 0.000627797 0.010860242 
CHCHD10 427.42 1.07 0.27 -3.97 7.0624E-05 0.002418829 
FOXK1 2845.90 1.07 0.32 -3.34 0.000846935 0.01332845 
RBM38 1224.72 1.07 0.33 -3.29 0.001019701 0.014812904 
TMUB1 1648.93 1.07 0.33 -3.22 0.001281995 0.017089493 
METRN 1736.04 1.07 0.32 -3.31 0.000937514 0.014073158 
ATAD3A 3795.74 1.07 0.32 -3.36 0.00077565 0.012630554 
POM121C 1691.66 1.07 0.34 -3.14 0.00170061 0.020543438 
RET 117.60 1.07 0.26 -4.07 4.66582E-05 0.001849596 
PPAP2C 466.67 1.07 0.35 -3.07 0.002131595 0.023525407 
CLUH 17085.03 1.07 0.32 -3.38 0.000721178 0.012046506 
ZNF787 1812.98 1.07 0.35 -3.07 0.002112427 0.023389797 
UFSP1 33.58 1.07 0.37 -2.86 0.004176185 0.035423326 
FBLN2 238.17 1.07 0.30 -3.61 0.0003098 0.006838236 
C15orf52 2308.63 1.07 0.21 -4.98 6.41479E-07 5.73828E-05 
KIAA1549 284.82 1.06 0.24 -4.40 1.06418E-05 0.0005906 
RNASEH2C 387.15 1.06 0.31 -3.49 0.000487566 0.009169339 
APRT 2683.25 1.06 0.33 -3.18 0.001477301 0.018673893 
PTPN23 3819.87 1.06 0.35 -3.06 0.002247242 0.024183143 
PNKP 1789.06 1.06 0.28 -3.78 0.000157581 0.00425125 
SLC25A39 8066.04 1.06 0.32 -3.31 0.000938011 0.014073158 
CST3 4058.55 1.06 0.27 -3.86 0.000111967 0.003368173 
MED16 2091.68 1.06 0.36 -2.97 0.002962883 0.028612441 
RP11-465B22.8 1119.09 1.06 0.30 -3.49 0.000490057 0.009203468 
C7orf50 3257.85 1.06 0.32 -3.27 0.001086526 0.015375861 
PTPRS 928.10 1.06 0.30 -3.55 0.000386977 0.008004449 
FAM207BP 33.70 1.06 0.35 -2.98 0.002855121 0.027989243 
GIGYF1 2645.31 1.06 0.31 -3.46 0.000538845 0.009779213 
LRWD1 1246.36 1.06 0.33 -3.22 0.001279182 0.017089493 
NR2F6 1444.93 1.06 0.30 -3.47 0.000517213 0.009516307 
SYNGR1 111.23 1.06 0.36 -2.89 0.003794234 0.033598093 
TPGS1 272.69 1.06 0.30 -3.50 0.000470441 0.009009271 
ARHGEF4 3662.24 1.06 0.24 -4.40 1.09254E-05 0.000599 
MT-ND6 36529.48 1.06 0.28 -3.75 0.000179551 0.004694911 
FLNC 93.72 1.06 0.34 -3.07 0.002167597 0.023711037 
DNM1 119.84 1.05 0.32 -3.28 0.001040037 0.015044024 
SORCS2 40.22 1.05 0.36 -2.93 0.003385315 0.031179252 
GPC1 9934.83 1.05 0.34 -3.09 0.002025297 0.022758648 
RELL2 321.92 1.05 0.31 -3.36 0.000786694 0.012719583 
GPR144 36.22 1.05 0.36 -2.89 0.00390999 0.034098918 
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SLC43A1 128.59 1.05 0.27 -3.95 7.91533E-05 0.002581941 
ISOC2 1186.13 1.05 0.33 -3.22 0.001285374 0.017104421 
ILVBL 2227.49 1.05 0.34 -3.06 0.002216655 0.024034977 
TBX1 92.83 1.05 0.36 -2.93 0.003386906 0.031179252 
NINJ1 3040.42 1.05 0.28 -3.82 0.000134146 0.003823852 
SIRPB2 34.25 1.05 0.35 -2.99 0.002820388 0.027835316 
THEM6 421.31 1.05 0.37 -2.87 0.004099873 0.034906687 
PER2 235.79 1.05 0.26 -3.98 6.84185E-05 0.002366601 
FANCE 492.62 1.05 0.30 -3.51 0.000440599 0.008732974 
DVL1 9114.82 1.05 0.33 -3.19 0.001400847 0.01808862 
MT-ND3 22969.29 1.05 0.31 -3.33 0.000865118 0.013489697 
PPP1R13L 7732.58 1.04 0.33 -3.20 0.001388635 0.01798684 
WDR4 3245.66 1.04 0.27 -3.82 0.000131848 0.003774184 
ADAMTSL4 398.75 1.04 0.32 -3.29 0.001001337 0.014655732 
CCND1 4598.99 1.04 0.16 -6.40 1.60113E-10 6.59713E-08 
ESRRA 2712.01 1.04 0.32 -3.25 0.001134185 0.015833179 
SBF1 8431.28 1.04 0.35 -2.99 0.002820995 0.027835316 
TMEM79 768.62 1.04 0.32 -3.24 0.001182867 0.016333084 
RPUSD1 1953.74 1.04 0.37 -2.78 0.005378559 0.041776627 
CYC1 4600.26 1.04 0.27 -3.87 0.000108985 0.003313715 
MBD3 3699.81 1.04 0.35 -2.99 0.002781107 0.027642335 
ALDH16A1 502.00 1.04 0.37 -2.81 0.004917422 0.039485788 
OXLD1 317.07 1.04 0.32 -3.25 0.001152862 0.016044482 
PSD4 2859.20 1.04 0.29 -3.61 0.000303131 0.006723774 
GIPC1 11654.42 1.03 0.34 -3.03 0.002423959 0.025352749 
40057.00 16352.67 1.03 0.31 -3.31 0.000936542 0.014073158 
ASPSCR1 874.76 1.03 0.34 -3.06 0.002182058 0.023811751 
WDR34 2869.03 1.03 0.33 -3.14 0.001717818 0.020651791 
PRR22 131.64 1.03 0.29 -3.57 0.000352591 0.007514392 
KLHL26 267.48 1.03 0.33 -3.10 0.001914807 0.022026757 
NOC4L 1534.39 1.03 0.35 -2.99 0.002799878 0.027747775 
KCTD11 420.33 1.03 0.34 -3.05 0.002260774 0.024261834 
RHOT2 4771.50 1.03 0.30 -3.42 0.000623571 0.01080089 
CISD3 992.15 1.03 0.32 -3.24 0.001195764 0.016423036 
PCNXL3 4860.32 1.03 0.34 -3.01 0.002644579 0.026811754 
LRRC45 763.48 1.03 0.32 -3.22 0.001264302 0.017008684 
VARS 10713.45 1.03 0.33 -3.07 0.002112197 0.023389797 
CTSD 1180.35 1.03 0.34 -3.05 0.002274739 0.024315741 
G6PC3 1216.02 1.03 0.34 -3.04 0.002327853 0.024708683 
ZDHHC12 2325.25 1.03 0.35 -2.93 0.003383209 0.031179252 
SH2D3A 2776.08 1.02 0.26 -3.87 0.000109182 0.003313715 
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CTD-2228K2.5 67.35 1.02 0.27 -3.85 0.000118466 0.003514569 
TM7SF2 870.20 1.02 0.31 -3.30 0.000974377 0.014495193 
ENDOG 175.72 1.02 0.35 -2.90 0.003748835 0.033359231 
LTBP3 1571.23 1.02 0.32 -3.19 0.001417351 0.018232469 
C16orf13 1204.27 1.02 0.33 -3.14 0.001704644 0.020560733 
KIF26A 58.65 1.02 0.38 -2.69 0.007120102 0.049464084 
DUSP6 602.40 1.02 0.27 -3.72 0.000201177 0.005055857 
RP11-54F2.1 213.82 1.02 0.19 -5.42 5.978E-08 9.5627E-06 
SIRT6 1393.96 1.02 0.32 -3.16 0.001581123 0.019581242 
TMEM38A 104.36 1.02 0.32 -3.19 0.001411108 0.018178666 
C20orf27 1964.11 1.02 0.35 -2.88 0.004026182 0.034517023 
NCAPH2 2976.95 1.02 0.29 -3.46 0.000535848 0.009740551 
EFS 852.73 1.02 0.30 -3.36 0.000790868 0.012738896 
PKN3 520.02 1.02 0.29 -3.49 0.000477505 0.009080612 
CDH4 1352.87 1.02 0.30 -3.40 0.000685857 0.011598999 
PC 3333.94 1.02 0.31 -3.27 0.001086725 0.015375861 
BRD4 4559.68 1.02 0.32 -3.16 0.001603292 0.019818149 
IMPDH1 4994.38 1.02 0.32 -3.14 0.001673871 0.020361764 
PER1 5302.32 1.02 0.35 -2.95 0.003161906 0.029939018 
YIF1A 2404.46 1.02 0.34 -3.02 0.002523252 0.026014143 
ATP6V0B 4893.20 1.02 0.36 -2.86 0.004255767 0.035834966 
RAC3 585.52 1.02 0.36 -2.84 0.004470161 0.037129373 
NCLN 10879.70 1.02 0.35 -2.89 0.003852641 0.033840027 
UBE2S 1114.82 1.02 0.28 -3.64 0.000277714 0.006400121 
CCDC61 401.86 1.02 0.29 -3.47 0.000528961 0.009654066 
SULT1A1 165.80 1.02 0.29 -3.55 0.000392242 0.008056373 
FOXRED2 555.11 1.02 0.28 -3.57 0.000356003 0.007575227 
ARRDC1 3173.95 1.02 0.32 -3.22 0.001281763 0.017089493 
CBLC 2056.54 1.01 0.29 -3.46 0.000544338 0.009803122 
LAT2 71.13 1.01 0.31 -3.22 0.001271118 0.017061591 
ZNF316 1132.30 1.01 0.32 -3.21 0.001341184 0.017585415 
MFSD10 7970.37 1.01 0.32 -3.13 0.00177309 0.021129455 
LTBR 5083.33 1.01 0.28 -3.57 0.000360655 0.007638353 
TRMT2A 1123.20 1.01 0.33 -3.06 0.002231577 0.024098677 
B4GALT2 5012.19 1.01 0.33 -3.12 0.001839333 0.021578433 
ARHGEF39 68.50 1.01 0.28 -3.61 0.000301518 0.006704671 
HOXC11 282.86 1.01 0.23 -4.34 1.40792E-05 0.000727079 
ADCK4 807.54 1.01 0.32 -3.15 0.00164014 0.020109099 
RAD23A 4718.26 1.01 0.31 -3.29 0.001000817 0.014655732 
MEX3A 107.49 1.01 0.29 -3.50 0.000462092 0.008962129 
ADCK5 586.51 1.01 0.31 -3.22 0.001264675 0.017008684 
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ZNF524 341.13 1.01 0.35 -2.88 0.004012855 0.034469661 
DCXR 834.38 1.01 0.31 -3.29 0.000998169 0.014655732 
RASIP1 675.34 1.01 0.32 -3.12 0.001790454 0.0212431 
PGP 820.60 1.01 0.25 -4.08 4.5977E-05 0.001827923 
BAK1 2542.84 1.01 0.33 -3.07 0.002125211 0.023510979 
AKT1S1 4733.54 1.01 0.33 -3.09 0.001997649 0.022635028 
RARA 480.67 1.01 0.32 -3.11 0.001866792 0.021639196 
DUSP23 650.19 1.01 0.30 -3.33 0.000866472 0.013490079 
C17orf53 532.40 1.01 0.24 -4.12 3.85807E-05 0.001614099 
MIR663A 255.94 1.01 0.32 -3.14 0.001688952 0.020467634 
AXL 852.90 1.01 0.17 -6.04 1.49893E-09 4.73976E-07 
ARFRP1 1872.26 1.01 0.29 -3.42 0.000620761 0.010779682 
TIMM17B 1402.80 1.01 0.35 -2.89 0.003896802 0.034051938 
WDR24 592.06 1.00 0.33 -3.01 0.002594935 0.026389929 
SNAPC4 1998.77 1.00 0.29 -3.45 0.000559083 0.010008348 
SEMA4C 557.59 1.00 0.30 -3.38 0.000736496 0.012210955 
TMEM175 691.18 1.00 0.30 -3.29 0.000993432 0.014634559 
C9orf16 1686.52 1.00 0.33 -3.06 0.002195828 0.023839395 
FZR1 2649.62 1.00 0.33 -3.06 0.002228433 0.024098677 
RP11-1055B8.7 740.57 1.00 0.35 -2.90 0.003788244 0.033578068 
FBXW9 498.76 1.00 0.30 -3.34 0.000850155 0.013363656 
RP11-215G15.5 235.10 1.00 0.20 -5.09 3.5582E-07 3.75046E-05 
TMEM134 800.21 1.00 0.32 -3.09 0.002021949 0.022758648 
PKP3 13159.86 1.00 0.30 -3.29 0.001013192 0.014770654 
ZFP36L1 8243.97 1.00 0.25 -4.07 4.7665E-05 0.001878553 
NDOR1 1805.92 1.00 0.34 -2.97 0.002978623 0.028682958 
GMEB2 1587.34 1.00 0.31 -3.28 0.001043383 0.015076381 
ZNF213 746.39 1.00 0.35 -2.87 0.00408169 0.034839129 
DRAP1 7103.01 1.00 0.23 -4.33 1.45841E-05 0.000739925 
SLC12A4 5020.33 1.00 0.31 -3.28 0.001049434 0.015147718 
RP11-1096G20.5 246.66 1.00 0.28 -3.62 0.000293556 0.006597482 
COMMD2 435.24 -1.00 0.26 3.84 0.00012252 0.003574915 
RP11-2H8.2 35.43 -1.00 0.37 2.70 0.006871068 0.048232271 
ARHGEF12 2745.08 -1.01 0.18 5.50 3.88844E-08 6.95672E-06 
VLDLR 92.20 -1.01 0.26 3.90 9.49052E-05 0.002969542 
PRKRIR 362.13 -1.01 0.26 3.82 0.000134977 0.003831489 
MYLIP 97.64 -1.01 0.26 3.82 0.000133327 0.003808513 
TNFSF10 247.29 -1.01 0.20 4.92 8.52443E-07 7.38259E-05 
AC005224.2 28.82 -1.01 0.36 2.81 0.00498291 0.039753053 
CTC-436P18.3 27.08 -1.01 0.36 2.78 0.005383 0.041776627 
RP13-631K18.5 36.87 -1.01 0.32 3.12 0.001795383 0.021246149 
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RFTN1P1 40.55 -1.01 0.32 3.21 0.00134686 0.017625853 
AP2B1 3365.29 -1.02 0.20 5.12 3.12266E-07 3.34321E-05 
RCBTB1 358.28 -1.02 0.22 4.66 3.20565E-06 0.000233087 
ROBO2 70.72 -1.02 0.27 3.85 0.00012054 0.003547569 
KRT75 1796.31 -1.02 0.15 6.64 3.09229E-11 1.50164E-08 
SLC35B4 248.73 -1.02 0.19 5.26 1.42099E-07 1.82275E-05 
OCRL 698.67 -1.02 0.19 5.51 3.64911E-08 6.61559E-06 
CTSO 55.38 -1.03 0.35 2.92 0.003462083 0.03161447 
ATG4A 64.05 -1.03 0.28 3.66 0.000249422 0.005894669 
KRT34 1606.18 -1.03 0.18 5.69 1.28334E-08 2.56611E-06 
SLFN5 3131.31 -1.04 0.24 4.26 2.08983E-05 0.000993548 
ZNF135 62.19 -1.04 0.33 3.18 0.001469539 0.018632549 
SPON1 29.17 -1.04 0.37 2.79 0.005210132 0.040901939 
KLF6 16751.19 -1.04 0.16 6.39 1.66308E-10 6.65085E-08 
DDX60 1745.46 -1.04 0.31 3.39 0.000701002 0.011796449 
RHOQ 33.69 -1.04 0.33 3.20 0.001396257 0.018046484 
KDELR3 71.01 -1.04 0.25 4.12 3.79287E-05 0.001591716 
TSPYL5 148.08 -1.04 0.25 4.23 2.30956E-05 0.001071778 
PIK3CB 563.23 -1.05 0.18 5.91 3.48811E-09 9.12075E-07 
YIPF6 487.20 -1.05 0.21 4.97 6.76316E-07 6.01037E-05 
RP11-517B11.7 37.17 -1.05 0.38 2.75 0.006035884 0.044773547 
SYTL2 46.78 -1.06 0.32 3.29 0.000986963 0.01459073 
SNCAIP 40.32 -1.06 0.35 3.01 0.002578651 0.026325829 
TAGLN 786.24 -1.07 0.22 4.89 1.01011E-06 8.47805E-05 
RASSF6 192.37 -1.08 0.24 4.49 7.01874E-06 0.000426044 
KRT15 2745.68 -1.08 0.15 7.35 2.03796E-13 2.13155E-10 
TMED2 3722.80 -1.08 0.21 5.23 1.72952E-07 2.09967E-05 
C2orf27A 70.51 -1.08 0.28 3.85 0.000116102 0.003461925 
PIK3IP1 159.42 -1.09 0.23 4.82 1.41715E-06 0.000114697 
RND1 75.76 -1.10 0.25 4.40 1.08094E-05 0.000595043 
COG6 258.16 -1.10 0.24 4.67 2.96438E-06 0.000216703 
RPS6KL1 37.99 -1.11 0.35 3.18 0.00145262 0.018516646 
ZNF165 368.98 -1.11 0.20 5.57 2.5655E-08 4.84488E-06 
FAM115A 181.01 -1.11 0.22 4.95 7.49602E-07 6.6184E-05 
CENPQ 189.16 -1.12 0.28 4.03 5.62844E-05 0.002108262 
LARP6 171.74 -1.12 0.19 5.74 9.50429E-09 1.9288E-06 
ANKRD19P 23.58 -1.12 0.39 2.91 0.003622536 0.032533439 
RCAN1 2603.32 -1.12 0.18 6.10 1.03261E-09 3.51011E-07 
CYP2R1 93.95 -1.12 0.27 4.20 2.71209E-05 0.001203951 
LCA5 19.52 -1.12 0.41 2.76 0.005861751 0.044058723 
FBXO32 44.10 -1.12 0.31 3.62 0.000295709 0.00662398 
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TCHH 63.62 -1.12 0.28 3.97 7.27619E-05 0.002461053 
ZXDA 109.78 -1.13 0.28 3.98 6.87168E-05 0.002366601 
S100A7 119.65 -1.13 0.22 5.20 2.04707E-07 2.39948E-05 
RND3 7959.37 -1.13 0.22 5.12 3.03432E-07 3.27442E-05 
INA 27.43 -1.13 0.38 3.01 0.002597615 0.026397433 
TXNIP 252.13 -1.13 0.25 4.58 4.56995E-06 0.000303651 
ZPLD1 36.07 -1.13 0.35 3.23 0.001244177 0.01679948 
KCNJ2 68.22 -1.13 0.35 3.21 0.001349603 0.017644757 
MGAT4A 41.98 -1.14 0.37 3.08 0.002048242 0.022865311 
ASNS 705.06 -1.14 0.22 5.28 1.27181E-07 1.72928E-05 
SLC27A6 115.23 -1.14 0.27 4.18 2.9055E-05 0.001270292 
NXT2 125.36 -1.15 0.26 4.34 1.4162E-05 0.000727079 
CD200 31.00 -1.15 0.36 3.17 0.001536268 0.019216779 
EPB41 361.26 -1.15 0.19 6.15 7.55016E-10 2.70157E-07 
AC005083.1 24.86 -1.15 0.39 2.93 0.003407772 0.031286616 
MAP3K8 627.75 -1.15 0.21 5.41 6.24097E-08 9.75384E-06 
APOBEC3G 31.43 -1.16 0.36 3.17 0.001503992 0.018917463 
BST2 42.90 -1.16 0.32 3.69 0.000227249 0.005478548 
HIST1H2BD 173.66 -1.16 0.20 5.83 5.44439E-09 1.23379E-06 
LRRK2 23.77 -1.16 0.42 2.79 0.005230626 0.04099183 
BPGM 635.21 -1.17 0.23 5.17 2.38653E-07 2.68179E-05 
GALNT5 368.05 -1.17 0.22 5.28 1.29217E-07 1.73956E-05 
IL1B 5626.22 -1.17 0.16 7.22 5.29352E-13 4.23388E-10 
ERBB2IP 1032.46 -1.18 0.22 5.44 5.40699E-08 8.96571E-06 
SNRNP27 114.19 -1.18 0.21 5.48 4.31824E-08 7.4323E-06 
MSMO1 4621.80 -1.18 0.24 4.98 6.21501E-07 5.6133E-05 
RP11-20B7.1 46.36 -1.19 0.30 3.99 6.50229E-05 0.002296405 
FYTTD1 754.82 -1.19 0.26 4.57 4.77388E-06 0.000312629 
AC107399.2 21.45 -1.19 0.39 3.06 0.002194606 0.023839395 
BEND7 102.89 -1.19 0.24 5.04 4.60455E-07 4.47349E-05 
RP11-690G19.3 27.14 -1.19 0.35 3.38 0.000733514 0.012197674 
RP11-3L8.3 56.25 -1.20 0.27 4.42 9.99077E-06 0.000559031 
ZSCAN31 102.59 -1.20 0.25 4.85 1.21122E-06 0.00010042 
RSAD2 192.83 -1.21 0.29 4.23 2.35208E-05 0.001084108 
LEPR 128.38 -1.22 0.25 4.84 1.28714E-06 0.000105429 
ERO1LB 29.83 -1.23 0.35 3.46 0.000530928 0.009676983 
ARL5B 1724.07 -1.23 0.25 4.88 1.05365E-06 8.78928E-05 
FAM46A 135.83 -1.23 0.24 5.19 2.12801E-07 2.47303E-05 
AC005682.6 20.58 -1.24 0.42 2.97 0.002970335 0.02864372 
DISP1 36.85 -1.25 0.40 3.09 0.002013977 0.022721133 
STRADB 80.93 -1.25 0.28 4.51 6.63607E-06 0.000408284 
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SELPLG 36.41 -1.27 0.37 3.45 0.000562561 0.010038252 
DNAJB9 219.89 -1.27 0.27 4.74 2.17705E-06 0.000166644 
SLC9A2 16.03 -1.27 0.45 2.80 0.005167454 0.040711269 
RP11-196G18.22 41.56 -1.27 0.32 3.97 7.19356E-05 0.00244527 
HEPHL1 569.61 -1.28 0.22 5.74 9.37452E-09 1.9288E-06 
OVCH2 28.82 -1.29 0.37 3.51 0.000446696 0.008815268 
BTG4 29.73 -1.29 0.38 3.36 0.000768939 0.012566419 
RP11-
1020M18.10 
109.99 -1.29 0.22 5.87 4.33041E-09 1.05144E-06 
PLA2G4C 71.89 -1.29 0.27 4.72 2.37625E-06 0.000180502 
ECHDC1 657.12 -1.29 0.22 5.97 2.31761E-09 6.85055E-07 
CYFIP2 21.83 -1.30 0.40 3.27 0.001073978 0.015299623 
CERKL 25.15 -1.31 0.39 3.38 0.000713863 0.011953695 
RAB6B 83.06 -1.31 0.28 4.71 2.4891E-06 0.000188024 
RP11-403A21.1 79.28 -1.31 0.27 4.89 1.00606E-06 8.47805E-05 
MYO16 331.65 -1.31 0.22 6.06 1.35062E-09 4.43346E-07 
DIO2 22.50 -1.32 0.45 2.90 0.003775658 0.033494554 
MOXD1 85.44 -1.32 0.26 4.99 5.99805E-07 5.54799E-05 
STC2 119.68 -1.32 0.23 5.65 1.60581E-08 3.11918E-06 
GPC4 45.74 -1.32 0.30 4.37 1.2644E-05 0.000679529 
IL7 66.16 -1.32 0.31 4.24 2.22125E-05 0.001045065 
GRIK1 13.80 -1.32 0.49 2.69 0.007148503 0.049586225 
PTPRR 15.57 -1.32 0.48 2.75 0.005916566 0.044274511 
IMPG1 19.16 -1.33 0.42 3.17 0.001542175 0.019237578 
ID4 51.04 -1.33 0.29 4.56 5.05434E-06 0.000327944 
SULT1E1 37.89 -1.35 0.35 3.87 0.000109477 0.003315288 
ENO2 36.83 -1.35 0.33 4.08 4.5878E-05 0.001827923 
APBA1 45.52 -1.35 0.34 4.02 5.70716E-05 0.002126035 
FN1 732.37 -1.35 0.19 7.07 1.53616E-12 1.09932E-09 
LANCL1 38.30 -1.36 0.39 3.50 0.000457612 0.008927038 
IL23A 136.77 -1.38 0.23 5.95 2.70754E-09 7.44259E-07 
RP1-93H18.7 16.47 -1.38 0.44 3.13 0.001722921 0.020676574 
CCDC115 161.99 -1.39 0.22 6.34 2.31427E-10 8.99061E-08 
TMEM217 241.21 -1.39 0.18 7.56 3.93689E-14 4.46083E-11 
N4BP2L1 18.71 -1.39 0.42 3.31 0.000947901 0.014194499 
HSD11B1 42.67 -1.40 0.31 4.43 9.28077E-06 0.000530213 
IL20 265.07 -1.40 0.23 5.97 2.41045E-09 6.92087E-07 
RP11-443P15.2 56.88 -1.40 0.33 4.29 1.80294E-05 0.000885001 
CCDC126 46.64 -1.40 0.31 4.59 4.49527E-06 0.000303651 
RP1-78O14.1 20.49 -1.41 0.41 3.43 0.000603668 0.010536678 
CAMK4 16.19 -1.41 0.49 2.88 0.003950799 0.034172405 
PLCL2 32.43 -1.41 0.39 3.65 0.000258057 0.006060111 
 
 
28 
 
SERINC3 1189.28 -1.41 0.19 7.64 2.14103E-14 2.80042E-11 
RP11-439L18.3 15.35 -1.42 0.49 2.89 0.003910237 0.034098918 
SOCS3 861.48 -1.43 0.31 4.59 4.48737E-06 0.000303651 
CXCL5 283.89 -1.43 0.28 5.16 2.48738E-07 2.77221E-05 
ATPAF1 318.40 -1.46 0.20 7.32 2.5558E-13 2.40499E-10 
SLC2A10 13.52 -1.46 0.48 3.04 0.002351335 0.02483996 
RP11-277P12.20 142.86 -1.46 0.22 6.61 3.73439E-11 1.69225E-08 
IGFBP3 871.07 -1.47 0.17 8.44 3.22263E-17 5.47726E-14 
RP11-96K19.2 15.89 -1.48 0.54 2.76 0.005763752 0.04358717 
VNN3 30.52 -1.50 0.39 3.79 0.000147738 0.004073185 
KLHL24 111.36 -1.52 0.25 6.20 5.77507E-10 2.12226E-07 
ADORA2BP 24.02 -1.53 0.39 3.96 7.56666E-05 0.002503256 
RP1-28O10.1 224.10 -1.54 0.23 6.74 1.57153E-11 8.21852E-09 
MIR146A 195.64 -1.54 0.29 5.33 9.99558E-08 1.40113E-05 
RRAGD 52.38 -1.54 0.30 5.07 4.04332E-07 4.13361E-05 
RP11-568N6.1 29.06 -1.55 0.38 4.05 5.03006E-05 0.001948538 
CASP7 286.33 -1.58 0.23 6.97 3.2612E-12 2.21712E-09 
FAM171B 67.39 -1.59 0.28 5.74 9.34446E-09 1.9288E-06 
CDKL2 19.22 -1.59 0.44 3.60 0.000323486 0.007105713 
CADPS2 14.06 -1.61 0.52 3.10 0.001914496 0.022026757 
REPS2 29.16 -1.62 0.35 4.57 4.78244E-06 0.000312629 
SERPINE3 43.91 -1.64 0.32 5.20 2.03699E-07 2.39948E-05 
MSRB3 60.95 -1.65 0.32 5.23 1.69468E-07 2.09408E-05 
KB-1460A1.5 17.99 -1.66 0.47 3.50 0.000472202 0.009017595 
TEPP 15.98 -1.67 0.46 3.60 0.000319723 0.00703442 
TUBA1A 535.97 -1.67 0.18 9.32 1.13575E-20 3.86071E-17 
MAP1B 118.14 -1.68 0.23 7.31 2.65315E-13 2.40499E-10 
AC104777.2 36.55 -1.68 0.36 4.70 2.5751E-06 0.000193445 
SYT14 40.15 -1.72 0.33 5.23 1.70952E-07 2.09408E-05 
SOX4 3302.44 -1.72 0.16 11.04 2.49378E-28 3.3908E-24 
AC023115.2 14.19 -1.74 0.49 3.57 0.000363481 0.007686239 
FZD3 107.90 -1.74 0.24 7.22 5.21551E-13 4.23388E-10 
S100A12 22.42 -1.74 0.42 4.20 2.64843E-05 0.001191025 
HAS2 15.75 -1.77 0.48 3.73 0.00018957 0.004845076 
VIM 471.24 -1.78 0.17 10.51 7.59215E-26 5.16152E-22 
NFKBIZ 11511.68 -1.78 0.19 9.23 2.60778E-20 7.09159E-17 
KCNJ5 38.35 -1.82 0.35 5.27 1.39448E-07 1.80579E-05 
POSTN 29.78 -1.83 0.53 3.47 0.000526519 0.009622418 
SPRR2A 433.82 -1.84 0.27 6.80 1.03889E-11 5.88574E-09 
BVES 35.85 -1.89 0.36 5.23 1.6806E-07 2.09408E-05 
MBD5 562.33 -1.89 0.21 9.06 1.33897E-19 3.03432E-16 
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LSMEM1 28.35 -1.89 0.45 4.21 2.50722E-05 0.001140155 
CXCL6 44.81 -1.90 0.34 5.54 3.02475E-08 5.63391E-06 
SPRR3 281.51 -1.92 0.28 6.93 4.32803E-12 2.80229E-09 
TLR3 58.90 -1.95 0.31 6.23 4.57619E-10 1.7284E-07 
RP11-79H23.3 117.66 -1.96 0.24 8.23 1.92715E-16 2.91149E-13 
IL16 141.60 -1.98 0.22 9.02 1.8425E-19 3.57892E-16 
UCHL1 25.30 -2.06 0.39 5.24 1.63328E-07 2.05627E-05 
SERPINB4 17.44 -2.71 0.52 5.21 1.89325E-07 2.2781E-05 
KIAA1683 14.82 -3.01 0.63 4.80 1.58728E-06 0.000124861 
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Table S2. List of genes regulated by NFKBIZ knockdown in primary KC after 24 h 
of IL-36α treatment 
 
  Base Mean log2 fold 
Change 
lfcSE stat P value P value adj. 
EIF3CL 90.67 4.06 1.13 -3.59 0.000331714 0.008152368 
KRT24 31.08 2.91 0.43 -6.75 1.47482E-11 9.70012E-09 
CAPN8 61.71 2.09 0.29 -7.25 4.10347E-13 2.983E-10 
FAM198B 44.03 1.88 0.31 -5.99 2.03957E-09 5.3152E-07 
SLITRK6 45.18 1.75 0.33 -5.33 1.00299E-07 1.57424E-05 
STXBP6 13.61 1.73 0.52 -3.29 0.00099468 0.017750032 
LIPH 29.41 1.64 0.36 -4.58 4.75827E-06 0.000360893 
NTSR1 78.88 1.52 0.25 -6.01 1.90292E-09 5.1979E-07 
STAC 26.41 1.44 0.40 -3.59 0.000333048 0.008156136 
LINC00887 20.71 1.41 0.41 -3.41 0.000657254 0.013310848 
MYH15 30.14 1.36 0.34 -3.97 7.13402E-05 0.002667673 
RIC3 117.85 1.36 0.21 -6.38 1.72605E-10 8.13769E-08 
DMRTA1 23.41 1.30 0.40 -3.29 0.000992507 0.017734168 
DCN 17.44 1.27 0.45 -2.83 0.004682933 0.049665678 
SCML2 92.89 1.27 0.24 -5.22 1.74412E-07 2.43331E-05 
ITGBL1 28.56 1.27 0.38 -3.33 0.000857423 0.015982091 
RP11-298I3.4 17.83 1.24 0.43 -2.88 0.004010271 0.044886435 
HSPD1P6 34.86 1.22 0.32 -3.83 0.000128662 0.004094669 
PHACTR3 60.59 1.22 0.27 -4.51 6.62191E-06 0.000445448 
DIRAS1 33.77 1.16 0.40 -2.91 0.00362251 0.042080834 
SDPR 243.29 1.16 0.21 -5.58 2.4665E-08 5.07779E-06 
GPR110 497.93 1.15 0.18 -6.43 1.27104E-10 6.5021E-08 
SYT8 268.62 1.14 0.21 -5.43 5.61872E-08 9.70073E-06 
MAP7D2 48.49 1.12 0.28 -3.97 7.26778E-05 0.002691222 
ABCC2 75.47 1.11 0.24 -4.60 4.18993E-06 0.000326957 
LINC00589 55.07 1.08 0.28 -3.91 9.18453E-05 0.003187356 
SFTA1P 58.81 1.08 0.28 -3.82 0.000130854 0.00414531 
PTGS1 511.23 1.07 0.17 -6.19 5.91133E-10 2.04118E-07 
CTD-2620I22.1 33.05 1.06 0.36 -2.98 0.002896516 0.035624827 
SMOC1 366.80 1.05 0.20 -5.26 1.41323E-07 2.07655E-05 
RGS2 307.53 1.04 0.20 -5.24 1.61151E-07 2.31855E-05 
PRUNE2 26.42 1.04 0.36 -2.90 0.003700374 0.042733745 
SPA17 45.81 1.04 0.29 -3.61 0.000308974 0.007787498 
ZNF583 58.68 1.04 0.26 -4.00 6.46924E-05 0.002495898 
MYEF2 71.56 1.02 0.25 -4.07 4.72542E-05 0.001977803 
ZNF239 91.37 1.02 0.23 -4.41 1.04794E-05 0.000637625 
LDHBP2 90.21 1.01 0.24 -4.21 2.59898E-05 0.001277475 
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AC073254.1 34.29 1.01 0.34 -2.95 0.003227682 0.038665004 
PLEKHA7 89.51 1.01 0.25 -3.96 7.50795E-05 0.002750658 
LINC00704 101.10 1.01 0.22 -4.48 7.35763E-06 0.000480401 
HS3ST2 148.52 1.01 0.22 -4.63 3.69191E-06 0.000298203 
SLC16A14 222.42 1.00 0.20 -4.91 8.93763E-07 9.4234E-05 
FAM189A2 62.36 -1.00 0.28 3.61 0.000300926 0.007616219 
SLIT3 230.67 -1.00 0.22 4.48 7.51757E-06 0.000482943 
CFD 43.13 -1.01 0.31 3.30 0.000980138 0.017581391 
LY6D 730.05 -1.01 0.16 6.28 3.38131E-10 1.37361E-07 
BRSK1 43.25 -1.01 0.31 3.30 0.000973688 0.017511168 
HOXC13-AS 55.52 -1.01 0.26 3.84 0.000124073 0.00398533 
GYLTL1B 1905.03 -1.01 0.22 4.68 2.87195E-06 0.000241875 
HSPG2 11564.52 -1.01 0.27 3.73 0.000187734 0.005368489 
POU3F1 92.69 -1.01 0.26 3.84 0.000121601 0.003938646 
KCTD11 149.38 -1.01 0.27 3.77 0.000160137 0.004805191 
PGLYRP4 148.05 -1.01 0.22 4.70 2.54566E-06 0.000220042 
PCOLCE 83.00 -1.01 0.24 4.16 3.2392E-05 0.001511481 
TYMP 4581.80 -1.01 0.22 4.52 6.30653E-06 0.000435529 
REEP2 76.79 -1.02 0.27 3.78 0.000159338 0.004802299 
RP11-178L8.4 76.41 -1.02 0.31 3.30 0.000950581 0.01723022 
SDK2 869.43 -1.02 0.24 4.21 2.51133E-05 0.001247714 
SMTNL1 26.72 -1.02 0.36 2.85 0.004327679 0.047326918 
HELZ2 5813.25 -1.02 0.25 4.17 3.10266E-05 0.001462589 
FADS3 1037.55 -1.03 0.19 5.45 5.12252E-08 9.07081E-06 
C3 465.87 -1.03 0.16 6.53 6.68566E-11 3.69369E-08 
RP11-540O11.1 37.41 -1.03 0.33 3.11 0.001885911 0.026909295 
YPEL3 660.07 -1.03 0.20 5.10 3.33169E-07 4.0015E-05 
PIK3IP1 498.63 -1.03 0.17 6.15 7.83048E-10 2.35119E-07 
CRAT 241.10 -1.04 0.22 4.70 2.549E-06 0.000220042 
ADAMTS13 104.37 -1.04 0.24 4.26 2.08188E-05 0.001085092 
TAPBPL 180.28 -1.04 0.21 4.93 8.32423E-07 8.84417E-05 
COASY 2348.99 -1.04 0.23 4.53 5.87339E-06 0.000411793 
ANKRD34A 42.51 -1.04 0.30 3.49 0.000482208 0.010555093 
FZD2 82.43 -1.05 0.32 3.33 0.000875477 0.0162528 
MTRNR2L10 55.86 -1.05 0.29 3.67 0.000243039 0.006518172 
EFNB3 66.44 -1.05 0.26 4.11 3.99571E-05 0.001768869 
DMTN 222.27 -1.05 0.26 4.00 6.31471E-05 0.002449964 
MT-TY 125.52 -1.05 0.23 4.59 4.36565E-06 0.000338755 
CPNE2 431.18 -1.05 0.19 5.41 6.30583E-08 1.04935E-05 
RP11-
277P12.20 
112.18 -1.06 0.23 4.61 3.9345E-06 0.000311937 
ENG 106.24 -1.06 0.29 3.68 0.000234302 0.006357919 
 
 
32 
 
LGALS9B 181.91 -1.06 0.21 4.99 5.90899E-07 6.63537E-05 
SNRNP27 120.27 -1.07 0.21 4.97 6.70389E-07 7.29087E-05 
SOCS2-AS1 34.52 -1.07 0.35 3.10 0.001947527 0.027532491 
RP11-
1212A22.1 
57.91 -1.07 0.32 3.36 0.000787142 0.015100013 
GPR37 29.64 -1.07 0.35 3.09 0.001989725 0.027928943 
C6orf1 1217.75 -1.07 0.23 4.76 1.94035E-06 0.000182314 
HAPLN3 266.92 -1.07 0.23 4.70 2.5683E-06 0.000220332 
SCN4B 707.59 -1.08 0.17 6.15 7.68511E-10 2.35119E-07 
LINC01023 23.73 -1.08 0.37 2.92 0.003497639 0.04097488 
BVES 46.92 -1.08 0.30 3.57 0.000355435 0.008582637 
FAM171A2 88.86 -1.08 0.34 3.18 0.001468619 0.022740549 
RHBDL2 24.91 -1.08 0.38 2.87 0.004165372 0.046210537 
SERINC3 1585.24 -1.08 0.16 6.67 2.6143E-11 1.6413E-08 
FKBP10 210.72 -1.09 0.25 4.43 9.53804E-06 0.000588122 
CORO1A 214.25 -1.09 0.23 4.73 2.2957E-06 0.000207647 
NYAP1 89.84 -1.09 0.30 3.65 0.000265543 0.006894125 
LGALS7B 931.50 -1.09 0.26 4.17 3.09335E-05 0.001462589 
FAM219A 512.66 -1.09 0.24 4.56 5.2364E-06 0.000379077 
RAB1B 33.70 -1.09 0.37 2.96 0.003037162 0.036959723 
LHX5 28.44 -1.10 0.35 3.13 0.001733432 0.025606591 
CRIP2 699.27 -1.10 0.23 4.72 2.36531E-06 0.000210772 
RAB6B 86.40 -1.10 0.25 4.38 1.17532E-05 0.000687979 
COL5A1 245.29 -1.11 0.25 4.35 1.3793E-05 0.000783986 
RHOQ 49.83 -1.11 0.29 3.84 0.000121449 0.003938646 
SYDE1 391.62 -1.11 0.25 4.36 1.29345E-05 0.000744382 
HOXC4 87.04 -1.11 0.26 4.29 1.80533E-05 0.000977852 
ADAMTS4 30.04 -1.11 0.38 2.97 0.003025565 0.03685106 
FMNL1 130.10 -1.11 0.25 4.53 5.79198E-06 0.000408157 
CCDC115 287.21 -1.11 0.18 6.26 3.95861E-10 1.51879E-07 
MARCKSL1 118.24 -1.12 0.30 3.76 0.000171446 0.005049068 
TUBA1A 624.18 -1.12 0.18 6.18 6.29244E-10 2.09222E-07 
PODNL1 31.93 -1.12 0.36 3.09 0.001986981 0.027918808 
LIF 184.44 -1.12 0.25 4.55 5.26953E-06 0.000379077 
MAP3K11 1824.36 -1.12 0.24 4.66 3.09117E-06 0.00025566 
ACSS1 228.69 -1.12 0.24 4.61 4.04233E-06 0.000317231 
SALL4 32.93 -1.12 0.35 3.22 0.001290772 0.020926104 
CENPQ 158.67 -1.13 0.21 5.34 9.08296E-08 1.442E-05 
ACBD4 285.67 -1.13 0.21 5.39 6.99621E-08 1.13684E-05 
PLXND1 91.30 -1.13 0.27 4.25 2.10833E-05 0.001094747 
SLC16A8 25.49 -1.14 0.39 2.94 0.003264253 0.038969547 
NXPH4 95.49 -1.14 0.30 3.73 0.000189537 0.005397698 
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FAM214B 1216.79 -1.14 0.22 5.18 2.21473E-07 2.94133E-05 
SP6 429.30 -1.15 0.24 4.73 2.26318E-06 0.000207647 
SERPING1 400.41 -1.15 0.21 5.54 3.03878E-08 5.91149E-06 
SPRED3 43.04 -1.15 0.33 3.50 0.000460265 0.010206017 
BLMH 387.27 -1.15 0.17 6.65 2.99076E-11 1.79601E-08 
THBS2 802.88 -1.15 0.18 6.36 2.03829E-10 9.08158E-08 
CCNJL 26.69 -1.16 0.37 3.11 0.001870603 0.02680162 
CTD-
2020K17.1 
26.53 -1.16 0.36 3.22 0.001270874 0.020748591 
SCARB1 2991.83 -1.16 0.23 5.01 5.38841E-07 6.15081E-05 
FN1 304.07 -1.16 0.18 6.38 1.76753E-10 8.13769E-08 
TMEM132A 3354.91 -1.16 0.23 4.97 6.69016E-07 7.29087E-05 
GDPD5 162.98 -1.16 0.26 4.54 5.69741E-06 0.000403552 
TMEM191A 68.05 -1.17 0.34 3.48 0.000498525 0.010790008 
SYNPO 2585.17 -1.17 0.24 4.88 1.04271E-06 0.000108286 
NOTCH4 35.04 -1.17 0.36 3.30 0.000967345 0.017462712 
ACE 24.07 -1.18 0.40 2.92 0.003480061 0.040872967 
HUNK 27.10 -1.18 0.37 3.19 0.001433596 0.022348565 
SV2A 132.35 -1.18 0.25 4.72 2.39885E-06 0.00021239 
GPAT2 63.95 -1.19 0.30 3.93 8.63229E-05 0.003065018 
IL20 56.19 -1.19 0.32 3.76 0.000166692 0.004956471 
FTH1P8 23.31 -1.19 0.39 3.06 0.002214819 0.02984495 
SLC17A9 80.11 -1.19 0.25 4.69 2.7174E-06 0.000230262 
VWA7 27.89 -1.19 0.37 3.27 0.001079926 0.018668253 
APOE 748.01 -1.20 0.22 5.52 3.35329E-08 6.25886E-06 
CYP27A1 78.85 -1.20 0.32 3.71 0.000209098 0.005846266 
SIPA1 656.02 -1.20 0.23 5.14 2.70849E-07 3.37024E-05 
BST2 197.93 -1.20 0.19 6.35 2.18371E-10 9.42544E-08 
PPP1R18 4297.35 -1.20 0.23 5.28 1.26839E-07 1.92516E-05 
PCSK9 11804.14 -1.21 0.22 5.42 6.06306E-08 1.02993E-05 
TMCC2 75.65 -1.21 0.29 4.23 2.38766E-05 0.001199215 
SLC39A2 19.35 -1.21 0.41 2.95 0.003220708 0.038614945 
POU2F2 1307.38 -1.22 0.19 6.25 4.16135E-10 1.55342E-07 
SPNS2 543.97 -1.22 0.23 5.23 1.70651E-07 2.40513E-05 
GPR68 577.04 -1.22 0.20 6.03 1.64512E-09 4.73383E-07 
MAP1B 410.31 -1.22 0.19 6.48 9.13939E-11 4.85512E-08 
CAPS 33.88 -1.22 0.37 3.33 0.000858749 0.015985237 
C1R 173.34 -1.22 0.20 6.20 5.65456E-10 2.00258E-07 
JDP2 617.13 -1.22 0.18 6.78 1.18876E-11 8.20959E-09 
CXCL16 1478.53 -1.23 0.23 5.45 4.93629E-08 8.85455E-06 
PLXNA3 1190.72 -1.23 0.22 5.47 4.47546E-08 8.13356E-06 
GS1-393G12.12 26.33 -1.24 0.41 3.00 0.002693966 0.034136756 
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KRT16P2 49.62 -1.24 0.29 4.23 2.30216E-05 0.001169025 
CSPG4 501.37 -1.24 0.26 4.72 2.32342E-06 0.000208383 
SCAMP5 42.71 -1.25 0.38 3.32 0.000915025 0.016783973 
ABCC10 1243.27 -1.25 0.23 5.52 3.3161E-08 6.25886E-06 
ACO2 1739.56 -1.25 0.17 7.53 5.18035E-14 5.11078E-11 
PAMR1 74.53 -1.26 0.27 4.69 2.71146E-06 0.000230262 
FAM195B 32.91 -1.26 0.39 3.25 0.001160528 0.019511564 
C6orf15 43.56 -1.26 0.33 3.82 0.000132048 0.004160174 
S100A8 8630.75 -1.27 0.22 5.77 7.97492E-09 1.85451E-06 
GPR173 31.34 -1.27 0.35 3.58 0.000346392 0.008438046 
TXNIP 3456.35 -1.27 0.24 5.29 1.24831E-07 1.91574E-05 
HEPHL1 3533.63 -1.27 0.21 6.17 6.80847E-10 2.13724E-07 
OSBPL7 212.33 -1.27 0.22 5.72 1.08056E-08 2.40721E-06 
ADCY4 34.53 -1.28 0.34 3.74 0.000183712 0.005308437 
SEZ6L2 403.34 -1.28 0.25 5.13 2.93584E-07 3.62051E-05 
IL23A 73.48 -1.28 0.25 5.16 2.47566E-07 3.14851E-05 
FCHO1 211.02 -1.29 0.26 4.96 7.11591E-07 7.67851E-05 
ARC 33.63 -1.29 0.36 3.55 0.000380604 0.009007532 
KAL1 83.06 -1.29 0.26 4.94 7.9037E-07 8.46247E-05 
TSPO 8371.87 -1.29 0.25 5.18 2.18777E-07 2.93374E-05 
TNS1 111.45 -1.29 0.30 4.26 2.07814E-05 0.001085092 
TUBB3 1857.49 -1.29 0.22 5.84 5.14911E-09 1.24771E-06 
PANX2 73.24 -1.30 0.27 4.84 1.32989E-06 0.000133554 
RP11-400F19.8 21.40 -1.30 0.45 2.92 0.003516065 0.041155837 
SOCS3 157.09 -1.30 0.26 5.03 4.82062E-07 5.54853E-05 
AC004463.6 22.13 -1.30 0.41 3.20 0.001362287 0.021577873 
CADPS2 17.83 -1.30 0.46 2.84 0.004443628 0.048185798 
TMEM92 124.71 -1.31 0.24 5.52 3.33742E-08 6.25886E-06 
S100A9 15585.29 -1.33 0.21 6.17 6.69343E-10 2.13724E-07 
NKX3-1 20.77 -1.33 0.42 3.16 0.001559432 0.023879019 
SLC43A2 569.07 -1.33 0.26 5.17 2.35661E-07 3.07071E-05 
LRRC3 171.66 -1.33 0.26 5.07 3.91625E-07 4.62318E-05 
SAMD14 18.99 -1.34 0.43 3.11 0.001880611 0.026909295 
ZMYND15 46.45 -1.36 0.30 4.48 7.6302E-06 0.000487909 
C1QTNF1 1349.56 -1.39 0.22 6.34 2.31811E-10 9.70235E-08 
SLC16A11 38.07 -1.39 0.36 3.90 9.44046E-05 0.003243572 
SYNGR3 28.03 -1.39 0.39 3.60 0.000313323 0.007868399 
CGB7 36.92 -1.40 0.32 4.31 1.64631E-05 0.000902332 
GPC4 56.32 -1.40 0.30 4.67 2.94823E-06 0.000246793 
TUBB2A 355.53 -1.40 0.19 7.33 2.23646E-13 1.78579E-10 
CSF2 39.14 -1.41 0.32 4.37 1.25808E-05 0.000727057 
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IGFBP6 436.68 -1.42 0.23 6.20 5.552E-10 2.00258E-07 
IL36G 383.12 -1.42 0.19 7.37 1.7061E-13 1.47279E-10 
ENO2 79.49 -1.43 0.28 5.16 2.44598E-07 3.14851E-05 
LGALS7 587.76 -1.43 0.27 5.25 1.48167E-07 2.15419E-05 
NACAD 118.79 -1.43 0.26 5.43 5.52136E-08 9.6533E-06 
S100A12 54.35 -1.44 0.36 4.00 6.44007E-05 0.002491602 
C19orf57 18.77 -1.45 0.46 3.17 0.001531504 0.023608405 
S100A7 326.28 -1.45 0.18 7.88 3.29226E-15 4.54727E-12 
CORO2B 53.56 -1.45 0.30 4.83 1.38393E-06 0.000135567 
AEBP1 212.84 -1.46 0.25 5.96 2.59318E-09 6.63279E-07 
APBA1 34.79 -1.46 0.35 4.17 3.08801E-05 0.001462589 
PLA2G2F 69.26 -1.47 0.27 5.50 3.75617E-08 6.91736E-06 
IL24 170.77 -1.48 0.19 7.67 1.7029E-14 1.96004E-11 
PRSS22 410.89 -1.48 0.19 7.68 1.62535E-14 1.96004E-11 
UCHL1 35.97 -1.49 0.33 4.50 6.8193E-06 0.000455015 
LITAF 2448.79 -1.50 0.14 10.35 4.21026E-25 1.9384E-21 
RP13-582O9.5 28.92 -1.50 0.37 4.08 4.55133E-05 0.001934244 
CNTNAP1 15.56 -1.50 0.50 3.03 0.002465369 0.031943415 
KCND1 80.61 -1.52 0.25 6.00 1.91929E-09 5.1979E-07 
SPRR3 227.33 -1.52 0.19 8.23 1.85835E-16 3.20845E-13 
LRRC3DN 137.36 -1.54 0.27 5.77 8.0561E-09 1.85451E-06 
JAK3 63.63 -1.54 0.30 5.11 3.23868E-07 3.92392E-05 
AIM1 3690.16 -1.55 0.15 10.28 9.04763E-25 3.12415E-21 
DERL3 126.08 -1.55 0.26 6.02 1.77037E-09 4.99027E-07 
PDZK1IP1 566.74 -1.56 0.18 8.60 7.92637E-18 1.82465E-14 
ELF3 19.38 -1.57 0.45 3.52 0.000437428 0.00990547 
MIR429 16.87 -1.57 0.48 3.25 0.001173527 0.019646978 
VNN3 34.10 -1.59 0.35 4.48 7.42522E-06 0.000481489 
hsa-mir-1199 26.95 -1.59 0.41 3.88 0.000103197 0.003468021 
KAZALD1 15.82 -1.59 0.48 3.35 0.000818648 0.015485891 
KCNJ5 195.48 -1.60 0.21 7.65 1.97443E-14 2.09775E-11 
DMBT1 32.38 -1.61 0.37 4.33 1.51885E-05 0.000842505 
IGFBP4 928.73 -1.62 0.25 6.58 4.58119E-11 2.63647E-08 
SLC22A31 38.39 -1.65 0.33 4.99 6.02067E-07 6.70625E-05 
SPRR2B 304.78 -1.66 0.20 8.40 4.64465E-17 9.16455E-14 
TEPP 62.31 -1.66 0.28 6.00 1.97445E-09 5.24443E-07 
CXCL6 31.24 -1.67 0.36 4.59 4.43058E-06 0.000341872 
GLI1 29.92 -1.67 0.41 4.07 4.78121E-05 0.001983125 
CNTD2 23.15 -1.71 0.43 4.01 6.02711E-05 0.002371695 
LCN2 3457.99 -1.72 0.16 10.64 1.94804E-26 1.34532E-22 
KRT16P5 79.38 -1.72 0.37 4.62 3.85974E-06 0.000308155 
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ADAMTS15 29.23 -1.72 0.41 4.24 2.22643E-05 0.001138943 
FAM131C 26.24 -1.72 0.40 4.28 1.87246E-05 0.001002417 
APH1A 3229.29 -1.79 0.22 8.14 4.06748E-16 6.24222E-13 
SPRR2A 1110.16 -1.82 0.20 9.23 2.59764E-20 7.17572E-17 
EBF4 21.39 -1.83 0.47 3.91 9.40591E-05 0.003243572 
HAS2 17.73 -1.88 0.47 4.04 5.26456E-05 0.002126144 
ATP13A2 133.64 -1.90 0.33 5.76 8.20766E-09 1.85843E-06 
CHST1 20.40 -1.93 0.48 4.06 4.92054E-05 0.002011045 
SERPINB4 27.36 -1.94 0.41 4.73 2.20374E-06 0.000204283 
IGFBP3 65.76 -1.99 0.27 7.33 2.32726E-13 1.78579E-10 
IL8 89.90 -2.03 0.27 7.45 9.42817E-14 8.68146E-11 
C12orf68 31.95 -2.03 0.42 4.82 1.4046E-06 0.000136622 
CREB3L1 17.96 -2.31 0.49 4.74 2.11112E-06 0.000197019 
CSF3 340.13 -2.49 0.23 10.91 1.04831E-27 1.44793E-23 
KM-PA-2 28.98 -3.90 1.30 3.01 0.002654495 0.033822772 
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Table S3. List of primer sequences for qPCR 
 
Primer Sequence 5`- 3` Gene 
hgIL36g-F CTGGAGCCACGATTCAGTCC IL36G 
hgIL36G-R AGGGTCCACACTTGCTGATTC IL36G 
hgS100A9-F GCTGGAACGCAACATAGAGAC S100A9 
hgS100A9-R TGCATTTGTGTCCAGGTCCTC S100A9 
hgLCN2-F AGAGCTACAATGTCACCTCCG LCN2 
hgLCN2-R TTAATGTTGCCCAGCGTGAAC LCN2 
hgDEFB4A-F CCAGCCATCAGCCATGAGGGT DEFB4A 
hgDEFB4A-R GGAGCCCTTTCTGAATCCGCA DEFB4A 
hgCXCL8-F AAGGTGCAGTTTTGCCAAGG CXCL8 
hgCXCL8-R CCCAGTTTTCCTTGGGGTCC CXCL8 
hgCCL20-F TGTCAGTGCTGCTACTCCAC CCL20 
hgCCL20-R GATTTGCGCACACAGACAAC CCL20 
hgIL17C-F CCGGCTTCCCTTACCCTATC IL17C 
hgIL17C-R GGTACTTCCAAGGAGGTTGGG IL17C 
hgRPL37a-F AGATGAAGAGACGAGCTGTGG RPL37A 
hgRPL37a-R CTTTACCGTGACAGCGGAAG RPL37A 
hgCXCL5-F AGCGCGTTGCGTTTGTTTAC CXCL5 
hgCXCL5-R TGGCGAACACTTGCAGATTAC CXCL5 
hgNFKBIZ-F ACACCCACAAACCAACTCTGG NFKBIZ 
hgNFKBIZ-R TGCTGAACACTGGAGGAAGTC NFKBIZ 
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Table S4. List of primer sequences for generation of luciferase constructs 
 
NFKBIZ 
reporter  
Primer Sequence 5`- 3` 
w/o STAT3 mutSTAT3-F GGCGCGCTCTTGCCAGTCCCCAAGAACCA 
mutSTAT3-R GACTGGCAAGAGCGCGCCCCGCACCCCTC 
w/o STAT1/3 mutSTAT1/3-F ATCCTGTACGGACGCATCCGGAGGAGGGGC 
mutSTAT1/3-R ATGCGTCCGTACAGGATGAGGCAATGCG 
w/o AP1 mutAP1-F CGCCTCCCTCTGCAGGCCCATCCCTCCAC 
mutAP1-R AGGGAGGCGGTGGAGGGAACCGGTTGGCC 
w/o KLF4 mutKLF4-F GGTCGGTCGCGCATTGCCTCATCCTGTAC 
mutKLF4-R GCAATGCGCGACCGACCGGTTGTTTGCCTG 
w/o NF-B mutNFkB-F CGCGCGCTGTAAGGGCAGGCAAACAACCGGT 
mutNFkB-R GCCTGCCCTTACAGCGCGCGGCTTCCAGCCT 
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Introduction
Psoriasis is a mixed autoimmune and autoinflammatory skin dis-
ease, affecting 2% to 3% of the population worldwide. Psoriatic skin 
lesions are characterized by keratinocyte hyperproliferation and a 
massive infiltration of immune cells, such as neutrophils, macro-
phages, and Th17 cells (1). The cytokine families IL-17 and IL-36 have 
been identified as key factors driving the establishment of psoriatic 
plaques (2). Therefore, state-of-the-art therapies comprise neu-
tralizing antibodies against IL-17 (3, 4), while IL-36 antagonists are 
currently tested in clinical trials (5). Although psoriasis therapy with 
neutralizing antibodies is very effective, disadvantages comprise 
high costs, difficult application routes, systemic side effects such as 
upper respiratory tract infections, and long-term therapy resistance 
due to the development of antidrug antibodies (6, 7). Therefore, 
effective new therapy approaches against psoriasis are needed.
Previously, IκBζ, encoded by the gene NFKBIZ, has been 
identified as a key regulator of transcription in psoriasis (8, 9). 
IκBζ represents an atypical member of the IκB family that is 
inducibly expressed and then accumulates in the nucleus, leading 
to the activation or repression of a selective subset of NF-κB tar-
get genes (10). Especially in keratinocytes, IL-17A, alone or even 
more potently in combination with TNF-α as well as IL-36 cyto-
kines, triggers a NF-κB– and STAT3-dependent transcriptional 
upregulation of IκBζ expression (9). Subsequently, IκBζ induces 
a subset of IL-36– and IL-17–responsive target genes in keratino-
cytes, including CXCL2, CXCL5, CXCL8, LCN2, DEFB4, or IL1B, 
which all have already been implicated in the pathogenesis of 
psoriasis (2). How IκBζ regulates these downstream target genes 
remains elusive. It is assumed that IκBζ recruits epigenetic mod-
ifiers, such as TET2 or the SWI/SNF complex, to the promoter 
sites of its target genes, leading to a change in DNA methylation 
or nucleosome remodeling (11, 12).
In agreement with its role as a key regulator of psoriasis-relat-
ed gene expression, IκBζ-deficient mice are completely protected 
against imiquimod-mediated (IMQ-mediated) or IL-36–medi-
ated psoriasis-like skin inflammation (8, 9). Moreover, human 
psoriatic skin lesions are characterized by an upregulated expres-
sion of IκBζ (8, 9). Altogether, these findings validate IκBζ as an 
attractive new therapeutic target in psoriasis. As IκBζ lacks any 
enzymatic activity, it is difficult to develop direct IκBζ inhibitors 
(13). Therefore, small molecule inhibitors blocking the induction 
or downstream function of IκBζ could represent an alternative 
strategy for targeting IκBζ in psoriasis.
CDK4 and CDK6, in complex with cyclin D1, cyclin D2, or cyclin 
D3, represent well known cell-cycle regulating kinases that can phos-
phorylate RB, leading to the release of E2F transcription factors and 
G1-S cell cycle transition (14). Consistently, amplification of CDK4 
and CDK6 as well as overexpression of cyclin D proteins are fre-
quently observed events in cancer, leading to the excessive prolifera-
tion of tumor cells (15, 16). ATP-competitive CDK4/6 inhibitors, such 
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for psoriasis. However, due to a lack of enzyme activity, direct inhi-
bition of IκBζ is not feasible. Key regulators in psoriasis constitute 
IL-17 and IL-36 family members (26, 27), which predominantly 
trigger a proinflammatory response in keratinocytes that is depen-
dent on IκBζ (8, 9). Thus, we screened for small-molecule inhibi-
tors that are able to block induction of IκBζ expression in response 
to either IL-36α or IL-17A. Previously, it was shown that IL-17–
induced IκBζ expression is strongly increased in combination with 
TNF-α (8, 9). Intriguingly, we found that 2 CDK4/6 inhibitors, abe-
maciclib (Figure 1A and Supplemental Figure 1A; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI134217DS1) and palbociclib (Supplemental Figure 1B), com-
pletely blocked IL-36α– or IL-17A/TNF-α–mediated induction of 
IκBζ expression in primary human keratinocytes. Moreover, we 
observed similar effects in response to IL-36γ, IL-1β, or the TLR 
ligands flagellin and poly(I:C) (Supplemental Figure 1, C and D), 
thereby revealing a conservation of this pathway in keratinocytes.
To explore whether these effects were due to a CDK4/6 inhib-
itor-mediated G1 cell cycle arrest, we repeated the experiments 
in synchronized and single cell cycle phase–arrested keratino-
cytes. IL-36α treatment triggered IκBζ induction in all phases of 
the cell cycle; induction was completely suppressed by abemaci-
clib (Supplemental Figure 1E). Moreover, depletion of RB by RNA 
interference did not influence IL-36–mediated induction or abe-
maciclib-mediated suppression of IκBζ (Supplemental Figure 1F), 
thereby clearly indicating that the effect of CDK4/6 inhibitors on 
IκBζ expression was independent of their ability to trigger cell cycle 
arrest. Instead, we revealed that CDK4/6-dependent induction of 
IκBζ was mediated at the transcriptional level, as palbociclib and 
abemaciclib treatment abrogated the expression of a luciferase 
construct harboring the NFKBIZ (IκBζ) promoter in IL-36α–stimu-
lated HaCaT cells (Figure 1B). Interestingly, also shRNA-mediated 
depletion of CDK4 or CDK6 was sufficient to suppress IL-36α– or 
IL-17A/TNF-α–dependent expression of IκBζ in human primary 
keratinocytes, thereby excluding off-target effects of the applied 
inhibitors (Figure 1, C and D). Accordingly, IκBζ-dependent target 
genes, such as CXCL2, CXCL5, or CXCL8, were strongly down-
regulated in IL-36α– and CDK4/6 inhibitor–treated keratinocytes 
(Figure 1E), as well as in CDK4- or CDK6-deficient cells (Figure 
1F), whereas other NF-κB–dependent but IκBζ-independent genes, 
such as NFKBIA or TNF, remained unaffected (Supplemental Fig-
ure 1G). Similar effects of pharmacological or shRNA-mediated 
inhibition of CDK4/6 were obtained in IL-17A and TNF-α–stim-
ulated cells (Supplemental Figure 1, H and I). CDK4/6 inhibitors 
have the potential to inhibit CDK9 kinase activity, although much 
higher concentrations are needed (17). To rule out effects deriv-
ing from the suppression of CDK9 activity, we transiently over-
expressed CDK4, CDK6, or CDK9 in HaCaT cells and analyzed 
IL-36α–mediated gene expression. Overexpression of CDK4 and 
CDK6, but not CDK9, could increase IL-36α–mediated, IκBζ- 
dependent target gene expression in keratinocytes, thereby further 
confirming the specificity of CDK4 and CDK6 in regulating proin-
flammatory target gene expression in keratinocytes (Figure 1G).
We hypothesized that CDK4 and CDK6 are not involved in 
the direct regulation of IκBζ target gene expression but rather 
trigger the expression of IκBζ, which in turn induces a second-
ary, IκBζ-dependent gene expression in stimulated keratinocytes. 
as palbociclib and abemaciclib, have been developed for anticancer 
therapy and were recently approved for treatment of breast cancer 
patients (17). Interestingly, common side effects of a CDK4/6 inhib-
itor therapy constitute neutropenia and leukopenia (17, 18). More-
over, it was found that CDK4/6 inhibition modulates immune cell 
functions in kinase-dependent or -independent manners (19–22). 
Mechanistically, it is assumed that these atypical functions of CDK4 
and CDK6 derive from their recently discovered role as cofactors for 
immune regulatory transcription factors (23–25). CDK6, especially, 
can colocalize at promoter regions of a subset of NF-κB, STAT3, or 
AP1 target genes, thereby changing the DNA-binding properties or 
activity of these transcription factors.
We screened for small-molecule inhibitors of IκBζ action in 
keratinocytes and identified CDK4/6 inhibitors as potent sup-
pressors of IL-36– and IL-17A/TNF-α–mediated IκBζ expression. 
Mechanistically, CDK4/6 inhibitors suppressed the activity of 
STAT3, which was identified as a major transcriptional regulator 
of IκBζ expression in keratinocytes. STAT3 activation was promot-
ed by CDK4/6-mediated phosphorylation of the methyltransfer-
ase EZH2, triggering the subsequent methylation of STAT3 and 
induction of IκBζ expression. Importantly, topical administration 
of CDK4/6 or EZH2 inhibitors on the skin completely prevented 
experimental psoriasis by suppressing STAT3 activation and con-
sequently, IκBζ expression in keratinocytes. Moreover, as cyclin 
D2, cyclin D3, and EZH2 were found to be overexpressed in human 
psoriatic skin lesions, we propose repurposing CDK4/6 and EZH2 
inhibitors for topical skin treatment of patients with psoriasis.
Results
CDK4/6 inhibitors suppress the expression of IκBζ and IκBζ-depen-
dent, proinflammatory genes in IL-36α– and IL-17A/TNF-α–stimu-
lated keratinocytes. IκBζ represents an attractive therapeutic target 
Figure 1. CDK4 and CDK6 regulate the expression of IκBζ and its 
proinflammatory target genes in IL-36α– and IL-17A/TNF-α–stimulated 
keratinocytes. (A) Human primary keratinocytes were treated for 1 hour 
with 100 ng/mL IL-36α or 200 ng/mL IL-17A and 10 ng/mL TNF-α. The 
CDK4/6 inhibitor abemaciclib (Abe) or an ethanol vehicle control (Ctrl) 
were added in parallel. Phosphorylation of RB (pRB) served as a control for 
CDK4/6 inhibition, and actin as a loading control. Relative mRNA levels of 
IκBζ (NFKBIZ) were normalized to the reference gene RPL37A. (B) Lucif-
erase assay of IκBζ (NFKBIZ) promoter activity in HaCaT cells that were 
cytokine-stimulated for 24 hours in the presence or absence of the CDK4/6 
inhibitors abemaciclib or palbociclib (Pal). Relative luciferase (luc) activity 
was normalized to an internal Renilla luciferase control that was transfect-
ed in parallel. Endogenous protein levels were analyzed as input controls 
by immunoblotting (bottom). (C and D) CDK4 and CDK6 were depleted 
in primary human keratinocytes by lentiviral transduction of shRNA. Ctrl 
shRNA– or CDK4/6 shRNA–depleted cells were treated with (C) IL-36α 
or (D) IL-17A/TNF-α, similar as in A. (E and F) Human primary keratino-
cytes were stimulated with IL-36α as in A. (E) Cytokine gene expression 
in CDK4/6 inhibitor–treated cells. (F) Relative gene expression levels in 
IL-36α–treated control or CDK4/6-depleted cells. (G) Transient overexpres-
sion of CDK4, CDK6, or CDK9 in HaCaT cells, treated for 1 hour with 100 ng/
mL IL-36α. (H) Cytokine gene expression in IL-36α–treated primary kerati-
nocytes overexpressing IκBζ in the presence or absence of abemaciclib. For 
all analyses, n = 3 ± SD. Significance was calculated using a 1-way ANOVA 
for multiple groups and a 2-tailed Student’s t test for comparing 2 groups: 
*P < 0.05; **P < 0.01; ***P < 0.001. 
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CDK6 increased the STAT3-mediated induction of NFKBIZ pro-
moter activity, whereas no synergistic effects could be observed 
when CDK4 and CDK6 were co-overexpressed with NF-κB p65 
or cJun (Figure 2A and Supplemental Figure 2A). In agreement, 
deletion of the STAT3-binding site abrogated the expression of the 
NFKBIZ luciferase reporter in IL-36α–stimulated, CDK4/6-over-
expressing HaCaT cells, whereas deletion of the NF-κB or AP1 
motif had only a minor or almost no effect (Supplemental Figure 
2B). Finally, transient overexpression of a constitutively active 
STAT3 mutant (STAT3C) abrogated the effects of CDK4/6 inhibi-
tion on the induction of IκBζ (Figure 2B) and IκBζ-dependent tar-
get gene expression in IL-36α–stimulated primary keratinocytes 
(Figure 2C), thereby validating STAT3 as the responsible tran-
scription factor for CDK4/6-mediated effects in keratinocytes.
Previous publications reported that CDK6 acts as a cofactor 
for STAT3, independently of its kinase function (23). Therefore, 
we tested if a kinase-dead mutant of CDK6 (CDK6 DN) could 
To test this hypothesis, we transiently overexpressed IκBζ in 
IL-36α– or IL17A/TNF-α–stimulated primary human keratinocytes 
in the presence or absence of abemaciclib (Figure 1H and Supple-
mental Figure 1J). In this setup, exogenous overexpression of IκBζ 
completely abolished abemaciclib-mediated suppression of IκBζ 
target gene expression, thereby validating CDK4/6-mediated 
transcriptional upregulation of IκBζ as a prerequisite for CDK4/6- 
dependent, proinflammatory gene expression in keratinocytes.
CDK4/6-dependent induction of IκBζ expression is mediat-
ed by STAT3 in a cyclin-dependent manner. Beside their known 
involvement in cell cycle regulation, CDK4 and CDK6 have been 
described to function as transcriptional cofactors for STAT3, 
NF-κB, or AP-1 (23–25). As we revealed a CDK4/6-dependent 
induction of IκBζ on the transcriptional level, we next explored 
the responsible transcription factor. Of note, binding sites for all 
3 transcription factors were previously identified at the NFKBIZ 
promoter region (9). Interestingly, expression of both CDK4 and 
Figure 2. STAT3 mediates CDK4/6-dependent IκBζ induction in keratinocytes. (A) Luciferase assay of the NFKBIZ promoter in HEK293T cells after transient 
expression of CDK4, CDK6, STAT3, or p65, alone or in combination. The plasmid amounts for STAT3 (200 ng) and p65 (70 ng) were adjusted to achieve similar 
luciferase activity in the absence of CDK4/6 expression. Overexpression of the HA-tagged CDK4 and CDK6 proteins was detected using a HA-antibody. (B) 
Primary human keratinocytes with a transient overexpression of hyperactive STAT3 (STAT3C) were treated for 1 hour with 100 ng/mL IL-36α and abemaciclib 
(Abe). NFKBIZ mRNA levels normalized to RPL37A. Immunoblot analysis of STAT3C overexpression and CDK4/6 inhibition. (C) IκBζ target gene expression in 
STAT3C-overexpressing primary keratinocytes. Treatment as in B. (D) Luciferase activity assay of the NFKBIZ promoter in HEK293T cells overexpressing STAT3 
alone or in combination with WT CDK6 (wt), hyperactive CDK6 (S178P), or a kinase-dead CDK6 mutant (CDK6 DN). For all analyses, n = 3 ± SD. Significance was 
calculated using a 1-way ANOVA for multiple groups and a 2-tailed Student’s t test for comparing 2 groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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in the differentiation and function of keratinocytes (31–33). More-
over, it was revealed that EZH2 can methylate STAT3 at lysine 49, 
140, or 180, thereby modulating STAT3 activity by affecting the 
subcellular localization or phosphorylation status of STAT3 at tyro-
sine 705 (34–36). We hypothesized that CDK4/6 might phosphory-
late EZH2 in keratinocytes, thus enabling EZH2-mediated methyl-
ation and activation of STAT3. Pull-down assays in HEK293T cells 
validated an interaction of CDK4 and CDK6 with EZH2 (Supple-
mental Figure 3C). In agreement, EZH2 inhibition by EPZ6438 or 
shRNA-mediated depletion of EZH2 inhibited STAT3 activation 
and induction of IκBζ in IL-36α– or IL-17A/TNF-α–stimulated kera-
tinocytes (Figure 3C and Supplemental Figure 3D). Furthermore, 
pharmacological inhibition or depletion of EZH2 effectively pre-
vented IκBζ-dependent target gene expression in IL-36α–treated 
keratinocytes (Supplemental Figure 3E). Thus, we hypothesized 
that CDK4/6 phosphorylates EZH2 in keratinocytes, thereby reg-
ulating EZH2-dependent activation of STAT3.
In primary human keratinocytes, expression of EZH2 itself 
was induced by IL-36α (Figure 3D), in line with its previous iden-
tification as an NF-κB–regulated target gene (37). Of note, EZH2 
harbors 2 potential CDK phosphorylation sites at threonine 345 
and 487 (Supplemental Figure 3F), which were previously shown 
to be phosphorylatable by CDK1/2, thereby modifying EZH2 
function (38–40). Indeed, phosphorylation of EZH2 at thre-
onine 345 (T345), but not at threonine 487 (T487) was induced 
in IL-36α– or IL-17A/TNF-α–treated keratinocytes, whereas abe-
maciclib treatment or CDK4/6 depletion completely abrogated 
this inducible EZH2 phosphorylation (Figure 3D and Supplemen-
tal Figure 3G). Moreover, phosphorylated EZH2 (T345) prefer-
entially interacted with STAT3 in HaCaT cells, whereas CDK4/6 
inhibition did not only abrogate the phosphorylation of EZH2 but 
also its interaction with STAT3 (Figure 3E).
These data suggest that CDK4/6-mediated phosphorylation of 
EZH2 at threonine 345 represents a regulatory switch, leading to the 
interaction of EZH2 with STAT3 and subsequent STAT3 activation. 
Accordingly, whereas WT EZH2 synergistically induced the expres-
sion of the NFKBIZ luciferase promoter in cooperation with CDK4/6 
and STAT3, an EZH2 mutant lacking the CDK4/6-directed phosphor-
ylation site (EZH2 T345A) abrogated CDK4/6- and STAT3-mediated 
NFKBIZ promoter-driven luciferase expression (Figure 3F). Further-
more, transient expression of a phospho-mimicking EZH2 (T345D) 
version could override abemaciclib-mediated suppression of IκBζ 
induction and IκBζ target gene expression in IL-36α–stimulated pri-
mary keratinocytes (Figure 3G), whereas transient overexpression 
of IκBζ abolished the effects of the pharmacological EZH2 inhibitor 
(Figure 3H). Finally, also STAT3C overexpression could override tar-
get gene expression defects in IL-36α–stimulated, EZH2-depleted 
keratinocytes (Supplemental Figure 3H), thereby validating STAT3 
as the main target for suppression of gene expression in EZH2 inhib-
itor-treated keratinocytes. Therefore, we conclude that IL-36α– and 
IL-17A/TNF-α–mediated, CDK4/6-dependent induction of IκBζ 
expression is mediated by phosphorylation of EZH2 at T345, thereby 
triggering an EZH2-dependent activation of STAT3 in keratinocytes.
CDK4/6-phosphorylated EZH2 mediates STAT3 methylation 
at K180, leading to IκBζ expression in keratinocytes. As reported 
before, EZH2 can methylate STAT3 at lysine 49, 140, or 180, 
thereby changing its transcription factor function or subcellular 
still synergize with STAT3 in driving the expression of the NFK-
BIZ luciferase reporter construct. Surprisingly, the kinase-dead 
mutant was not able to cooperate with STAT3 anymore, whereas a 
hyperactive version of CDK6 (CDK6 S178P) further increased the 
activity of the NFKBIZ promoter in a STAT3-dependent manner 
(Figure 2D). Accordingly, cyclin D2 and cyclin D3, which associate 
with CDK4/6 to activate their kinase function (14), synergized with 
CDK4/6 and STAT3 in activating the NFKBIZ luciferase promot-
er, whereas cyclin D1 failed to do so (Supplemental Figure 2, C and 
D). Moreover, cyclin D2 and cyclin D3 overexpression significantly 
elevated the expression of NFKBIZ and its target genes in IL-36α–
stimulated keratinocytes (Supplemental Figure 2, E and F).
Cyclin D2 and cyclin D3 levels are transcriptionally regulat-
ed by NF-κB (28, 29). Therefore, we hypothesized that IL-36α or 
IL-17A/TNF-α stimulation results in a transient NF-κB–dependent 
upregulation of cyclin D2/D3, thereby explaining the cooperation 
of CDK4/6 and STAT3 in triggering IκBζ expression. Indeed, we 
detected a rapid binding of NF-κB p65 to the promoter regions of 
CCND2 and CCND3 upon stimulation of primary keratinocytes 
with IL-36α (Supplemental Figure 2G). Consequently, IL-36α 
stimulation led to increased expression of CCND2 and CCND3 in 
a p65-dependent manner (Supplemental Figure 2H), thus validat-
ing a NF-κB–mediated transcriptional upregulation of cyclin D2 
and cyclin D3 in stimulated keratinocytes. Although p65 failed to 
cooperate with CDK4/6 in the induction of the NFKBIZ promoter 
directly (Figure 2A), we hypothesized that NF-κB participates in the 
induction of IκBζ in keratinocytes by transcriptionally upregulating 
cyclin D2/D3 levels, leading to activation of CDK4/6. In agreement, 
whereas knockdown of p65/RELA abrogated IκBζ expression in 
IL-36α–stimulated keratinocytes, exogenous overexpression cyclin 
D2 could fully restore the expression of NFKBIZ and its target genes 
in IL-36α–stimulated primary keratinocytes (Supplemental Figure 
2I). Thus, our data imply that IL-36α and IL-17A/TNF-α stimulation 
of keratinocytes first activates NF-κB, leading to an upregulation of 
cyclin D2 and D3 levels. Subsequently, CDK4 and CDK6 become 
activated, leading to a STAT3-mediated induction of IκBζ.
CDK4 and CDK6 phosphorylate EZH2 to induce STAT3-me-
diated IκBζ expression. Next, we explored the mechanism of how 
CDK4 and CDK6 regulate STAT3-mediated expression of IκBζ. Of 
note, in chromatin immunoprecipitation (ChIP) analyses, CDK4 
and CDK6 were found to localize to the NFKBIZ promoter region, 
which depended on the presence of STAT3 (Supplemental Figure 
3A). Vice versa, knockdown of CDK6 abrogated the binding of 
STAT3 at the NFKBIZ promoter (Supplemental Figure 3B). We rea-
soned that this interdependency was due to a CDK4/6-dependent 
regulation of STAT3 activity in keratinocytes. Accordingly, where-
as the putative CDK-dependent phosphorylation site of STAT3 at 
threonine 727 (T727) remained unaffected (30), phosphorylation 
of STAT3 at tyrosine 705 (Y705), a prerequisite for STAT3 activa-
tion, was completely absent in abemaciclib-treated or CDK4/6- 
deficient cells after stimulation with IL-36α (Figure 3, A and B). 
As CDK4 and CDK6 are not able to directly trigger Y705 STAT3 
phosphorylation, we assumed that CDK4/6-mediated activation of 
STAT3 might be exerted through an altered availability or activity 
of a cofactor needed for STAT3 activation in keratinocytes.
Previously, EZH2, a methyltransferase that directs H3K27me3 
in conjunction with the PRC2 complex, was found to be important 
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Figure 3. CDK4 and CDK6 phosphorylate EZH2 to induce STAT3 activation. (A) STAT3 activity was detected by analyzing the phosphorylation state at tyrosine 
705 (Y705) and threonine 727 (T727) of STAT3 in primary human keratinocytes. After overnight starvation, cells were stimulated for 1 hour with IL-36α or IL-17A/
TNF-α in the presence or absence of abemaciclib (Abe). (B) STAT3 activity in CDK4- and CDK6-depleted keratinocytes. Stimulation as in A. (C) Immunoblot detec-
tion of phosphorylated STAT3 (Y705) in IL-36α–stimulated keratinocytes, in which EZH2 function was suppressed by the EZH2 inhibitor EPZ6438 (EPZ, 10 μM) or 
shRNA-mediated knockdown. Detection of H3K27me3 controlled effective EZH2 inhibition or depletion. (D) Immunoblot detection of phosphorylated EZH2 at 
threonine 345 (T345) and threonine 487 (T487) in abemaciclib-treated or CDK4/6-depleted keratinocytes following stimulation with IL-36α. (E) Coimmunoprecipi-
tation of EZH2 and STAT3 in HaCaT cells treated for 30 minutes with IL-36α in the presence or absence of abemaciclib. An EZH2-specific antibody or IgG was used 
for pull down of protein complexes. STAT3 and pEZH2 (T345) were detected by immunoblotting. (F) Luciferase activity assay of the NFKBIZ promoter in HEK293T 
cells, which transiently overexpress CDK6, WT EZH2 (wt), mutant EZH2 (T345A), or STAT3, alone or in combination. Equal protein expression was detected by 
immunoblotting. n = 3 ± SD. (G) Gene expression in IL-36α– and abemaciclib-treated, primary keratinocytes following transient expression of a phospho-mimicking 
EZH2 (T345D) mutant. Input controls (left). mRNA levels of NFKBIZ and its target genes were normalized to RPL37A (right). n = 3 ± SD. (H) Overexpression of IκBζ 
overrides the inhibitory effects of EPZ6438 (EPZ) on IL-36α–stimulated gene expression in primary keratinocytes. n = 3 ± SD. Significance was calculated using a 
1-way ANOVA for multiple groups and a 2-tailed Student’s t test for comparing 2 groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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localization (34–36). Thus, we immunoprecipitated STAT3 in 
STAT3- and EZH2-overexpressing HEK293T cells in the pres-
ence or absence of abemaciclib, and analyzed the methylation 
status of STAT3 using a pan-methyl-lysine–specific antibody. 
Simultaneous overexpression of EZH2 and STAT3 induced 
methylation of STAT3, as expected, whereas CDK4/6 inhibi-
tion abrogated lysine methylation of STAT3 (Figure 4A). Fur-
thermore, lysine methylation of STAT3 was detectable upon 
Figure 4. CDK4/6-dependent, EZH2-mediated methylation of STAT3 at lysine 180 induces IκBζ expression in keratinocytes. (A and B) Detection of 
methylated STAT3 by coimmunoprecipitation. EZH2 and STAT3 (A) or CDK6 and STAT3 (B) were transiently expressed in HEK293T cells. After 1 hour of 
treatment with (A) abemaciclib (Abe) or (B) EPZ6438 (EPZ), cell lysates were prepared and subjected to immunoprecipitation using a STAT3-specific 
antibody or control IgG. (C) NFKBIZ promoter-driven luciferase activity in HEK293T cells, transiently expressing CDK6 and EZH2, alone or in combination 
with WT (wt) STAT3 or methylation-defective STAT3 mutant (K180R). n = 3 ± SD. (D) Analysis of IκBζ and IκBζ target gene expression in STAT3 wt or STAT3 
K180R-expressing HaCaT cells. STAT3 wt or STAT3 K180R constructs were transiently expressed in STAT3-KO HaCaT cells, followed by stimulation for 1 
hour with IL-36α. n = 3 ± SD. (E) Chromatin immunoprecipitation (ChIP) of STAT3, EZH2, or IgG control in STAT3-KO HaCaT cells reconstituted with either 
STAT3 wt or STAT3 K180R after 30 minutes of stimulation with IL-36α. Fold enrichment at the NFKBIZ promoter or at the myoglobin genomic region (MB; 
as negative control) was calculated relative to the IgG control. n = 3 ± SD. (F) ChIP of STAT3, EZH2, CDK4, and CDK6 in IL-36α–stimulated HaCaT cells stim-
ulated for 30 minutes with IL-36α. Shown is the fold enrichment over IgG control. n = 3 ± SD. Significance was calculated using a 1-way ANOVA for multiple 
groups and a 2-tailed Student’s t test for comparing 2 groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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of this pathway in skin biopsies from patients with psoriasis. 
Human psoriatic lesions, compared with nonpsoriatic lesions 
or unaffected skin, were characterized by an upregulation of 
CCND2 and CCND3 (Figure 5A). In contrast, CCND1 levels were 
decreased or remained unaffected in lesional skin biopsies. This 
is in line with our previous observation (Supplemental Figure 
2, C and D) that cyclin D1, unlike cyclin D2 and cyclin D3, did 
not synergize with CDK4/6 and STAT3 in increasing NFKBIZ 
promoter activity or expression of IκBζ and its target genes. In 
addition, EZH2 mRNA levels were significantly upregulated in 
human psoriatic skin lesions (Figure 5B). Immunohistochemistry 
further demonstrated that, on the protein level, human EZH2, 
which was only weakly expressed in normal skin, was strongly 
overexpressed in the basal cell compartment of psoriatic skin 
lesions, revealing a typical nuclear localization (Figure 5C).
Next, we asked if an upregulation of cyclin D2, cyclin D3, 
and EZH2 can be also detected in relevant psoriasis mouse mod-
els. In the standard model using the TLR7 agonist imiquimod 
(IMQ), psoriasis-like skin inflammation was triggered by daily 
application of an IMQ-containing cream on the ears for 6 days, 
while in a second model daily intradermal injections of IL-36α 
into the skin of mouse ears were employed for 5 consecutive 
days. After 6 or 7 days of treatment, not only skin inflammation 
but also increased expression of Ccnd2, Ccnd3, and Ezh2 mRNA 
was detectable in both animal models (Figure 5, D and E). 
Moreover, increased protein levels of cyclin D2/D3 and EZH2 
could be detected in the epidermis of IMQ-treated mouse ears 
(Figure 5F). Thus, in addition to the previously demonstrated 
overexpression of IκBζ in psoriasis (8, 9), a hyperactive cyclin 
D-CDK4/6 pathway and elevated EZH2 expression are evident 
in murine and human psoriatic skin lesions.
Topical application of inhibitors targeting CDK4/6 or EZH2 
protects against experimental psoriasis in vivo. IκBζ is one of the 
key transcriptional regulators in the pathogenesis of psoriasis 
(8, 9). Due to our finding that CDK4/6 and EZH2 inhibitors 
suppressed psoriasis-related, proinflammatory gene expression 
downstream of IL-36α or IL-17A/TNF-α, we next investigated 
the potential of CDK4/6 and EZH2 inhibitors to block experi-
mental psoriasis in vivo. Moreover, we reasoned that topical 
application of both inhibitors would be sufficient, as the epider-
mis constitutes the main target for CDK4/6 and EZH2 inhibi-
tion. A prerequisite for efficient takeup of small-molecule inhib-
itors from the skin are hydrophobicity of these substances. Thus, 
we selected more hydrophobic inhibitors, such as abemaciclib 
(for CDK4/6 inhibition) or CPI-169 (44) (for EZH2 inhibition) 
that are more likely to penetrate the outer skin barrier. Psoria-
sis-like skin inflammation was induced in the abovementioned 
psoriasis model by daily application of an IMQ-containing 
cream on the ears of WT mice for 6 days, before animals were 
sacrificed and analyzed at day 6 (45). Abemaciclib, CPI-169, and 
ethanol as vehicle control were applied daily on the ear skin in 
parallel to IMQ (Supplemental Figure 5A). Whereas IMQ-treat-
ed ears exerted ear thickening, along with keratinocyte hyper-
proliferation and immune cell infiltration, topical application of 
abemaciclib or CPI-169 strongly suppressed IMQ-induced, pso-
riasis-like skin inflammation (Figure 6, A and B). Both inhibitors 
effectively penetrated the skin and inhibited CDK4/6 or EZH2, 
co-overexpression of CDK6 and STAT3, whereas pharmacolog-
ical EZH2 inhibition abrogated STAT3 methylation (Figure 4B). 
Thus, CDK4/6 might indeed trigger an EZH2-dependent meth-
ylation and activation of STAT3.
EZH2-dependent methylation sites of STAT3 at lysine 49, 
140, and 180 were previously identified by mass spectrometric 
analyses in tumor cells (34–36). Thus, we substituted all 3 lysine 
methylation sites with arginine residues and tested the STAT3 
mutants for their potential to activate NFKBIZ luciferase promoter 
expression. Whereas mutations of STAT3 at K49 and K140 had no 
effect on the induction of NFKBIZ promoter expression, alone or 
in combination with CDK6 and EZH2 (Supplemental Figure 4A), 
mutation of lysine 180 (STAT3 K180R), abrogated STAT3-medi-
ated NFKBIZ promoter activation (Figure 4C). Thus, we hypoth-
esized that CDK4/6-activated EZH2 methylates STAT3 at lysine 
180, which is needed to induce IκBζ expression in stimulated kera-
tinocytes. In agreement, reconstitution of CRISPR/Cas9-gener-
ated STAT3 knockout keratinocytes with WT STAT3, but not with 
the STAT3 K180R mutant, fully reconstituted IκBζ expression 
and IκBζ-mediated target gene induction upon IL-36α or IL-17A/
TNF-α stimulation (Figure 4D and Supplemental Figure 4B). This 
correlated with an absence of nuclear translocation of STAT3 
K180R in IL-36α–treated keratinocytes (Supplemental Figure 
4C), as observed before (34). Accordingly, mutant STAT3 K180R 
and EZH2 were unable to bind to the NFKBIZ promoter region 
in IL-36α–stimulated keratinocytes (Figure 4E). Thus, whereas 
IL-36α stimulation triggered WT STAT3 binding to the NFKBIZ 
promoter region together with EZH2 and CDK4/6, inhibition of 
CDK4/6 (Abe) or EZH2 (EPZ) abrogated the recruitment of this 
multiprotein complex (Figure 4F). These results therefore sug-
gest that CDK4 and CDK6 phosphorylate EZH2 to induce EZH2- 
dependent K180 STAT3 methylation, leading to the recruitment of 
the heteromeric complex to the NFKBIZ promoter and subsequent 
induction of IκBζ and its target gene expression in keratinocytes.
Finally, we wanted to know if cytokines that activate the classi-
cal JAK/STAT3 pathway could override CDK4/6- or EZH2 inhibi-
tor-mediated suppression of STAT3 activation. As revealed before 
(41–43), stimulation of primary keratinocytes with the cytokines 
IL-6, IL-20, or IL-22, which are upregulated in psoriatic lesions, 
led to the phosphorylation of STAT3 (Supplemental Figure 4D 
and refs. 41–43). Of note, neither abemaciclib nor EPZ6438 was 
able to abrogate STAT3 phosphorylation under these conditions, 
implying that CDK4/6 and EZH2 specifically control phosphory-
lation of STAT3 upon stimulation with IL-36α or IL-17A/TNF-α. 
Importantly, even though IL-6, IL-20, or IL-22 could reestablish 
STAT3 phosphorylation in IL-36α– and abemaciclib-treated kera-
tinocytes, stimulation with these cytokines failed to restore IκBζ 
and its target gene expression (Supplemental Figure 4, E and F), 
nor was it able to reestablish the nuclear translocation of STAT3 in 
keratinocytes (Supplemental Figure 4G). This finding implies that 
CDK4/6-EZH2–mediated methylation of STAT3 is distinguished 
from the activation of STAT3 by the JAK/STAT pathway.
Human and murine psoriatic lesions are characterized by over-
expression of cyclin D2, cyclin D3, and EZH2. Our findings suggest 
that CDK4 and CDK6 mediate the phosphorylation of EZH2 in 
a cyclin D–dependent manner, leading to STAT3 activation and 
IκBζ expression. We therefore investigated a potential relevance 
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infiltration upon IMQ treatment (Figure 6E). Of note, also the 
number of infiltrating plasmacytoid dendritic cells (pDCs) and 
myeloid dendritic cells (mDCs) was significantly suppressed by 
application of both inhibitors (Supplemental Figure 5B). Impor-
tantly, whereas IMQ treatment effectively induced IκBζ expres-
sion in the skin, along with phosphorylation of EZH2 at T345 
as detected by loss of pRB (for CDK4/6 inhibition) or H3K27me3 
(for EZH2 inhibition) expression in the epidermis of treated 
mice (Figure 6C). Moreover, abemaciclib treatment significant-
ly suppressed the infiltration of neutrophils, macrophages, and 
T cells in IMQ-treated mice (Figure 6D), while topical applica-
tion of the EZH2 inhibitor CPI-169 fully abrogated immune cell 
Figure 5. Increased expression of cyclin D2, cyclin D3, and EZH2 in human and murine psoriasis. (A) Expression data from skin biopsies of 64 healthy 
individuals and 58 patients with psoriasis were analyzed from the GEO profile data set GDS4602. Shown are normalized expression values for CCND1, CCND2, 
and CCND3. EZH2 mRNA (B) and protein levels (C) in human skin samples from healthy individuals and patients with psoriasis; retrieved from the same data 
set as in A and B. Significance was calculated with a 1-way ANOVA test: *P < 0.05; **P < 0.01; ***P < 0.001. Scale bars: 100 μm. (D) Analysis of Ccnd2, Ccnd3, 
and Ezh2 mRNA levels in IMQ-treated mice ears at day 6. Values were normalized to Actin. n = 6 per group ± SEM. (E) Analysis of Ccnd2, Ccnd3, and Ezh2 
mRNA levels in IL-36α–treated mice ears at day 5. n = 6 per group ± SEM. Significance was calculated using a 2-tailed Student’s t test: *P < 0.05; **P < 0.01; 
***P < 0.001. (F) IHC staining of EZH2, cyclin D2, and cyclin D3 in untreated (Ctrl) and IMQ-treated mouse ears at day 6. Scale bars: 40 μm.
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EZH2 in IMQ- or IL-36–mediated psoriasis-like skin inflamma-
tion mouse models effectively prevented psoriasis induction in 
vivo, by suppressing STAT3-mediated induction of IκBζ expres-
sion and IκBζ target gene expression.
CDK4/6 and EZH2 inhibitors effectively attenuate already 
established psoriasis-like skin inflammation in vivo. As CDK4/6 and 
EZH2 inhibitors could fully prevent the onset of psoriasis in vivo, 
we next investigated if inhibition of the CDK4/6-EZH2 pathway 
also attenuates already established psoriatic disease. We there-
fore first induced psoriasis-like skin inflammation in mice with 
IMQ and then topically applied abemaciclib or CPI-169 after day 
2 of IMQ treatment (Figure 7A). Already, 3 treatments with IMQ 
effectively induced ear swelling and keratinocyte hyperprolifer-
ation. These psoriasis-like symptoms could be fully reversed by 
starting topical application of abemaciclib or CPI-169 (Figure 
7, B and C, and Supplemental Figure 6A). Moreover, psoriasis- 
related, proinflammatory gene expression as well as infiltration 
of neutrophils, macrophages, and T cells, which was detectable 
at the third day of IMQ treatment, were fully resolved by both 
inhibitors (Supplemental Figure 6B and Figure 7D). Finally, inhi-
bition of CDK4/6 or EZH2 abrogated IκBζ expression as well as 
phosphorylation of STAT3, as detected by immunoblot analyses 
of whole skin lysates at day 6 (Figure 7E).
Similar results were obtained by topical application of abe-
maciclib or CPI-169 on established skin lesions in the IL-36α pso-
riasis-like mouse model. In this experimental setup, application of 
both inhibitors at day 4 effectively resolved IL-36α–induced ear 
swelling, keratinocyte hyperproliferation, and immune cell infiltra-
tion as well as psoriasis-associated gene expression, IκBζ expres-
sion, and activation of STAT3 (Figure 7, F–I, and Supplemental Fig-
ure 6C). Thus, topical application of CDK4/6 and EZH2 inhibitors 
not only prevented the onset of experimental skin inflammation, 
but also resolved already established psoriasis-associated symp-
toms in IMQ- or IL-36α–treated mice. In view of its increased activ-
ity in human psoriatic skin and the results obtained in psoriasis-like 
mouse models, inhibition of this pathway by topical application of 
CDK4/6 and EZH2 inhibitors could therefore provide a new thera-
peutic strategy for the treatment of patients with psoriasis.
Discussion
CDK4/6 inhibitors have been developed and approved for the 
treatment of patients with cancer in order to restrain hyperprolif-
eration of tumor cells (17). Recently, it was found that CDK4 and 
CDK6 do not only control cell cycle progression by phosphorylation 
of RB, but also regulate immune cell differentiation and function 
(20, 21, 48). In this context, CDK4 and CDK6 have been implicat-
ed as transcriptional cofactors that activate a subset of NF-κB or 
STAT3 target genes (23–25). Based on our results in cultured kera-
tinocytes, human skin biopsies, and mouse models, we propose to 
repurpose CDK4/6 inhibitors for psoriasis therapy. Moreover, our 
results uncovered a new pathway involving CDK4/6-mediated 
phosphorylation of EZH2 and EZH2-dependent methylation and 
activation of STAT3, leading to the inducible expression of IκBζ 
and IκBζ-dependent target genes in keratinocytes. These findings 
also suggest the use of EZH2 inhibitors to treat psoriasis.
IκBζ, encoded by NFKBIZ, constitutes a risk gene for the 
development of psoriasis (49). Moreover, we recently reported 
and of STAT3 at Y705, topical administration of abemaciclib or 
CPI-169 completely abrogated these signaling events (Figure 6F 
and Supplemental Figure 5C). As a positive control, stabilization 
of the CDK4/6 substrate pRB (46) and EZH2-directed H3K27 
methylation were strongly reduced in either CDK4/6 or EZH2 
inhibitor-treated mouse skin (Figure 6F). Accordingly, expres-
sion of IκBζ target genes, such as Cxcl2 and Cxcl5, and DC- and 
T cell–derived cytokines, such as Il17a or Il23a, was significantly 
downregulated in IMQ- and abemaciclib- or IMQ- and CPI-169–
treated skin (Supplemental Figure 5D).
Treatment of mice with the TLR7 agonist IMQ represents 
a standard mouse model for psoriasis (45). However, IMQ acti-
vates immune cells in the first instance, rather than an initial 
keratinocyte-derived proinflammatory response, as it is likely 
to happen in human psoriasis pathogenesis. Thus, we addi-
tionally investigated the therapeutic effects of abemaciclib or 
CPI-169 in an IL-36–triggered psoriasis-like dermatitis mouse 
model (Supplemental Figure 5E). As previously reported (9, 
47), repeated intradermal injections of IL-36α into the skin of 
mouse ears induced ear swelling, and keratinocyte hyperpro-
liferation along with immune cell infiltration (Figure 6, G and 
H). As a control for drug penetration in the skin of IL-36–treat-
ed animals, effective inhibition of CDK4/6 and EZH2 meth-
yltransferase activity was controlled by staining for pRB and 
H3K27me3, respectively (Supplemental Figure 5F). Similar to 
the IMQ mouse model, topical application of abemaciclib or 
CPI-169 effectively blocked keratinocyte hyperproliferation 
and immune cell infiltration (Figure 6, G and H). Moreover, 
both inhibitors suppressed IL-36–mediated expression of IκBζ, 
phosphorylation of EZH2 at T345, and activation of STAT3 
(pSTAT3 Y705) in the skin of treated mouse ears (Figure 6I). 
Accordingly, IκBζ target gene expression and key cytokine 
expression, such as Il17a and Il23a, were effectively blocked as 
well (Supplemental Figure 5G). Thus, inhibition of CDK4/6 or 
Figure 6. CDK4/6 and EZH2 inhibition prevents IMQ- and IL-36–mediated 
psoriasis-like skin lesions in vivo. (A) Ear thickness measurements during 
topical treatment of mice with IMQ with or without abemaciclib (Abe; 10 μL 
of a 2% solution) or the EZH2 inhibitor CPI-169 (CPI, 10 μL of a 5% solution). 
n = 6 mice per group ± SEM. (B) H&E staining of untreated (Ctrl), IMQ-, IMQ 
and Abe–, or IMQ and CPI–treated ears. Scale bars: 100 μm. (C) Phospho-RB 
(pRB) and H3K27me3 staining after 6 days of treatment validated effective 
CDK4/6 and EZH2 inhibition, respectively. Scale bars: 40 μm. (D) Infiltrat-
ing immune cells in mouse ears at day 6 of treatment were quantified as 
follows: Neutrophils: CD45+, CD11b+, Ly6G+; macrophages: CD45+, CD11b+, 
F4/80+; T cells: CD45+, CD3+, and αβ-TCR+ or γδ-TCR+. n = 3 mice per group ± 
SEM. (E) Flow cytometry analysis of IMQ-treated or IMQ and CPI-169–treat-
ed mouse ears at day 6. (F) Protein levels in untreated (Ctrl) and treated 
mouse skin tissue at day 6. (G) Ear thickness of IL-36α–treated mice at day 
5. Ears of mice were daily treated by intradermal injections with 1 μg IL-36α. 
Control mice received injections with PBS. Additionally, mice received 
topical treatment with ethanol as control (Veh), 2% abemaciclib (Abe), or 
5% CPI-169 (CPI). n = 6 mice per group ± SEM. (H) H&E staining of PBS- or 
IL-36α–treated ears at day 5. Scale bars: 100 μm. (I) Immunoblot analysis of 
IκBζ, EZH2 phosphorylation (pEZH2 T345) and STAT3 activation (pSTAT3 
Y705) in treated mouse skin tissue at day 5. pRB and H3K27me3 were 
analyzed as positive controls for drug action. Significance was calculated 
using a 1-way ANOVA for multiple groups and a 2-tailed Student’s t test for 
comparing 2 groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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RB failed to restore IκBζ expression upon CDK4/6 inhibition. 
Moreover, IκBζ expression was principally induced by IL-36 
stimulation in all phases of the cell cycle, except for G0-arrest-
ed cells that revealed a weaker IκBζ expression. Importantly, 
although IκBζ expression does not rely on CDK4/6-mediated 
cell cycle progression, CDK4/6 inhibitors might also have bene-
ficial effects in psoriasis treatment by additionally blocking kera-
tinocyte hyperproliferation, which is a hallmark of psoriasis (2).
In this study, we demonstrate a major role for STAT3 in driving 
keratinocyte-specific IκBζ expression. IκBζ expression in kerati-
nocytes is predominantly controlled from the proximal promoter 
2 of the NFKBIZ locus, containing different transcription factor 
binding sites than the better investigated distal promoter 1 (9). 
So far, we have not compared the promoter usage in distinct cell 
types, but we consider it likely that the contribution of the indi-
vidual promoters and STAT3 to IκBζ expression differs among 
different cell types. Our experiments show that CDK4 and CDK6 
do not directly phosphorylate STAT3 but EZH2, which induces 
IκBζ and IκBζ-dependent proinflammatory target gene expres-
sion in a STAT3-dependent manner. This finding seems surpris-
ing at the first glance, since EZH2, as part of the PRC2 complex, 
is mainly involved in gene repression through trimethylation of 
H3K27. Recently, however, EZH2 was also found to induce gene 
expression independently of the PRC2 complex, via interaction 
with β-catenin or the SWI/SNF complex (51, 52). CDK4/6 phos-
phorylated EZH2 at T345, thereby inducing an EZH2-dependent 
methylation of STAT3 at K180, and subsequent induction of IκBζ 
expression by STAT3. EZH2 phosphorylation at T345 was previ-
ously described to be mediated by CDK1 and CDK2, leading to 
an EZH2-directed epigenetic silencing of genes during G2 phase 
(39, 53). Thus, even though CDK-mediated phosphorylation of 
EZH2 at T345 seems to be conserved, its impact on EZH2 func-
tion and the choice of methylation substrates might depend on 
the specific stimulus or cell cycle phase.
Upon CDK4/6-mediated phosphorylation, EZH2 preferen-
tially interacted with STAT3, resulting in STAT3 K180 methyla-
tion and enhanced STAT3 activation. Similar observations were 
made in glioblastoma, where IL-6–induced STAT3 activation is 
controlled by EZH2-mediated trimethylation of STAT3 at K180 
(34). Thus, phosphorylation of EZH2 might induce a switch in 
EZH2 function from H3K27 trimethylation and transcriptional 
repression to noncanonical functions, including STAT3 meth-
ylation and gene activation. Whether this gene-activating func-
tion of EZH2 requires the PRC2 repressor complex or whether it 
is PRC2-independent remains to be resolved. In addition to its 
main function in transcriptional repression, non-PRC functions 
of EZH2 via direct binding to transcriptional regulators have 
been reported before. For instance, EZH2 was shown to act as a 
cofactor for transcription factors (such as the androgen receptor, 
β-catenin, or NF-κB), leading to target gene activation (52, 54, 55). 
Similar to other nonhistone targets, however, the exact molecular 
events that link STAT3 methylation to STAT3 activation are cur-
rently unknown. In agreement with a previous report (34), our 
data imply that K180 methylation of STAT3 might be needed for 
the nuclear import of phosphorylated STAT3.
Regardless of the detailed mechanism of EZH2-mediated STAT3 
activation, our study has also important clinical implications. Our 
that IκBζ is overexpressed in human psoriatic lesions, whereas 
global and keratinocyte-specific IκBζ KO mice are completely 
protected against psoriasis-like skin inflammation in several 
psoriasis models (8, 9, 50). Mechanistically, IκBζ is transcrip-
tionally induced in keratinocytes by IL-17 and IL-36, which trig-
gers the expression of psoriasis-relevant target genes encoding 
for selective chemokines and cytokines and antimicrobial pro-
teins. Deficiency of IκBζ therefore prevents the recruitment of 
neutrophils and monocytes that are needed for skin inflamma-
tion (9, 50). Collectively, our data suggest that interfering with 
IκBζ expression or function in keratinocytes might be a prom-
ising strategy for psoriasis therapy. As IκBζ is crucial for both 
IL-36 and IL-17 signaling, CDK4/6 inhibitors might be applica-
ble for different subtypes of psoriasis.
Unfortunately, based on a lack of enzyme activity, direct 
pharmacological inhibition of IκBζ function remains diffi-
cult (13). We therefore sought to block the transcriptional 
induction of IκBζ and identified small-molecule inhibitors 
of CDK4/6 and EZH2 as potent suppressors of IκBζ expres-
sion in keratinocytes. CDK4 and CDK6 have been previous-
ly shown to modulate several immune-relevant transcription 
factors by both kinase-dependent and -independent mecha-
nisms (23–25). In the present study, we clearly demonstrate 
that STAT3-mediated induction of IκBζ expression is kinase- 
dependent, as ATP-competitive CDK4/6 inhibitors such as abe-
maciclib or palbociclib abolished IκBζ expression. Consistent 
with these findings, a hyperactive but not a dominant-negative 
version of CDK6 increased NFKBIZ promoter activity. Moreover, 
cyclin D2 and cyclin D3 elevated the expression of NFKBIZ and 
its target genes, supporting the need for CDK4/6 kinase activity.
Despite the requirement of the kinase activity, the involve-
ment of CDK4/6 could be separated from its classical role in cell 
cycle regulation and phosphorylation of RB. Thus, depletion of 
Figure 7. CDK4/6 and EZH2 inhibitors attenuate established psoriasis-like 
skin lesions in vivo. All analyses were performed with n = 6 mice per group ± 
SEM. (A) Treatment scheme for the therapy using the IMQ mouse model. To 
explore whether CDK4/6 and EZH2 inhibitors suppress already-established 
psoriasis-like skin inflammation, mice were first treated with IMQ, followed 
by the application of 2% abemaciclib or 5% CPI-169 solution starting at the 
third IMQ application. (B) Ear thickness measurements during treatment. (C) 
H&E staining of untreated (Ctrl), IMQ-, IMQ and Abe–, or IMQ and CPI–treat-
ed ears. H&E staining shows the prevalence of psoriasis-like symptoms at 
IMQ day 2 when the inhibitors were applied for the first time. Scale bars: 100 
μm. (D) Quantification of infiltrating immune cells in mouse ears at day 6. 
Immune cell subpopulations were quantified as in Figure 6D. n = 3 mice per 
group ± SEM. (E) Protein levels in untreated (Ctrl) and IMQ-treated mouse 
skin tissue in the presence or absence of abemaciclib or CPI-169 at day 6. 
Mice were treated as in A. FOXM1 and H3K27me3 were analyzed as positive 
controls for drug action. (F) Treatment scheme in the IL-36–induced psoriasis 
mouse model. IL-36–mediated psoriasis-like dermatitis was induced by 
administration of 1 μg IL-36α at every second day. Control mice received PBS. 
Starting from day 4 of IL-36α injection, ethanol as Vehicle (Veh), 2% abe-
maciclib, or 5% CPI-169 were daily applied by topical administration. (G) Ear 
thickness measurements during IL-36α treatment. (H) H&E staining of PBS- 
or IL-36α–treated ears at day 9. Scale bars: 100 μm. (I) Immunoblot analysis 
in IL-36α–treated mouse skin tissue at day 9. Significance was calculated 
using a 1-way ANOVA for multiple groups and a 2-tailed Student’s t test for 
comparing 2 groups: *P < 0.05; **P < 0.01; ***P < 0.001.
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indicated, cells were starved overnight, before cytokine treatment, 
by removing cell culture supplements from the growth medium.
Generation of knockdown cells. Lentiviral particles were produced 
in HEK293T cells using the second-generation packaging system 
(pMD2.G, 12259; and psPAX2, 12260; Addgene). Keratinocytes were 
transduced in the presence of 8 μg/mL polybrene, packaging plasmids, 
and 5 μg of the respective shRNA construct (all from Dharmacon): 
pLKO.1-puro (sh ctrl); pLKO.1-TRCN0000009876 (shCDK4); pLKO.1-
TRCN0000010473 (shCDK6); pTRIPZ-EZH2 (V2THS63066, shEZH2); 
pLKO.1-TRCN0000040167 (shRB); pTRIPZ noncoding ctrl (RHS4743); 
pLKO.1-TRCN0000020840 (shSTAT3); pLKO.1-TRCN0000014683 
(shRELA), followed by puromycin selection (1 ng/mL, Invitrogen). For 
induction of EZH2 knockdown, pTRIPZ ctrl and pTRIPZ-EZH2–express-
ing cells were treated for 24 hours with 2 μg/mL doxycycline (AppliChem) 
before stimulation and harvest of the cells.
Luciferase constructs and reporter assays. Luciferase constructs 
were generated as described and based on the pInducer20 plasmid 
(Addgene, 44012) (9). HEK293T cells (1 × 104) were transfected for 
24 hours using HeBS buffer and CaCl2 and a mixture of 400 ng firefly 
luciferase vector and 100 ng TK-Renilla vector. For expression of other 
proteins, the following concentrations were purchased from Addgene: 
70 ng p65 (catalog 106453), 200 ng cJun (catalog 102758), STAT3 
(catalog 8706) or EZH2-HA (catalog 24230) constructs, and 500 ng 
CDK4-HA (catalog 1868), CDK6-HA (catalog 1866), CDK6DN (cat-
alog 1869), cyclin D1-HA (catalog 11181), cyclin D2 (catalog 8958), 
and cyclin D3 (catalog 10912). Additionally, CDK6 S178P expression 
construct was a gift from Michael Kracht (University of Giessen, Ger-
many) (58). For transfection of HaCaT cells, 3 × 105 cells were trans-
fected for 4 hours using Lipofectamine 3000 and a mixture of 800 
ng firefly luciferase vector, 200 ng TK-Renilla vector, and 4 μg expres-
sion or control plasmids according to the manufacturer’s instructions 
(Thermo Fisher Scientific, L3000015). At 36 hours after transfection, 
luciferase activity was measured with the Dual Luciferase Reporter 
Assay Kit (Promega, E2980). Expression of the reporter constructs 
was calculated as the fold induction over unstimulated transfected 
cells, using data from 3 independent experiments.
Transient overexpression in HEK293T, HaCaT cells, and primary 
keratinocytes. HEK293T cells (ACC 635, DSMZ Braunschweig, Ger-
many) were transfected using HeBS buffer and CaCl2. HaCaT cells 
and primary keratinocytes were transfected with Lipofectamine 
3000 according to the manufacturer’s instructions (Thermo Fisher 
Scientific, L3000015). Five-microgram expression constructs were 
incubated with 3 × 105 cells for 4 hours. Thirty-six to 48 hours after 
transfection, cells were harvested and analyzed. NFKBIZ (catalog 
44012), CDK9-HA (catalog 28102), and Flag-STAT3C (catalog 8722) 
expression constructs were purchased from Addgene and pINTO-
GFP-EZH2 T345A and pINTO-GFP-EZH2 T345D were provided by 
Danny Reinberg (Howard Hughes Medical Institute, New York Uni-
versity Langone Medical Center, New York, New York, USA).
Generation of STAT3 mutants. Mutation of STAT3 at K49, K140, 
and K180 was performed by site-directed mutagenesis of the human 
STAT3 pcDNA3 construct from Addgene (catalog 71447), which was 
previously cloned into the Strep-tagged backbone (pEXPR-IBA103). 
Substitution of the amino acid was performed with self-designed 
primers (Supplemental Table 1 and ref. 59).
CRISPR/Cas9 gene editing of STAT3 KO HaCaT cells. The CRISPR/
Cas9 one vector system was used to generated STAT3 KO HaCaT cells 
results suggest that targeting of the CDK4/6-EZH2-STAT3 pathway 
not only suppresses cytokine-mediated induction of IκBζ and proin-
flammatory target gene expression, but also inhibits immune cell 
recruitment and skin inflammation. We demonstrate in the IMQ- 
and IL-36–mediated psoriasis-like mouse models that both CDK4/6 
and EZH2 inhibitors completely blocked the development of psori-
atic skin lesions. The therapeutic effect of the inhibitors concurred 
with a suppression of IκBζ expression and a strong inhibition of IκBζ 
target gene expression, including chemokines (e.g., Cxcl2, Cxcl5), 
cytokines (e.g., Il1f9, Il1b, Il17a, Il23a), and antimicrobial proteins 
(e.g., Lcn2). In contrast, genes that were not IκBζ-dependent, such 
as NFKBIA and TNF, remained unaffected upon CDK4/6 or EZH2 
inhibition. These findings further support the view of a rather selec-
tive role of IκBζ in the control of immune responses and also indicate 
that inhibition of IκBζ will be associated with fewer side effects than 
a broad inhibition of NF-κB by toxic IKK inhibitors.
In line with previous reports showing an upregulated 
expression of IκBζ in psoriasis (8, 9), we detected an increased 
nuclear accumulation of EZH2 and elevated cyclin D2 and D3 
levels, both in mouse models of psoriasis and in human pso-
riatic skin lesions. Previous studies also found that mutations 
in the STAT3 signaling pathway constitute a risk factor for 
the development of psoriasis (43), while constitutively active 
STAT3 characterizes the epidermis of human psoriatic lesions 
(56). Collectively, this suggests that the CDK4/6-EZH2-STAT3 
pathway is hyperactive in psoriatic skin lesions. As inhibition of 
IκBζ blocks multiple signaling pathways in psoriasis, targeting 
IκBζ might increase overall therapy responses as well as pre-
vent the development of therapy resistance. Due to the clini-
cal availability of hydrophobic CDK4/6 and EZH2 inhibitors, 
we propose formulation of these inhibitors in, for example, 
a cream for topical treatment of psoriatic skin lesions. Topi-
cal drug administration will also restrict potential side effects 
and might be especially promising for those patients who have 
developed resistance to current psoriasis therapies.
Methods
Cell culture and treatment. HaCaT cells were obtained from Petra 
Boukamp (57) and maintained in DMEM with 10% FCS and antibi-
otics. Human primary keratinocytes were freshly isolated from fore-
skin and maintained in CnT-07S medium with gentamycin (CELL-
nTEC). Recombinant human IL-36α (6995-IL; aa 6-158), IL-36γ 
(6835-IL; aa 18-169), and mouse IL-36α (7059-ML; aa 6-160) 
were purchased from R&D Systems. Recombinant IL-17A (catalog 
11340174), TNF-α (catalog 11343013), IL-1β (catalog 11340013), 
IL-6 (catalog 11340064), IL-20 (catalog 11340203), and IL-22 (cat-
alog 11340223) were ordered from Immunotools. Flagellin (vac-
fla) and polyI:C (vac-pic) were purchased from Invivogen. In cell 
culture experiments, all cytokines were used at 100 ng/mL end 
concentration, except for IL-17A (200 ng/mL) and TNF-α (10 ng/
mL). Flagellin was applied at 10 ng/mL and poly I:C was added at 
a final concentration of 100 ng/mL. The following inhibitors were 
purchased from Selleckchem: abemaciclib mesylate (LY2835219, 
S17158), palbociclib isethionate (S1579), EPZ6438 (tazemetostat, 
S7128), and CPI-169 (S7616). If not otherwise indicated, the inhibi-
tors were used in cell cultures at the following concentrations: abe-
maciclib (16 μM), palbociclib (50 μM), and EPZ6438 (10 μM). When 
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CDK6 (MilliporeSigma, HPA002637), EZH2 (Cell Signaling, 5246), 
STAT3 (MA1-13042, Thermo Fisher Scientific) or β-Gal (sc-19119, 
Santa Cruz) as an IgG control, overnight at 4°C. For endogenous IPs 
immune complexes were precipitated with protein A/G PLUS aga-
rose beads and eluted by 6× SDS-PAGE sample buffer.
Cytokine array. Cytokine levels were detected from primary 
human keratinocytes that had been treated for 24 hours with 100 
ng/mL IL-36α, using the human cytokine array from R&D Systems 
(ARY005B) according to the manufacturer′s instructions. Prior to 
analysis, input lysates were normalized to equal cell numbers. Spot 
intensity was quantified with the dot blot analyzer from ImageJ and 
normalized to the reference spots. Relative expression levels are rep-
resented as mean pixel intensities.
Gene expression analysis by qPCR. Gene expression analyses 
were performed as described (9). Relative gene expression was ana-
lyzed using self-designed primers ordered at Metabion (Supplemen-
tal Table 2). Relative mRNA levels were calculated by normalization 
to the human reference gene RPL37A or the mouse reference gene 
Actin using the 2-ΔΔCt method.
Mice. Experiments were conducted in accordance with the Ger-
man law guidelines of animal care. Ears of female C57BL/6 mice 
(8–12 weeks old, Jackson Laboratory) were topically treated for 6 
consecutive days with 5 mg Aldara cream (containing 5% imiquim-
od, 3M Pharmaceuticals) and 10 μL abemaciclib (2% in 10 μL eth-
anol), 10 μL CPI-169 (5% in 10 μL ethanol), or vehicle control. At 
day 7, mice were sacrificed and analyzed. In the therapeutic mouse 
model, IMQ was applied first to establish psoriasis-like skin lesions. 
Then, starting on the third day of IMQ administration (IMQ day 
2), IMQ and the inhibitors were added in parallel until mice were 
sacrificed at day 6 (IMQ day 6). In the IL-36α–mediated psoriasis 
model, ears of male C57BL/6 mice (8–12 weeks old, Jackson Labo-
ratory) were treated by intradermal injections of 1 μg murine IL-36α 
(7059-ML, R&D Systems) or PBS control for 5 consecutive days. For 
application of abemaciclib (2% in ethanol), CPI-169 (5% in etha-
nol), or the vehicle control, substances were mixed with Miglyol 812 
(Carl Roth) in a ratio of 1:2. Inhibitors were topically applied 6 hours 
before intradermal injections of IL-36α or PBS. Mice were sacrificed 
and analyzed at day 6. For treatment of established psoriasis-like 
skin disease, mice were treated every second day with IL-36α for 8 
days, followed by the analysis of the mice at day 9 (IL-36 day 9). 
Both abemaciclib and CPI-169 were applied daily on the skin, start-
ing from the third IL-36α administration (IL-36 day 4).
Flow cytometry. Sample preparation was performed as described 
(9). The following anti-mouse antibodies from BioLegend were 
used: anti-CD45 FITC (catalog 103107), anti-CD11b Pacific Blue 
(catalog 101223), anti-Ly6G PE (catalog 127607), anti-F4/80 APC 
(catalog 123115), anti-CD11c Pacific Blue (catalog 117322), anti–
MHC-II APC (catalog 107613), anti-CD172a PE (catalog 144011), 
and anti–Siglec-H PE (catalog 129605). Anti–PDCA-1 APC (17-
2092-80) and anti-αβTCR Pacific Blue (catalog HM3628) were pur-
chased from Invitrogen, and anti-γδTCR APC (catalog 17-5711-82) 
from MilliporeSigma. Acquisition was performed with the LSRII 
flow cytometer (Becton Dickinson) and live, single cells were gated 
using the FlowJo (Tree Star) software.
Histology. Ear sections from mice were fixed in 10% formalin (Carl 
Roth) and subsequently embedded in paraffin. Five-micrometer sec-
tions were prepared and incubated with the following antibodies from 
according to the protocol of Shalem et al. (60). The guide RNA against 
STAT3 (forward: 5′-CACCGACTGCTGGTCAATCTCTCCC-3′, reverse: 
5′-AAACGGGAGAGATTGACCAGCAGTC-3′) was cloned into the Cas9 
containing lentiCRISPRv2 containing Cas9 vector (Addgene, 52961), fol-
lowed by lentiviral transduction and puromycin selection.
Synchronization of HaCaT cells. Synchronization of the cells with 
a double thymidine block was performed as described (61). After the 
second thymidine block, cells were released in normal medium. At 
0, 4, 10, and 14 hours after release, cells were stimulated with IL-36α 
and/or abemaciclib for 1 hour. Propidium iodide staining was per-
formed by flow cytometry (LSRII, Becton Dickinson) to detect the cell 
cycle phase at the time point of cell harvest.
Western blot analysis. Western blot analysis was performed as 
described (9). The following antibodies were used and purchased 
from Cell Signaling: anti-IκBζ (catalog 9244), anti-pSTAT3 at Tyr705 
(catalog 9145), anti-pSTAT3 at Ser727 (catalog 9134), anti-STAT3 
(catalog 12640), anti-p65 (catalog 8242), anti-EZH2 (catalog 5246), 
anti-pRB (at Ser807/811; catalog 8516), anti-FoxM1 (catalog 5436), 
anti-H3 (catalog 4499), anti-CDK4 (catalog 12790), anti-CDK6 
(catalog 13331), anti-CDK9 (catalog 2316), anti-cyclin D1 (catalog 
2978), anti-cyclin D2 (catalog 3741), anti-cyclin D3 (catalog 2936), 
anti-cJun (catalog 9165), anti-H3K27me3 (catalog 9733), anti-GAP-
DH (catalog 2118), anti-H3 (catalog 9715) and anti–β-actin (catalog 
3700). Anti–α-Tubulin (T9026) was purchased from MilliporeSigma. 
Anti–β-Gal (sc377257) and anti-GFP (sc9996) were obtained from 
Santa Cruz Biotechnology. Anti-pEZH2 at T345 (catalog 61242) and 
anti-pEZH2 at T487 (catalog 12820) were purchased from Active 
Motif and anti–pan-methyl-lysine antibody was purchased from 
Enzo (ADI-KAP-TF121-E). For detection of mouse IκBζ, a self-made 
rabbit antiserum raised against peptides CSAPGSPGSDSSDFSS and 
CLHIRSHKQKASGQ was applied (50). 
Chromatin immunoprecipitation (ChIP). ChIP assays were per-
formed as described (62). After sonification, chromatin was incubat-
ed with protein G–coupled Dynabeads (10004D, Invitrogen) and 2 
μg STAT3 (Thermo Fisher Scientific, MA1-13042), CDK4 (Cell Sig-
naling, 12790), CDK6 (MilliporeSigma, HPA002637), EZH2 (Diag-
enode, C15410039), NF-κB p65 (Diagenode, C15310256), or control 
IgG antibody (Abcam, ab46540) overnight at 4°C. The promoter 
region of myoglobulin (MB) served as an internal negative control 
(forward: 5′- CTCTGCTCCTTTGCCACAAC-3′, reverse: 5′-GAGT-
GCTCTTCGGGTTTCAG-3′). ChIP primers corresponding to the 
promoter region of NFKBIZ (forward 5′-GCCTTAACTGGGCTAA-
CAGC-3′, reverse 5′-CTGGCAAGTCCTGGAAGGAG-3′), CCND2 
(forward 5′-GGGAGAGGGAGGAGAGCTAA-3′, reverse 5′-GAGAG-
GTGAGGGCAGAGAGA-3′), and CCND3 (forward 5′- GGCAAT-
TACAGCCACATTCC-3′, reverse 5′-GGTGGCAACAGACACTGC-
TA-3′) were self-designed. Data from 2 independent experiments are 
presented as the fold enrichment, calculated over the percentage of 
input from the IgG control ChIP.
Coimmunoprecipitation (CoIP). Cells were lysed by mechanical 
disruption using a Dounce homogenizer and standard lysis buffer 
(50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 1x Protease 
inhibitor cocktail, Roche). Subsequently, lysates were sonicated for 
5 minutes at high power (Bioruptor, Diagenode), followed by pre-
clearing of the lysates with protein A/G PLUS agarose beads (Santa 
Cruz, sc-2003) for 1 hour at 4°C. Precleared lysates were incubated 
either with antibodies specific for CDK4 (Cell Signaling, 12790), 
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Supplemental Figure 1. Effects of CDK4/6 inhibition on IL-17A/TNFα-stimulated 
keratinocytes and analysis of possible cell cycle effects. 
  3 
(A) IκBζ protein and mRNA (NFKBIZ) expression in human primary keratinocytes stimulated 
for 24 h with IL-36α or IL-17A/TNFα with or without abemaciclib (Abe, added for 2 h). 
Suppression of Rb phosphorylation controlled effective CDK4/6 inhibition. (B) IκBζ expression 
in human primary keratinocytes stimulated for 1 h with 100 ng/mL IL-36α or 200 ng/mL IL-17A 
and 10 ng/mL TNFα with or without palbociclib (Pal). (C + D) IκBζ expression in primary human 
keratinocytes treated with IL-36 (100 ng/mL for 1 h) (C), flagellin, IL-1β (both 100 ng/mL for 
1h), or poly(I:C) (10 ng/mL for 4 h) in the presence or absence of abemaciclib (D). (E) IκBζ 
expression in synchronized HaCaT cells. Cells were synchronized by double thymidine block. 
At different times after release (0 -16 h), cells were stimulated in the different cell cycle phases 
for 1 h with 100 ng/mL IL-36α in the presence or absence of abemaciclib (Abe). The different 
cell cycle phases at the time of cell harvesting were controlled by PI staining. (F) IκBζ protein 
levels in RB-deficient HaCaT cells treated with IL-36α and abemaciclib. (G) Expression of IκBζ-
independent genes in CDK4/6 inhibitor-treated and CDK4/6-depleted keratinocytes. 
Stimulation as in (B). (H + I) Expression of IκBζ target genes in human primary keratinocytes 
stimulated for 1 h with 100 ng/mL IL-17A and 10 ng/mL TNFα, following CDK4/6 inhibition (H) 
or shRNAs (I). (J) Effect of IκBζ overexpression on CDK4/6-controlled cytokine expression in 
IL-17A/TNFα-stimulated primary keratinocytes. Treatment as in (B). All analyses: n = 3 ± SD. 
Significance was calculated using a 1-way ANOVA for multiple groups and a 2-tailed Student’s 
t-test comparing two groups: *p < 0.05; **p < 0.01; ***p < 0.001, n.s. = not significant. 
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Supplemental Figure 2. CDK4/6 regulate STAT3-mediated IκBζ induction in a cyclin 
D2/D3-dependent manner. (A) NFKBIZ promoter activity in HEK293T cells transiently 
overexpressing CDK4, CDK6 or cJun, alone or in combination. Relative luciferase activity was 
  5 
normalized to co-transfected Renilla luciferase control. (B) Analysis of the NFKBIZ promoter 
in IL-36α-stimulated HaCaT cells using luciferase constructs that harbor deletions of NF-κB, 
STAT3 or AP1 binding sites. CDK4, CDK6 or GFP as control were transiently co-
overexpressed in parallel. Relative luciferase activity was normalized to co-transfected Renilla 
control. (C + D) NFKBIZ promoter activity in HEK293T cells transiently overexpressing STAT3 
and CDK4 (C) or STAT3 and CDK6 (D), alone or in combination with cyclin D1, cyclin D2 and 
cyclin D3 overexpression. (E) Gene expression in primary human keratinocytes transiently 
overexpressing cyclin D2 or cyclin D3. Cells were stimulated for 1 h with 100 ng/mL IL-36α. 
Relative mRNA levels were normalized to RPL37A. (Ctrl = cells overexpressing empty control 
vector). (F) Cytokine levels in supernatants of cells, treated for 24 h with IL-36α, similar as in 
(E). n = 2. (G) p65 binding to the CCND2 and CCND3 locus in primary human keratinocytes. 
Cells were treated for 5 min with 100 ng/mL IL-36α. (H) CCND2 and CCND3 mRNA levels in 
control knockdown (Ctrl) or RELA knockdown cells, treated for 15 min with IL-36α, similar as 
in (E). (I) Transient overexpression of cyclin D2 in control or RELA-depleted primary human 
keratinocytes, treated for 1 h with IL-36α, similar as in (E). Significance was calculated using 
a 1-way ANOVA for multiple groups and a 2-tailed Student’s t-test comparing two groups: *p 
< 0.05; **p < 0.01; ***p < 0.001, n.s. = not significant. All analyses: n = 3 ± SD. 
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Supplemental Figure 3. Extended analysis of CDK4/6-mediated phosphorylation of 
EZH2 at T345 that induces STAT3 activation. (A) Chromatin immunoprecipitation (ChIP) of 
CDK4, CDK6 or IgG (control). Control or STAT3-deficient HaCaT cells were treated for 30 min 
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with 100 ng/mL IL-36α. Relative binding was calculated as the fold enrichment over IgG. (MB 
= myoglobulin promoter; internal negative control). Equal CDK4/6 and STAT3 levels were 
controlled by immunoblot analysis of the ChIP input. (B) STAT3 ChIP in IL-36α-stimulated, 
CDK6-deficient cells. Stimulation and analysis as in (A). (C) Detection of CDK4/6 interaction 
with EZH2 in HEK293T cells. EZH2 was transiently overexpressed together with CDK4 or 
CDK6. CDK4/6-EZH2 complexes were pulled down using a CDK4- or a CDK6-specific 
antibody or control IgG. (D) STAT3 activity was analyzed by immunoblot detection of 
phosphorylated STAT3 (Y705) in keratinocytes, treated for 1 h with 100 ng/mL IL-17A and 10 
ng/mL TNFα in the presence or absence of active EZH2. Detection of H3K27me3 controlled 
effective EZH2 inhibition (EPZ = EPZ6438 or EZH2 shRNA knockdown). (E) Gene expression 
in EPZ6438-treated or EZH2-depleted human primary keratinocytes (Treatment: 100 ng/mL 
IL-36α). mRNA levels were normalized to RPL37A. (F) CDK4/6 substrate sequence and 
putative CDK phosphorylation sites of human EZH2 (marked in red). (G) Analysis of EZH2 
activation by immunoblot detection of T345- or T487-phosphorylated EZH2 in IL-17A/TNFα-
treated keratinocytes. Cells were treated as in (D), with or without abemaciclib (Abe) or 
CDK4/6-specific shRNAs. (H) Analysis of IL-36α-mediated IκBζ induction and target gene 
expression in EZH2-depleted HaCaT cells, which overexpress a hyperactive STAT3 (STAT3C) 
version. Treatment: 1 h with 100 ng/mL IL-36α. Significance was calculated using a 1-way 
ANOVA for multiple groups and a 2-tailed Student’s t-test comparing two groups: *p < 0.05; 
**p < 0.01; ***p < 0.001, n.s. = not significant. All analyses: n = 3 ± SD. 
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Supplemental Figure 4. Extended analysis of EZH2-mediated methylation of STAT3 in 
keratinocytes. (A) Analysis of NFKBIZ promoter activity in HEK293T cells transiently 
overexpressing CDK6 and EZH2, alone or in combination with wildtype STAT3 or mutant 
STAT3 K49R and K140R. Relative luciferase activity was normalized to co-transfected Renilla 
  9 
control. (B) Expression of IκBζ and its target genes in STAT3 KO HaCaT cells, transiently 
overexpressing wildtype STAT3 or STAT3 K180R. Cells were treated for 1 h with 200 ng/mL 
IL-17A and 10 ng/mL TNFα. Relative mRNA levels of NFKBIZ and its target genes were 
normalized to RPL37A. (C) STAT3 KO HaCaT cells transiently overexpressing wildtype STAT3 
or mutant STAT3 (K180R) were stimulated for 1 h with 100 ng/mL IL-36α, followed by nuclear 
fractionation of the cells and immunoblot analysis. GAPDH and H3 were used as markers for 
the cytoplasmic and nuclear fraction, respectively. (D) Primary human keratinocytes were 
treated for 1 h with 100 ng/mL IL-6, IL-20 or IL-22 in the presence or absence of abemaciclib 
(Abe) or EPZ6438 (EPZ). (E + F) Primary human keratinocytes were treated for 1 h with 100 
ng/mL IL-36α, in the presence or absence of abemaciclib (Abe), IL-6, IL-20 or IL-22, similar as 
in (D). (E) Immunoblot analysis of IκB and pSTAT3 (Y705). Actin served as a loading control. 
(F) mRNA levels normalized to RPL37A, treated as in (E) (G) Nuclear fractionation of primary 
human keratinocytes treated as in (E). GAPDH and H3 were used as markers for the 
cytoplasmic and nuclear fraction, respectively. Significance was calculated using a 1-way 
ANOVA test: *p < 0.05; **p < 0.01; ***p < 0.001, n.s. = not significant. All analyses: n = 3 ± SD. 
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Supplemental Figure 5. Extended analysis of the in vivo effects of CDK4/6 or EZH2 
inhibition on psoriasis induction in the imiquimod (IMQ)- and IL-36 mouse models. (A) 
Treatment scheme for induction of IMQ-mediated, psoriasis-like skin inflammation. Mice 
received daily topical applications of IMQ-containing Aldara cream and abemaciclib (Abe; 10 
µL of a 2% solution) or CPI-169 (CPI, 10 µL of a 5% solution). (B) Characterization of infiltrating 
dendritic cell subsets into the ears of IMQ-treated mice by flow cytometry at day 6. 
Plasmocytoid dendritic cells (pDC) were detected as CD45+, CD11c+, MHC-II+, PDCA-1+, 
  11 
Siglec-H+, and myeloid derived dendritic cells (mDC) were analyzed as CD45+, CD11c+, MHC-
II+, CD172a+. n = 6 ears per group ± SEM. (C) IHC staining of phosphorylated STAT3 at Y705 
(pSTAT3) in the epidermis of treated mice at day 6. Scale bar: 40 µM. (D) Gene expression 
analysis of IκBζ target genes in IMQ-, IMQ/Abe- and IMQ/CPI-treated skin samples at day 6. 
Relative mRNA expression was normalized to Actin. (E) IL-36α treatment scheme with topical 
application of abemaciclib or CPI-169 as in (A). 1 μg murine IL-36α or PBS control was 
intradermally injected into one ear of the mice for five consecutive days. (F) IHC staining in ear 
skin sections of PBS or IL-36α-treated mice at day 5. pRB and H3K27me3 served as a marker 
for effective inhibition of CDK4/6 and EZH2, respectively. Scale bar: 40 µM. (G) Expression of 
IκBζ target genes in IL-36α-, IL-36α/Abe- and IL-36α/CPI-treated skin samples of IL-36α-
treated mice at day 5. All analyses: n = 6 per group ± SEM. Significance was calculated using 
a 1-way ANOVA test for multiple groups and a 2-tailed Student’s t-test comparing two groups: 
*p < 0.05; **p < 0.01; ***p < 0.001. 
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Supplemental Figure 6. Extended analysis of the in vivo effects of CDK4/6 or EZH2 
inhibition on already established IMQ- and IL-36-mediated psoriasis-like skin 
inflammation. (A) IHC staining of pRB (marker for CDK4/6 inhibition) and H3K27me3 (marker 
for EZH2 inhibition) at day 6 of IMQ treatment. (B) Gene expression analysis of IMQ-treated 
animals either at day 2 (starting time point of inhibitor treatment, IMQ day 2) or at day 6 (24 h 
after the last inhibitor application, IMQ day 6). Relative mRNA levels were normalized to Actin. 
(C) Gene expression analysis of IL-36α-treated animals either at day 4 (starting time point of 
inhibitor treatment, IL-36α day 4) or at day 9 (24 h after the last inhibitor application, IL-36α 
day 9). Relative mRNA levels were normalized to Actin. All analyses: n = 6 per group ± SEM. 
Significance was calculated using a 1-way ANOVA test: *p < 0.05; **p < 0.01; ***p < 0.001.  
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Supplementary Table S1. Primers used for silent mutagenesis of STAT3. 
K49R forward GACTGGGCATATGCAGCCAGCAGAGAGTCACATGCCACG 
K49R reverse CACCAACGTGGCATGTGACTCTCTGCTGGCTGCATATGC 
K140R forward CGTAGTGACAGAGAGGCAGCAGATGTTG 
K140R reverse GGTTGTAGACGACGGAGAGACAGTGATG 
K180R forward AACTACAAAACCCTCAGGAGCCAAGGAGACATGC 
K180R reverse GTACAGAGGAACCGAGGACTCCCAAAACATCAAC 
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Supplementary Table S2. Gene expression primer. 
Human_CXCL2_forward TGATTTCACAGTGTGTGGTCAAC 
Human_CXCL2_reverse TCTCTGCTCTAACACAGAGGG 
Human_CXCL5_forward AGCGCGTTGCGTTTGTTTAC 
Human_CXCL5_reverse TGGCGAACACTTGCAGATTAC 
Human_CXCL8_forward AAGGTGCAGTTTTGCCAAGG 
Human_CXCL8_reverse CCCAGTTTTCCTTGGGGTCC 
Human_LCN2_forward AGAGCTACAATGTCACCTCCG 
Human_LCN2_reverse TTAATGTTGCCCAGCGTGAAC 
Human_IL1B_forward TCAGCCAATCTTCATTGCTCAAG 
Human_IL1B_reverse GGTCGGAGATTCGTAGCTGG 
Human_NFKBIZ_forward ACACCCACAAACCAACTCTGG 
Human_NFKBIZ_reverse TGCTGAACACTGGAGGAAGTC 
Human_NFKBIA_forward AAGTGATCCGCCAGGTGAAG 
Human_NFKBIA_reverse CTCACAGGCAAGGTGTAGGG 
Human_TNF_forward CAAGGACAGCAGAGGACCAG 
Human_TNF_reverse CCG GATCATGCTTTCAGTGC 
Human_RPL37A_forward AGATGAAGAGACGAGCTGTGG 
Human_ RPL37A _reverse CTTTACCGTGACAGCGGAAG 
Human_CDK4_forward TCTCGAGGCCAGTCATCCTC 
Human_CDK4_reverse GCAGTCCACATATGCAACACC 
Human_CDK6_forward GGTACAGAGCACCCGAAGTC 
Human_CDK6_reverse CTCCTGGGAGTCCAATCACG 
Human_EZH2_forward CTGCTTCCTACATCGTAAGTGC 
Human_EZH2_reverse GTGAGAGCAGCAGCAAACTC 
Human_CCND2_forward AGCTGTGCATTTACACCGAC 
Human_CCND2_reverse CATGCTTGCGGATCAGAGAC 
Human_CCND3_forward ACTGGCTCTGTTCGGATGC 
Human_CCND3_reverse AGCGCTGCTCCTCACATAC 
Human_RELA_forward AGGCTATCAGTCAGCGCATC 
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Human_RELA_reverse AGCATTCAGGTCGTAGTCCC 
Mouse_Cxcl2_forward CGCCCAGACAGAAGTCATAGC 
Mouse_Cxcl2_reverse CTTTGGTTCTTCCGTTGAGGG 
Mouse_Cxcl5_forward CCCTACGGTGGAAGTCATAGC 
Mouse_Cxcl5_reverse GAACACTGGCCGTTCTTTCC 
Mouse_Lcn2_forward AATGTCACCTCCATCCTGGTC 
Mouse_Lcn2_reverse ACTGGTTGTAGTCCGTGGTG 
Mouse_Il1b_forward AGCTGAAAGCTCTCCACCTC 
Mouse_Il1b_reverse GCTTGGGATCCACACTCTCC 
Mouse_Nfkbiz_forward AACTCGCCAAGAGACCAGTG 
Mouse_Nfkbiz_reverse AGAGCCACTGACTTGGAACG 
Mouse_Il1f6_forward GCCTGTTCTGCACAAAGGATG 
Mouse_Il1f6_reverse ACAGCGATGAACCAACCAGG 
Mouse_Il1f9_forward GTCAGCGTGACTATCCTCCC 
Mouse_Il1f9_reverse TGGCTTCATTGGCTCAGGG 
Mouse_Il23a_forward CAGCTCTCTCGGAATCTCTGC 
Mouse_Il23a_reverse TGTCCTTGAGTCCTTGTGGG 
Mouse_Il17a_forward GCCCTCAGACTACCTCAACC 
Mouse_Il17a_reverse TTCCCTCCGCATTGACACAG 
Mouse_Actin_forward AGGAGTACGATGAGTCCGGC 
Mouse_Actin_reverse GGTGTAAAACGCAGCTCAGTA 
Mouse _Ccnd2_forward CTCACGTGTGATGCCCTGAC 
Mouse _ Ccnd2_reverse TGTTCAGCAGCAGAGCTTCG 
Mouse _ Ccnd3_forward TTGCATCTATACGGACCAGGC 
Mouse _ Ccnd3_reverse GAGACAGGCGGTGCAGAATC 
Mouse_Ezh2_forward ACTGCTTCCTACATCCCTTCC 
Mouse_Ezh2_reverse ACGCTCAGCAGTAAGAGCAG 
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